Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 28	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 29	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 30	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 31	MAR 31	LPCI now available as a replacement to LDPCI

NEWS 32 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:48:08 ON 03 APR 2008

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:48:24 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 APR 2008 HIGHEST RN 1011757-08-6
DICTIONARY FILE UPDATES: 2 APR 2008 HIGHEST RN 1011757-08-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-542,759-1 - quinoline.str





chain nodes :
11 18 20 21 23 24 25 26 27 28 30 31 32 33 34 35 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
1-25 1-26 2-23 2-24 3-20 3-21 4-11 5-38 6-27 7-35 7-37 8-33 8-34 9-31
9-32 10-28 10-30 11-18 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 1-25 1-26 2-3 2-23 2-24 3-4 3-20 3-21 4-5 4-11 5-6 5-7 5-38
6-10 6-27 7-8 7-35 7-37 8-9 8-33 8-34 9-10 9-31 9-32 10-28 10-30 11-18

exact bonds :
11-12
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 :

G1:H,Ak,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 20:CLASS
21:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 30:CLASS
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:49:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10758 TO ITERATE

18.6% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 208944 TO 221376
PROJECTED ANSWERS: 226 TO 848

L2 5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:49:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 213849 TO ITERATE

100.0% PROCESSED 213849 ITERATIONS 637 ANSWERS
SEARCH TIME: 00.00.03

L3 637 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	179.28	179.49

FILE 'CAPLUS' ENTERED AT 16:50:23 ON 03 APR 2008

FILE COVERS 1907 - 3 Apr 2008 VOL 148 ISS 14
FILE LAST UPDATED: 2 Apr 2008 (20080402/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 79 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 79 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:97048 CAPLUS
DOCUMENT NUMBER: 148:191958
TITLE: Benzothiophene derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as inhibitors of Rho kinase
INVENTOR(S): Kahraman, Mehmet; Borchardt, Allen J.; Cook, Travis G.; Davis, Robert L.; Gardiner, Elisabeth M. M.; Malecha, James W.; Noble, Stewart A.; Prins, Thomas J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 184pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008011560	A2	20080124	WO 2007-US73971	20070720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080021217	A1	20080124	US 2007-780735	20070720
US 20080021026	A1	20080124	US 2007-780834	20070720
PRIORITY APPLN. INFO.:			US 2006-832634P P	20060720
			US 2007-915772P P	20070503

OTHER SOURCE(S): MARPAT 148:191958
GI

L4 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention relates to heteroaryl compds. I, processes for preparing them, pharmaceutical prepns. comprising them, and their pharmaceutical use. I are inhibitors of Rho kinase, useful in the treatment of, e.g., hypertension, etc. In compds. I, A is (un)substituted heteroaryl; G1 is (un)substituted fused bicyclic heteroaryl; G2 is (un)substituted (CH2)mZ(CH2)p and null, wherein m and p are 0 to 4, Z is (un)substituted NH, NHC(O), O, C(O), or null, etc.; G3 is (un)substituted alkyl, aryl, alkoxy, etc.; G4 is H, halo, (un)substituted NH2, alkyl, alkoxy, etc.; including pharmaceutically acceptable salts, esters, or prodrugs thereof. For instance, the invention compound II was prepared and gave 9.5% (or 18.6%) lowering of IOP (intraocular pressure) vs. control at 0.3% (or 1.0%) in monkeys.
IT 1003907-65-0P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzothiophene derivs. as inhibitors of Rho kinase)
RN 1003907-65-0 CAPLUS
CN Methanone, [2-(2-amino-4-pyrimidinyl)-3-methylbenzo[b]thien-5-yl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



L4 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:71271 CAPLUS
DOCUMENT NUMBER: 148:168570
TITLE: Preparation of nitrogen-containing heterocyclyl benzamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors
INVENTOR(S): Ebdrup, Soeren; Andersen, Henrik Sune
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 146pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008006702	A1	20080117	WO 2007-EP56467	20070628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			EP 2006-117119 A	20060713

OTHER SOURCE(S): MARPAT 148:168570
GI



I



II

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Title compds. represented by the formula I [wherein R1-R8 = independently H, halo, alkenyl, etc.; R9 = H, halo, OH, etc.; and pharmaceutically acceptable acids or bases, or optical isomers or tautomers thereof] were prepared as 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitors. For example, II was provided in a multi-step synthesis starting from the reaction of 4-[(tert-butoxycarbonyl)amino]benzoic acid with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane. Three of the prepared compds. were tested for inhibition of 11βHSD1 with IC50 values of 43-128 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

IT 1002097-88-2P, 1-[4-[(Octahydroquinolin-1-yl)carbonyl]phenyl]pyrrolidine-3-carboxylic acid 1002097-89-3P, [4-[3-[(Morpholin-4-yl)carbonyl]pyrrolidin-1-yl]phenyl](octahydroquinolin-1-yl)methanone 1002097-90-6P, [4-[3-[(4-Hydroxymethylpiperidin-1-yl)carbonyl]pyrrolidin-1-yl]phenyl](octahydroquinolin-1-yl)methanone 1002097-92-8P, [4-[3-[(4-Hydroxypiperidin-1-yl)carbonyl]pyrrolidin-1-yl]phenyl](octahydroquinolin-1-yl)methanone 1002097-93-9P, 1-[4-[(Octahydroquinolin-1-yl)carbonyl]phenyl]pyrrolidine-3-carboxylic acid N-(tetrahydropyran-4-yl)amide 1002097-94-0P, (Octahydroquinolin-1-yl)[4-[3-[(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)carbonyl]pyrrolidin-1-yl]phenyl]methanone 1002097-96-2P, N-[1-[4-[(Octahydroquinolin-1-yl)carbonyl]phenyl]pyrrolidin-3-yl]acetamide 1002098-24-9P 1002098-25-0P 1002098-40-9P 1002098-52-3P 1002098-55-6P 1002098-63-6P, [4-(3-Benzyloxypyrrolidin-1-yl)phenyl](octahydroquinolin-1-yl)methanone RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heterocyclylbenzamide derivs. as 11β-hydroxysteroid dehydrogenase type 1 inhibitors)

RN 1002097-88-2 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1002097-89-3 CAPLUS
CN Methanone, [4-[3-(4-morpholinylcarbonyl)-1-pyrrolidinyl]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



RN 1002097-90-6 CAPLUS
CN Methanone, [4-[3-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-1-pyrrolidinyl]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1002097-92-8 CAPLUS
CN Methanone, [4-[3-[(4-hydroxy-1-piperidinyl)carbonyl]-1-pyrrolidinyl]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1002097-93-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1002097-94-0 CAPLUS
CN Methanone, [1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-pyrrolidinyl]-2-oxa-5-azabicyclo[2.2.1]hept-5-yl- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1002097-96-2 CAPLUS
CN Acetamide, N-[1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 1002098-24-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[(3R)-1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1002098-25-0 CAPLUS
CN Urea, N,N-dimethyl-N'-[(3R)-1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1002098-40-9 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[4-[(3R)-3-(phenylmethoxy)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1002098-52-3 CAPLUS

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Urea, N-(1-methylethyl)-N'-[(3S)-1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1002098-55-6 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[4-[(3-endo)-3-(2-pyridinyloxy)-8-azabicyclo[3.2.1]oct-8-yl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 1002098-63-6 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[4-[3-(phenylmethoxy)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1176166 CAPLUS
DOCUMENT NUMBER: 147:469141
TITLE: Benzamides as 11β-hydroxysteroid dehydrogenase type 1 active compounds and their preparation, pharmaceutical compositions and use in the treatment of metabolic syndrome
INVENTOR(S): Ebdrup, Soeren; Andersen, Henrik Sune
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007115935	A1	20071018	WO 2007-EP52929	20070327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2006-112359 A 20060407

OTHER SOURCE(S): MARPAT 147:469141
GI

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB A class of compds. of the general formula I, their use in therapy, pharmaceutical compns. comprising the compds., as well as their use in the manufacture of medicaments are described. The compds. modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. Compds. of formula I wherein R1 and R2 are taken together with nitrogen they are attached forming (un)substituted 8- to 11-membered (un)saturated (bi/tri)cyclic ring; R1 is H, C1-4 alkyl, and cyclopropyl; R2 is (un)substituted adamantyl; R3 is substituted cyclopentyl, substituted cyclohexyl, substituted CH2-cyclohexyl, pyrrolidinyl, etc.; X is O, S, SO, SO2, (un)substituted methylene and NH and derivs.; R4 is H, C1-4 alkyl, CF3, halo, C1-4 alkoxy, etc.; and their pharmaceutically acceptable acid and base salts, optical isomers, mixts. of optical isomers, racemic mixts. and tautomeric forms thereof, are claimed. Example compound II was prepared by etherification of benzyl 4-hydroxybenzoate with 4-hydroxycyclohexanecarboxylic acid Et ester; the resulting 4-(4-ethoxycarbonylcyclohexyloxy)benzoic acid benzyl ester underwent hydrogenation to give 4-(4-ethoxycarbonylcyclohexyloxy)ben zoic acid, which underwent amidation with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride to give the corresponding amide, which underwent hydrolysis to give compound II. All the invention compds. were evaluated for their 11βHSD1 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 360 nM.

IT 952588-35-1P 952588-49-7P 952588-61-3P
952588-63-5P 952588-77-1P 952588-78-2P
952588-79-3P 952588-80-6P 952588-85-1P
952588-86-2P 1002098-55-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(drug candidate; prepn. of benzamides as 11β-hydroxysteroid dehydrogenase type 1 modulators useful in the treatment of metabolic syndromes)

RN 952588-35-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]- (CA INDEX NAME)



RN 952588-49-7 CAPLUS
CN Cyclohexanecarboxamide, 4-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]- (CA INDEX NAME)



L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 952588-61-3 CAPLUS
CN 2-Pyridinesulfonamide, N-[4-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]cyclohexyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 952588-63-5 CAPLUS
CN Cyclopropanecarboxamide, N-[cis-4-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 952588-78-2 CAPLUS
CN Methanone, [4-[(4-hydroxycyclohexyl)methoxy]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



RN 952588-79-3 CAPLUS
CN Methanone, [4-[[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-piperidinyl]methoxy]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 952588-77-1 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[4-[[1-(2-pyridinylsulfonyl)-4-piperidinyl]methoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 952588-80-6 CAPLUS
CN Methanone, [4-[[1-(ethylsulfonyl)-4-piperidinyl]methoxy]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 952588-85-1 CAPLUS
CN Benzoic acid,
3-[[4-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]meth
yl]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 952588-86-2 CAPLUS
CN Benzoic acid,
4-[[4-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenoxy]meth
yl]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1002098-55-6 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[4-[(3-endo)-3-(2-pyridinyloxy)-8-
azabicyclo[3.2.1]oct-8-yl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:512060 CAPLUS
DOCUMENT NUMBER: 146:501049
TITLE: Preparation of benzimidazolyl and indolyl amide derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1
INVENTOR(S): Kilburn, John Paul; Andersen, Henrik Sune; Kampen, Gita Camilla Tejlgaard; Ebdrup, Soeren
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 126pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051811	A2	20070510	WO 2006-EP68017	20061101
WO 2007051811	A3	20080124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-110226 A 20051101

OTHER SOURCE(S): MARPAT 146:501049
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = substituted alkyl; R2 = H, halo, alkyl, etc.; X = N or CR3, wherein R3 = H, CN, alkyl, etc.; if R4 is absent, A and N together form an (un)substituted and saturated heterobicyclic or heterotricyclic ring; if R4 = H or alkyl, A = (un)substituted adamantyl], and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). Thus, e.g., II was prepared by acylation of trifluoroacetate salt of III with 2-furoic acid. Details for bioassays are described (no data). As modulators of 11βHSD1, I should prove useful for the treatment and prevention of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

IT 936348-11-7P 936348-16-2P 936348-18-4P 936348-21-9P 936348-26-4P 936348-27-5P 936348-29-7P 936348-30-0P 936348-31-1P 936348-32-2P 936348-33-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolyl and indolyl amide derivs. as modulators of 11β-hydroxysteroid dehydrogenase type 1)

RN 936348-11-7 CAPLUS
CN Methanone, [1-[2-[(methylsulfonyl)methoxy]ethyl]-1H-benzimidazol-5-yl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



RN 936348-16-2 CAPLUS
CN Methanone, [1-[2-(methylsulfonyl)ethyl]-1H-benzimidazol-5-yl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



RN 936348-18-4 CAPLUS
CN Methanone, (octahydro-1(2H)-quinolinyl)[1-[2-(2H-tetrazol-5-yl)ethyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 936348-21-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[2-[5-[(octahydro-1(2H)-quinolinyl)carbonyl]-1H-benzimidazol-1-yl]ethyl]- (CA INDEX NAME)



RN 936348-26-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[2-[5-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]-1H-benzimidazol-1-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 936348-27-5 CAPLUS
CN 4-Morpholinecarboxamide, N-[2-[5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1H-benzimidazol-1-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 936348-29-7 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[2-[5-[(octahydro-1(2H)-quinolinyl)carbonyl]-1H-benzimidazol-1-yl]ethyl]-, 1,1-dioxide (CA INDEX NAME)



RN 936348-30-0 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[2-[5-[(octahydro-1(2H)-quinolinyl)carbonyl]-1H-benzimidazol-1-yl]ethyl]- (CA INDEX NAME)



RN 936348-31-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[2-[5-[(octahydro-1(2H)-quinolinyl)carbonyl]-1H-benzimidazol-1-yl]ethyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 936348-32-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[2-[5-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]-1H-benzimidazol-1-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 936348-33-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[2-[5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1H-benzimidazol-1-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 936348-82-2P 936348-83-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazolyl and indolyl amide derivs. as modulators of
11β-hydroxysteroid dehydrogenase type 1)
RN 936348-82-2 CAPLUS
CN Methanone, [1-(2-azidoethyl)-1H-benzimidazol-5-yl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



RN 936348-83-3 CAPLUS
CN Methanone, [1-(2-aminoethyl)-1H-benzimidazol-5-yl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)

L4 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:512058 CAPLUS
DOCUMENT NUMBER: 146:481830
TITLE: Substituted benzamide and 11β-hydroxysteroid dehydrogenase type 1 and their preparation and pharmaceutical use
INVENTOR(S): Andersen, Henrik Sune; Joergensen, Anker Steen; Kilburn, John Paul; Kampen, Gita Camilla Tejlgaard; Ebdrup, Soeren
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 185pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051810	A2	20070510	WO 2006-EP68015	20061101
WO 2007051810	A3	20080124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:	EP 2005-110228	A	20051101
	EP 2006-116808	A	20060707

OTHER SOURCE(S): MARPAT 146:481830
GI

L4 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The use of substituted amides of formula I for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compds. as pharmaceutical compns., are described. Also a class of substituted amides of formula I, their use in therapy, pharmaceutical compns. comprising the compds., as well as their use in the manufacture of medicaments are described. Compound of formula I wherein R1 is H, acyl, (amino)sulfonyl, (amino)sulfinyl, etc.; R2 is H, C1-6 alkyl, and C3-6 cycloalkyl; R1R2 taken together with N to form (un)substituted (un)saturated 3- to 12-membered (mono/bi)heterocyclic ring; A is (un)substituted (un)saturated 5- to 12-membered (bi/tri)heterocyclic; R5 is H, C1-6 alkyl, C3-6 cycloalkyl, halo, OH, and CN; R6 and R7 is H, C1-6 alkyl, F, trihalomethyl, and trihalomethoxy; R6R7 taken together to give (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic; and their prodrugs, pharmaceutically acceptable acid and base salts, optical isomers, mixts. of optical isomers, racemic mixts., tautomeric forms thereof, are claimed. The compds. are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. Example compound II was prepared by amidation ot 4-(tert-butoxycarbonylaminomethyl)benzoic acid with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride; the resulting [4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester underwent methylation with Me iodide to give methyl-[4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester, which underwent hydrolysis to give (4-methylaminomethylphenyl)-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methanone, which underwent acetylation with acetyl chloride to give compd. II. All the invention compds. were evaluated for their 11βHSD1 inhibitory activity. From the assay, it was detd. that compd. II exhibited an IC50 value of 19 nM.

IT 936018-23-4P 936018-25-6P 936018-27-8P
936018-34-7P 936018-43-8P 936018-87-0P
936019-21-5P 936019-23-7P 936019-25-9P
936019-80-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. as 11β-hydroxysteroid dehydrogenase type 1 inhibitors useful in the treatment of diseases)

RN 936018-23-4 CAPLUS
CN Benzamide, N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 936018-25-6 CAPLUS
CN Benzamide, 3-cyano-N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 936018-27-8 CAPLUS
CN Benzamide, 3-fluoro-N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 936018-34-7 CAPLUS
CN Benzamide, N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 936018-43-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 936018-87-0 CAPLUS
CN Methanesulfonamide, N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



RN 936019-21-5 CAPLUS
CN 1-Piperidinecarboxamide, N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)

L4 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 936019-23-7 CAPLUS
CN 4-Morpholinecarboxamide, N-methyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]- (CA INDEX NAME)



L4 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 936019-25-9 CAPLUS
CN Urea, N,N'-dimethyl-N-[[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]methyl]-N'-phenyl- (CA INDEX NAME)



RN 936019-80-6 CAPLUS
CN Methanone, [4-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)methyl]phenyl](octahydro-1(2H)-quinolinyl)- (CA INDEX NAME)



L4 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:213433 CAPLUS
DOCUMENT NUMBER: 144:274294
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Bishoff, Francois Paul; Bracken, Mirielle; Pieters, Serge Marie Aloysius; Mercken, Marc Hubert; De Winter, Hans Louis Jos; Berthelot, Dieder Jean-Claude
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N. V., Belg.
SOURCE: PCT Int. Appl., 369 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006024932	A1	20060309	WO 2005-IB2595	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1789398	A1	20070530	EP 2005-780525	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035772	A	20070912	CN 2005-80034228	20050808
JP 2008509129	T	20080327	JP 2007-524423	20050808
IN 2007KN00752	A	20070713	IN 2007-KN752	20070301

PRIORITY APPLN. INFO.:

US 2004-599810P	P	20040806
US 2004-599317P	P	20040806
US 2004-599811P	P	20040806
WO 2005-IB2595	W	20050808

OTHER SOURCE(S): MARPAT 144:274294
GI

L4 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; A1 = (un)substituted alkyl; Q1= O, S, CO, CS, NHCO, CONH, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; R3 = (un)substituted alk(en)yl, aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.

IT 876766-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-36-8 CAPLUS

CN Quinoline,
1-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]deca hydro- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:152738 CAPLUS
DOCUMENT NUMBER: 144:254142
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Baxter, Ellen; Bischoff, Francois Paul; Boyd, Robert; Braeken, Mirielle; Coats, Steven; Huang, Yifang; Jordan, Alfonzo; Luo, Chi; Mercken, Marc Hubert; Reynolds, Charles H.; Ross, Tina Morgan; Tounge, Brett A.; Schulz, Mark; De Winte, Hans Louis Jos; Pieters, Serge Maria Aloysius; Reitz, Allen B.
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017836	A2	20060216	WO 2005-US28191	20050808
WO 2006017836	A3	20060629		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1776349	A2	20070425	EP 2005-785256	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035771	A	20070912	CN 2005-80034122	20050808
JP 2008509165	T	20080327	JP 2007-525074	20050808
IN 2007KN00762	A	20070713	IN 2007-KN762	20070301

PRIORITY APPLN. INFO.:
US 2004-599811P P 20040806
US 2004-599317P P 20040806
US 2004-599810P P 20040806
WO 2005-US28191 W 20050808

OTHER SOURCE(S): MARPAT 144:254142
GI

L4 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; A1 = (un)substituted alkyl; Q1 = O, S, CO, CS, NHCO, CONH, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl; m = 0-1; L1 = O, S, SO, SO2, etc.; R3 = (un)substituted alk(en)yl, aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.

IT 876766-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-36-8 CAPLUS

CN Quinoline,
1-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]deca hydro- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:149827 CAPLUS
DOCUMENT NUMBER: 144:254141
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Baxter, Ellen; Boyd, Robert; Coats, Steve; Jordan, Alfonzo; Reitz, Allen; Reynolds, Charles H.; Scott, Malcolm; Schulz, Mark; De Winter, Hans Louis Jos
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 382 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017844	A1	20060216	WO 2005-US28340	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1776350	A1	20070425	EP 2005-786778	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035770	A	20070912	CN 2005-80034011	20050808
JP 2008509167	T	20080327	JP 2007-525078	20050808
IN 2007KN00792	A	20070713	IN 2007-KN792	20070306

PRIORITY APPLN. INFO.:		US 2004-599317P	P 20040806
		US 2004-599810P	P 20040806
		US 2004-599811P	P 20040806
		WO 2005-US28340	W 20050808

OTHER SOURCE(S): MARPAT 144:254141
GI

L4 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; q = 0-1; A2 = (un)substituted alkyl; R = (un)substituted hetero/aryl, arylalkyl, hetero/cycloalkyl, partially unsatd. carbocyclyl, spiroheterocyclyl; provided that when q = 0; R is other than hetero/aryl; Q3 = O, S, CO, CS, OCO, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; L1 = O, S, SO, SO2, CO, NH and derivs., etc.; R3 = (un)substituted cyclo/alkyl, alkenyl, hetero/aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.

IT 876766-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-36-8 CAPLUS
CN Quinoline, 1-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]deca hydro- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1012143 CAPLUS
DOCUMENT NUMBER: 143:398877
TITLE: Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
AUTHOR(S): Coppola, Gary M.; Kukkola, Paivi J.; Stanton, James L.; Neubert, Alan D.; Marcopulos, Nicholas; Bilci, Natalie A.; Wang, Hua; Tomaselli, Hollis C.; Tan, Jenny; Aicher, Thomas D.; Knorr, Douglas C.; Jeng, Arco Y.; Dardik, Beatriz; Chatelain, Ricardo E.
CORPORATE SOURCE: Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6696-6712
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:398877
AB High-throughput screening identified 5 as a weak inhibitor of 11β-HSD1. Optimization of the structure led to a series of perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A tertiary benzamide is required for biol. activity and substitution of the terminal benzamide with either electron-donating or -withdrawing groups is tolerated. The majority of the compds. show selectivity of >20 to >700-fold over 11β-HSD2. Analogs which showed >50% inhibition of 11β-HSD1 at 1 μM in an cellular assay were screened in an ADX mouse model. A maximal response of >70% reduction of liver corticosterone levels was observed for three compds.; 9m, 25 and 49.
IT 735351-53-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 735351-53-8 CAPLUS
CN Benzamide, N-[2-amino-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-2,4-dichloro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 735344-54-4P 735344-66-8P 735344-67-9P
735344-68-0P 735344-71-5P 735344-72-6P
735344-77-1P 735344-80-6P 735344-86-2P
735344-91-9P 735344-96-4P 735345-00-3P
735345-01-4P 735345-02-5P 735345-13-8P
735345-14-9P 735345-16-1P 735345-19-4P
735345-20-7P 735345-39-8P 735345-67-2P
735346-13-1P 735346-18-6P 735346-30-2P
735346-32-4P 735346-34-6P 735346-35-7P
735346-42-6P 735346-45-9P 735346-54-0P
735346-68-6P 735346-71-1P 735346-87-9P
735348-43-3P 867288-45-7P 867288-48-0P
867288-49-1P 867288-74-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 735344-54-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-66-8 CAPLUS
CN Benzamide, 4-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-67-9 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-68-0 CAPLUS
CN Benzamide, 4-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-71-5 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-72-6 CAPLUS
CN Benzamide, 4-cyano-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-77-1 CAPLUS
CN Benzamide, 2-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-80-6 CAPLUS
CN Benzoic acid, 4-[[[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]amino]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-86-2 CAPLUS
CN Quinoline, 1-[4-[[(4-fluorophenyl)methyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-91-9 CAPLUS
CN Benzamide, 2-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-96-4 CAPLUS
CN Benzamide, 4-fluoro-N-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-00-3 CAPLUS
CN Benzamide, 4-(methylsulfonyl)-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-01-4 CAPLUS
CN Benzamide, 2,4-difluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-02-5 CAPLUS
CN Benzamide, 4-chloro-2-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-13-8 CAPLUS
CN Benzamide, 3-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-14-9 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-16-1 CAPLUS
CN Benzamide, 4-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-19-4 CAPLUS
CN Benzamide, 4-chloro-2-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-20-7 CAPLUS
CN Benzamide, 4-(aminosulfonyl)-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-39-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-67-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-13-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[2-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-18-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-34-6 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-35-7 CAPLUS
CN Benzamide, N-hexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735346-30-2 CAPLUS
CN Benzamide, N-[2-(acetylamino)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-2,4-dichloro-, rel- (CA INDEX NAME)

Relative stereochemistry.

RN 735346-32-4 CAPLUS
CN Quinoline, decahydro-1-[4-(1-piperidinylcarbonyl)benzoyl]-, (4aR,8aS)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735346-42-6 CAPLUS
CN Benzamide, N-cyclohexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

RN 735346-45-9 CAPLUS
CN Benzamide, N-(2-methylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-54-0 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(3-pyridinylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-68-6 CAPLUS
CN Benzamide, N-(1-methylethyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-71-1 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-87-9 CAPLUS
CN Quinoline, 1-[4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-43-3 CAPLUS
CN Benzamide, N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 867288-45-7 CAPLUS
CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-48-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[2-methyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 867288-49-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-74-2 CAPLUS
CN Quinoline, decahydro-1-[4-[(phenylsulfonyl)amino]benzoyl]-, (4aR,8aS)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 735351-41-4P 735351-43-6P 735351-51-6P
735351-54-9P 735351-55-0P 867288-57-1P
867288-58-2P 867288-59-3P 867288-60-6P
867288-66-2P 867288-67-3P 867288-78-6P
867288-79-7P 867288-92-4P 867288-93-5P
867288-94-6P 867288-95-7P 867288-96-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 735351-41-4 CAPLUS

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-54-9 CAPLUS
CN Benzoic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-55-0 CAPLUS
CN Benzoic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Quinoline, decahydro-1-(4-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-43-6 CAPLUS
CN Quinoline, 1-(4-aminobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-51-6 CAPLUS
CN Quinoline, 1-(4-amino-3-nitrobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA
INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 867288-57-1 CAPLUS
CN Quinoline, 1-(4-amino-2-chlorobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-58-2 CAPLUS
CN Quinoline, 1-(4-amino-2-methoxybenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-59-3 CAPLUS
CN Quinoline, 1-(4-amino-2-propoxybenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-60-6 CAPLUS
CN Quinoline, decahydro-1-[(4-nitro-1-naphthalenyl)carbonyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-66-2 CAPLUS
CN Quinoline, decahydro-1-(3-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 867288-79-7 CAPLUS
CN Benzoyl chloride, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 867288-92-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-nitro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 867288-93-5 CAPLUS
CN Quinoline, decahydro-1-(3-methyl-4-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-67-3 CAPLUS
CN Quinoline, 1-(3-aminobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-78-6 CAPLUS
CN Quinoline, decahydro-1-[4-(methylamino)benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-94-6 CAPLUS
CN Quinoline, 1-(2-chloro-4-nitrobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-95-7 CAPLUS
CN Quinoline, decahydro-1-(2-methoxy-4-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-96-8 CAPLUS

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Quinoline, decahydro-1-[4-nitro-2-(2-propenyloxy)benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 867288-56-0P 867288-61-7P 867288-71-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 867288-56-0 CAPLUS
CN Quinoline, 1-(4-amino-3-methylbenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 867288-61-7 CAPLUS
CN Quinoline, 1-[(4-amino-1-naphthalenyl)carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 867288-71-9 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:347016 CAPLUS
DOCUMENT NUMBER: 142:411252
TITLE: Preparation of azabicyclooctane derivatives as CXCR3 antagonists
INVENTOR(S): Habashita, Hiromu; Suzuki, Ryo; Shibayama, Shiro; Tanihiro, Tatsuya; Kaneko, Yousuke; Egashira, Hiromu; Nishiyama, Eiji; Yamatsuta, Katsura; Fujita, Setsuko
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035534	A1	20050421	WO 2004-JP14864	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2007015927	A	20070125	JP 2003-349033	20031008
JP 2007015930	A	20070125	JP 2004-266040	20040913
PRIORITY APPLN. INFO.:			JP 2003-349033 A	20031008
			JP 2004-266040 A	20040913

OTHER SOURCE(S): MARPAT 142:411252
GI



I

AB Title compds. I [ring A = (un)substituted heterobicycle, heterotricycle; ring B = (un)substituted cycle; Y = bond, spacer] were prepared For example, 1,3,3-trimethyl-6-(2-naphthoyl)-6-azabicyclo[3.2.1]octane (II) was prepared from 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane. In 11β-HSD1 inhibition assays, the IC50 value of compound II was 29 nM. Compds. I are claimed useful for the treatment of inflammation, allergy, etc. Formulations are given.
IT 850366-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclooctane derivs. as CXCR3 antagonists for treatment

L4 ANSWER 10 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
of treatment of inflammation, allery, etc.)
RN 850366-84-6 CAPLUS
CN Quinoline, decahydro-1-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:284145 CAPLUS
DOCUMENT NUMBER: 142:355177
TITLE: Preparation of aminoquinolines for treating inflammatory and immune diseases
INVENTOR(S): Lin, Chu-Chung; Liu, Jen-Fuh; Chang, Chih-Wei; Chen, Shu-Jen; Xiang, Yibin; Cheng, Pei-Chin; Jan, Jiing-Jyh
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 819,646.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050070573	A1	20050331	US 2004-953937	20040929
US 20040209902	A1	20041021	US 2004-819646	20040406
US 7183413	B2	20070227		
AU 2004229404	A1	20041028	AU 2004-229404	20040406
AU 2004229404	B2	20080110		
CA 2521619	A1	20041028	CA 2004-2521619	20040406
EP 1613322	A2	20060111	EP 2004-759214	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522814	T	20061005	JP 2006-509778	20040406

PRIORITY APPLN. INFO.: US 2003-462495P P 20030411
US 2004-551750P P 20040309
US 2004-819646 A2 20040406
WO 2004-US10695 W 20040406

OTHER SOURCE(S): MARPAT 142:355177
GI

L4 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. I [X1-X4 = C; R1, R2 = H, alkyl; or R1 and R2 together are cycloalkyl; R3, R4 = H, AN(B)D; R5-R8 = H, alkyl, or halo; A = alkyl optionally containing 1-6 heteroatoms; B = H, alkyl; D = alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; or B and D together are heterocycloalkyl or heteroaryl] that bind to CXCR3 receptors and therefore are useful for treating inflammatory and immune diseases, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloro-2-methylquinoline, was given. Ninety exemplified compds. I were tested for their efficacy in blocking activation of CXCR3 using a DELFIA GTP-binding kit (Wallac Oy, Turku, Finland). Unexpectedly, 51 compds. showed IC50 values lower than 1.0 μM, 22 compds. showed IC50 values between 1 μM and 10.0 μM, and 17 compds. showed IC50 values greater than 10.0 μM. The pharmaceutical composition comprising the compound I is disclosed.

IT 849111-24-6P 849111-38-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoquinolines for treating inflammatory and immune diseases)

RN 849111-24-6 CAPLUS
CN Propanamide, 3-[[2-[(6-chloro-2-methyl-4-quinolinyl)amino]ethyl][(4-methoxyphenyl)sulfonyl]amino]-N-[2-methoxy-4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]- (CA INDEX NAME)

L4 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 849111-38-2 CAPLUS
CN Propanamide, N-[2-methoxy-4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-3-[[(4-methoxyphenyl)sulfonyl][2-[(1,2,3,4-tetrahydro-7-methyl-9-acridinyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L4 ANSWER 12 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:182640 CAPLUS
DOCUMENT NUMBER: 142:280220
TITLE: Preparation of quinazoline-2,4(1H,3H)-dione derivatives as gonadotropin-releasing hormone antagonists
INVENTOR(S): Hamamura, Kazumasa; Oda, Tsuneo; Kusaka, Masami; Kanzaki, Naoyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 541 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019188	A1	20050303	WO 2004-JP12322	20040820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536313	A1	20050303	CA 2004-2536313	20040820
JP 2005097276	A	20050414	JP 2004-241721	20040820
EP 1657238	A1	20060517	EP 2004-772278	20040820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070010537	A1	20070111	US 2006-569391	20060222
PRIORITY APPLN. INFO.:			JP 2003-298637 A	20030822
			WO 2004-JP12322 W	20040820

OTHER SOURCE(S): MARPAT 142:280220
GI



I



II

L4 ANSWER 12 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title quinazoline-2,4(1H,3H)-dione derivs. I [wherein R1 = H or (un)substituted hydrocarbyl; ring A = (un)substituted aromatic 6-membered ring; ring B = (un)substituted (hetero)cyclyl; W = O or S; X1 and X2 = independently H, (un)substituted hydrocarbyl, or heterocyclyl; or X1 and X2 together form =O, =S, or (un)substituted =NH; Y = a bond or (un)substituted alkylene], or salts or prodrugs thereof are prepared as gonadotropin-releasing hormone antagonists. For example, the compound II was prepared in a multi-step synthesis. I inhibited 75.4-99.9% of human gonadotropin releasing hormone at the concentration of 10 nM. I are useful for the treatment of prostatic hyperplasia, hysteromyoma, endometriosis, uterus fibroma, etc. (no data). Formulations containing I as an active ingredient were also described.
IT 847168-16-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazoline-2,4(1H,3H)-dione derivs. as gonadotropin-releasing hormone antagonists)
RN 847168-16-5 CAPLUS
CN Quinoline, 1-[4-chloro-3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:175164 CAPLUS
DOCUMENT NUMBER: 142:240612
TITLE: Synthesis of 9-azasteroid partial structures via Birch reduction as key step
AUTHOR(S): Stanetty, Peter; Kasemann, Olaf; Mereiter, Kurt; Mihovilovic, Marko D.
CORPORATE SOURCE: Institute of Applied Synthetic Chemistry, Vienna University of Technology, Vienna, Austria
SOURCE: ARKIVOC (Gainesville, FL, United States) (2005), (5), 83-95
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ark/journal/2005/I05_Fisera/1277/LF-1277E.pdf
PUBLISHER: Arkat USA Inc.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:240612
AB A high-energy intermediate model for the inhibition of the ergosterol biosynthesis suggests 9-azasteroids as potential antimycotics. Key step for the approach described in this work involves a Birch reduction of substituted quinoline structures. The diastereoselectivity of this reaction was studied. Subsequent functionalization to incorporate the lipophilic properties of the steroidal core afforded N-substituted perhydro-quinolinols as mimics of the AB-ring system of steroids.
IT 845465-41-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of subunits of 9-azasteroid partial via stereoselective Birch reduction)
RN 845465-41-0 CAPLUS
CN Quinoline, 1-[4-(1,1-dimethylethyl)benzoyl]decahydro-6,6-dimethoxy-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:6434 CAPLUS
DOCUMENT NUMBER: 142:240600
TITLE: Diastereoselective synthesis of 2,5-disubstituted decahydroquinolines via ring-rearrangement metathesis and zirconium-mediated cyclization
AUTHOR(S): Neidhoefer, Juergen; Blechert, Siegfried
CORPORATE SOURCE: Institut fuer Chemie, Technische Universitaet Berlin, Berlin, 10623, Germany
SOURCE: Synthesis (2004), (18), 3047-3054
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:240600
GI



I



II



III

AB A diastereoselective approach to 2,5-substituted decahydroquinolines by zirconium-mediated cyclization of unsatd. α,α'-disubstituted piperidines I is described. The required piperidines could be obtained from secondary sulfonamides II via ruthenium-catalyzed ring-rearrangement metathesis (RRM) in high yields. Racemic trans-195A (III) and 2-epi-trans-195A were synthesized in 8 steps starting with butyraldehyde and cyclohex-2-enol.
IT 844638-92-2P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(diastereoselective synthesis of 2,5-disubstituted decahydroquinolines via ring-rearrangement metathesis and zirconium-mediated cyclization)
RN 844638-92-2 CAPLUS
CN Quinoline, decahydro-5-methyl-1-(4-nitrobenzoyl)-2-propyl-, (2R,4aS,5R,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 14 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 844638-93-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(diastereoselective synthesis of 2,5-disubstituted decahydroquinolines via ring-rearrangement metathesis and zirconium-mediated cyclization)
RN 844638-93-3 CAPLUS
CN Quinoline, decahydro-5-methyl-1-(4-nitrobenzoyl)-2-propyl-, (2R,4aR,5S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:964830 CAPLUS
DOCUMENT NUMBER: 141:410932
TITLE: Preparation of benzo[1,2,5]thiadiazoles as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions
INVENTOR(S): Allison, Brett; McAtee, Laura C.; Phuong, Victor K.; Rabinowitz, Michael H.; Shankley, Nigel P.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: U.S. Pat. Appl. Publ., 81 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224983	A1	20041111	US 2004-811292	20040326
US 7241759	B2	20070710		
AU 2004261547	A1	20050210	AU 2004-261547	20040326
CA 2520546	A1	20050210	CA 2004-2520546	20040326
WO 2005012275	A2	20050210	WO 2004-US9589	20040326
WO 2005012275	A3	20060511		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008899	A	20060418	BR 2004-8899	20040326
EP 1675837	A2	20060705	EP 2004-785868	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829704	A	20060906	CN 2004-80014470	20040326
JP 2006528241	T	20061214	JP 2006-532352	20040326
MX 2005PA10484	A	20060310	MX 2005-PA10484	20050928
NO 2005005002	A	20051214	NO 2005-5002	20051027
IN 2005KN02161	A	20061013	IN 2005-KN2161	20051031
US 20070276016	A1	20071129	US 2007-775535	20070710

PRIORITY APPLN. INFO.: US 2003-458638P P 20030328
US 2004-811292 A1 20040326
WO 2004-US9589 W 20040326

OTHER SOURCE(S): MARPAT 141:410932
GI

L4 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title [[(2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]benzamides I [wherein R1, R2 = independently H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, naphthyl, benzoylalkyl, Ph, etc.; or NR1R2 = (un)substituted 10-oxa-4-azatricyclo[5.2.1.02,6]dec-4-yl, heterocyclyl, 8-oxo-1,5,6,8-tetrahydro-2H-4H-1,5-methanopyrido[1,2-a][1,5]diazocin-3-yl; R1 = independently (cyclo)alkyl, alkenyl, Ph, furanyl, thienyl, benzyl, pyrrolyl, OH, alkoxy, SH, CN, NO2, NH2, halo, etc.; Rb = independently alkyl, halo; and enantiomers, diastereomers, hydrates, solvates, and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin 2 (CCK2) receptor modulators. For example, 4-bromo-2-aminobenzoic acid piperidine amide (3-step preparation given) was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole in pyridine to afford II (74%). The latter showed binding to CCK2R specific zinc finger proteins fused with the herpes simplex virus VP16 activation domain with pKi of 7.6 and behaved as a competitive antagonist in a guinea pig gastric corpeal muscle assay with pKB of 8.8. Thus, I and their pharmaceutical compns. are useful for the treatment of CCK2 mediated conditions, such as pancreatic adenocarcinoma, pain, eating disorders, gastroesophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anemia, and Zollinger-Ellison syndrome (no data).
IT 791099-32-6P, 2,1,3-Benzothiadiazole-4-sulfonic acid N-[5-chloro-2-[(octahydroquinolin-1-yl)carbonyl]phenyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCK2 modulator; preparation of [[(benzo[1,2,5]thiadiazol-4-yl)sulfonyl]amino]benzamides as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions)
RN 791099-32-6 CAPLUS
CN Quinoline, 1-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-4-chlorobenzoyl]decahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878302 CAPLUS
DOCUMENT NUMBER: 141:360694
TITLE: Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
INVENTOR(S): Kampen, Gita Camilla Tejlgaard; Andersen, Henrik Sune
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 297 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089416	A2	20041021	WO 2004-DK254	20040406
WO 2004089416	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615666	A2	20060118	EP 2004-725887	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522750	T	20061005	JP 2006-504357	20040406
EP 1782859	A2	20070509	EP 2007-102700	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1785424	A2	20070516	EP 2007-102701	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1787982	A2	20070523	EP 2007-102177	20040406
EP 1787982	A3	20070530		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1854487	A2	20071114	EP 2007-114939	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1862181	A2	20071205	EP 2007-115299	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060111348	A1	20060525	US 2005-254125	20051011

PRIORITY APPLN. INFO.: DK 2003-565 A 20030411

L4 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

US 2004-537099P	P	20040116
DK 2003-568	A	20030411
US 2003-467443P	P	20030502
DK 2003-778	A	20030522
US 2003-475195P	P	20030602
EP 2004-725884	A3	20040406
EP 2004-725887	A3	20040406
EP 2004-725888	A3	20040406
EP 2004-725889	A3	20040406
EP 2004-725890	A3	20040406
WO 2004-DK254	W	20040406

OTHER SOURCE(S): MARPAT 141:360694
AB The invention discloses combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
IT 94673-00-4 96370-40-0 464154-88-9 778586-10-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxysteroid dehydrogenase inhibitor-antihypertensive agent combination for treatment of metabolic syndrome and related conditions)
RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



RN 96370-40-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate (ester) (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

DK 2003-566	A	20030411
DK 2003-567	A	20030411
DK 2003-569	A	20030411
DK 2003-570	A	20030411
DK 2003-571	A	20030411
US 2003-467284P	P	20030502
US 2003-467362P	P	20030502
US 2003-467363P	P	20030502
US 2003-467437P	P	20030502
US 2003-467453P	P	20030502
US 2003-467800P	P	20030502
DK 2003-776	A	20030522
DK 2003-777	A	20030522
US 2003-474421P	P	20030530
US 2003-475157P	P	20030602
DK 2003-972	A	20030627
DK 2003-988	A	20030630
DK 2003-989	A	20030630
DK 2003-990	A	20030630
DK 2003-998	A	20030702
US 2003-486078P	P	20030710
US 2003-486094P	P	20030710
US 2003-486095P	P	20030710
US 2003-486097P	P	20030710
US 2003-486098P	P	20030710
DK 2003-1910	A	20031222
DK 2004-9	A	20040106

L4 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 464154-88-9 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro- (9CI) (CA INDEX NAME)



RN 778586-10-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, acetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878301 CAPLUS
DOCUMENT NUMBER: 141:360721
TITLE: Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to treat cancer and inflammation-associated diseases and to minimize the side effects associated with glucocorticoid receptor agonist therapy
INVENTOR(S): Kampen, Gita Camilla Tejlgaard; Andersen, Henrik Sune
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089415	A2	20041021	WO 2004-DK248	20040406
WO 2004089415	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615667	A2	20060118	EP 2004-725890	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522744	T	20061005	JP 2006-504351	20040406
EP 1782859	A2	20070509	EP 2007-102700	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1785424	A2	20070516	EP 2007-102701	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1787982	A2	20070523	EP 2007-102177	20040406
EP 1787982	A3	20070530		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1854487	A2	20071114	EP 2007-114939	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1862181	A2	20071205	EP 2007-115299	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060094699	A1	20060504	US 2005-246814	20051007

L4 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
PRIORITY APPLN. INFO.:

DK 2003-565	A	20030411
DK 2003-566	A	20030411
DK 2003-568	A	20030411
DK 2003-569	A	20030411
DK 2003-570	A	20030411
DK 2003-571	A	20030411
US 2003-467284P	P	20030502
US 2003-467362P	P	20030502
US 2003-467363P	P	20030502
US 2003-467443P	P	20030502
US 2003-467453P	P	20030502
US 2003-467800P	P	20030502
DK 2003-776	A	20030522
DK 2003-778	A	20030522
US 2003-475157P	P	20030602
US 2003-475195P	P	20030602
DK 2003-972	A	20030627
DK 2003-988	A	20030630
DK 2003-989	A	20030630
DK 2003-990	A	20030630
DK 2003-998	A	20030702
US 2003-486078P	P	20030710
US 2003-486094P	P	20030710
US 2003-486095P	P	20030710
US 2003-486097P	P	20030710
US 2003-486098P	P	20030710
DK 2003-1910	A	20031222

L4 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

DK 2004-9	A	20040106
US 2004-537099P	P	20040116
DK 2003-567	A	20030411
US 2003-467437P	P	20030502
DK 2003-777	A	20030522
US 2003-474421P	P	20030530
EP 2004-725884	A3	20040406
EP 2004-725887	A3	20040406
EP 2004-725888	A3	20040406
EP 2004-725889	A3	20040406
EP 2004-725890	A3	20040406
WO 2004-DK248	W	20040406

OTHER SOURCE(S): MARPAT 141:360721
AB The invention discloses combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.
IT 94673-00-4 96370-40-0 464154-88-9
778586-10-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxysteroid dehydrogenase inhibitor-glucocorticoid agonist combination to treat cancer and inflammation-associated diseases and minimize side effects associated with glucocorticoid agonist therapy)
RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



RN 96370-40-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate (ester) (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 464154-88-9 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro- (9CI) (CA INDEX NAME)



RN 778586-10-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, acetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:872724 CAPLUS
DOCUMENT NUMBER: 141:366223
TITLE: Pharmaceutical use of substituted amides as 11β-hydroxysteroid dehydrogenase type 1 modulators, especially inhibitors, for treating metabolic
INVENTOR(S): Andersen, Henrik Sune; Kampen, Gita Camilla Tejlgaard; Christensen, Inge Thoger; Mogensen, John Patrick; Larsen, Annette Rosendal; Kilburn, John Paul
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089470	A2	20041021	WO 2004-DK250	20040406
WO 2004089470	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615698	A2	20060118	EP 2004-725891	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522746	T	20061005	JP 2006-504353	20040406
EP 1787982	A2	20070523	EP 2007-102177	20040406
EP 1787982	A3	20070530		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1854487	A2	20071114	EP 2007-114939	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1862181	A2	20071205	EP 2007-115299	20040406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060111366	A1	20060525	US 2005-265794	20051011

PRIORITY APPLN. INFO.:
DK 2003-565 A 20030411
US 2003-467800P P 20030502
DK 2003-972 A 20030627

L4 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

DK 2003-988	A	20030630
DK 2003-989	A	20030630
DK 2003-990	A	20030630
DK 2003-998	A	20030702
US 2003-486078P	P	20030710
US 2003-486094P	P	20030710
US 2003-486095P	P	20030710
US 2003-486097P	P	20030710
US 2003-486098P	P	20030710
DK 2003-1910	A	20031222
DK 2004-9	A	20040106
US 2004-537099P	P	20040116
DK 2003-566	A	20030411
DK 2003-567	A	20030411
DK 2003-568	A	20030411
DK 2003-569	A	20030411
DK 2003-570	A	20030411
DK 2003-571	A	20030411
US 2003-467284P	P	20030502
US 2003-467362P	P	20030502
US 2003-467363P	P	20030502
US 2003-467437P	P	20030502
US 2003-467443P	P	20030502
US 2003-467453P	P	20030502
DK 2003-776	A	20030522
DK 2003-777	A	20030522
DK 2003-778	A	20030522

L4 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

US 2003-474421P	P	20030530
US 2003-475157P	P	20030602
US 2003-475195P	P	20030602
EP 2004-725887	A3	20040406
EP 2004-725888	A3	20040406
EP 2004-725890	A3	20040406
WO 2004-DK250	W	20040406

OTHER SOURCE(S): MARPAT 141:366223
GI



II



III

AB The invention is directed to the use of substituted amides of formula R3CONR1R2 (I), and their optical isomers or mixture of optical isomers, including racemates, and tautomers, their prodrugs, pharmaceutically acceptable salts, [wherein R1 = (un)substituted cyclo/hetcyclo/aryl/hetaryl/alkyl, het/aryl, etc.; R2 = H, (un)substituted aryl/cycloalkyl/alkylcarboxy/alkyl, het/aryl; or R1NR2 = (un)substituted (un)saturated bi/tricyclic ring containing 4-10 carbons, and 0-2 heteroatoms; R3 = (un)substituted cyclo/hetcyclo/aryl/alkyloxy/hetaryl/arylalkyl/alkyl, alkenyl, alkynyl, het/aryl] for modulating, especially inhibiting, the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and use of their pharmaceutical compns. in the treatment, prevention, prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. The invention is also directed to the prepn. of certain title compds. I. For instance, acylation of 1H-benzimidazole-5-carboxylic acid with N-cyclohexyl-N-methylamine in THF in the presence of HOBT/EDAC/DIPEA gave amide II in 49% yield. Pyrazole-4-carboxamide (III) inhibited 11β-HSD1 enzyme with an IC50 = 0.04 μM. I are useful for treating metabolic disorders, type II diabetes, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, obesity, hypertension, diabetic late complications, neurodegenerative and psychiatric disorders and adverse effects of treatment or therapy with glucocorticoid receptor agonists.

IT 94673-00-4P, (Octahydroquinolin-1-yl)phenylmethanone
96370-40-0P, Benzoic acid 1-benzoyldecahydroquinolin-4-yl ester
464154-88-9P, (7-Hydroxyoctahydroquinolin-1-yl)phenylmethanone
778586-10-0P, Acetic acid 1-benzoyldecahydroquinolin-4-yl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted amides as 11β-hydroxysteroid dehydrogenase type 1 modulators, especially inhibitors, for treating metabolic disorders, type II diabetes and related diseases)

RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



RN 96370-40-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 464154-88-9 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 778586-10-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, acetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780704 CAPLUS
DOCUMENT NUMBER: 141:296035
TITLE: Preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators
INVENTOR(S): Mathews, Ian Richard
PATENT ASSIGNEE(S): Avidex Limited, UK
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081011	A1	20040923	WO 2004-GB1008	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220310	A1	20040923	AU 2004-220310	20040310
CA 2519063	A1	20040923	CA 2004-2519063	20040310
EP 1603917	A1	20051214	EP 2004-719006	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008365	A	20060321	BR 2004-8365	20040310
CN 1761664	A	20060419	CN 2004-80006886	20040310
JP 2006520372	T	20060907	JP 2006-505937	20040310
MX 2005PA09667	A	20060127	MX 2005-PA9667	20050909
NO 2005004710	A	20051213	NO 2005-4710	20051013
IN 2005CN02624	A	20070406	IN 2005-CN2624	20051013
US 20070021428	A1	20070125	US 2006-547448	20060620
US 7276505	B2	20071002		
US 20080045527	A1	20080221	US 2007-845837	20070828

PRIORITY APPLN. INFO.:
GB 2003-5876 A 20030314
GB 2003-19429 A 20030819
WO 2004-GB1008 W 20040310
US 2006-547448 A3 20060620

OTHER SOURCE(S): MARPAT 141:296035
GI

L4 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Title compds. [I; R1, R3 = H, F, Cl, Br, NO2, cyano, alkyl, fluoroalkyl, chloroalkyl, alkoxy, fluoroalkoxy; R4 = CO2H (ester), CONR6R7, NR7COR6, NR7COOR6, NHCONR6R7, NHCSNR6R7; R6 = H, (Alk)mQ; m = 0, 1; Alk = (substituted) alkylene, alkenylene, alkynylene, carbocyclylene which may contain ≥1 O, S, NR8; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl; Q = H, NR9R10; R9, R10 = H, alkyl, alkenyl, alkynyl, cycloalkyl, ester group, (substituted) carbocyclyl, heterocyclyl; R9R10N = (substituted) heterocyclyl; R7 = H, alkyl; R6R7 = atoms to form (substituted) heterocyclyl; X = bond, (Z)n(Alk), (Alk)(Z)n; Z = O, S, NH; n = 0, 1], were prepared Thus, 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoic acid (preparation given) was stirred with DMF, diisopropylethylamine, 3-dimethylaminopropylamine, and HTBU at room temperature for 2 h to give 40% N-[(3-dimethylamino)propyl] 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzamide (AV1142005). The latter inhibited interleukin-2 production by human Jurkat T cells by 65% at 30 μM.

IT 763147-07-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators)

RN 763147-07-5 CAPLUS
CN Quinoline, 1-[4-(6-fluoro-1,3-dihydro-3-oxo-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:633903 CAPLUS
DOCUMENT NUMBER: 141:173975
TITLE: Preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
INVENTOR(S): Coppola, Gary Mark; Damon, Robert Edson; Kukkola, Paivi Jaana; Stanton, James Lawrence
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065351	A1	20040805	WO 2004-EP571	20040123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
CA 2513349	A1	20040805	CA 2004-2513349	20040123
EP 1590319	A1	20051102	EP 2004-704554	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006938	A	20060103	BR 2004-6938	20040123
CN 1741986	A	20060301	CN 2004-80002540	20040123
JP 2006517199	T	20060720	JP 2006-500009	20040123
US 20060205772	A1	20060914	US 2005-542759	20050816
PRIORITY APPLN. INFO.:			US 2003-442532P P	20030124
			WO 2004-EP571 W	20040123

OTHER SOURCE(S): MARPAT 141:173975
GI

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. [I; R1, R2 = H, CN, halo, NO2, etc.; or R1 and R2 together with the carbon atoms they are attached to form an optionally substituted 5-7 membered (hetero)aromatic ring; R3 = alkyl; or R3 and R2 together with the amide group to which R3 is attached and the carbon atoms to which R2 and the amide are attached form (un)substituted 5-7 membered carbocyclic or heterocyclic ring; R4 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; or NR4R3 = (un)substituted 5-8 membered ring, 8-12 membered fused bicyclic ring (both ring systems may contain another heteroatom selected from O, N and S); W = NR5COR6, NR5CO2R6, NR5CONR6R7, etc.; R5, R7 = H, alkyl, aralkyl; R6 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; X, Y = CH, N; or X:Y = CH2, O, S, NR10 (R10 = H, alkyl)] which lower intracellular glucocorticoid concns. in mammals, in particular, intracellular cortisol levels in humans, were prepared E.g., two alternative routes for preparation of the amide II were given. The compds.
I were tested for inhibition of 11β-HSD1 (specific data given for representative compds. I). The compds. I improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compds. I lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compds.I may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compds. I may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compds. I for the preparation of medicaments, in

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
particular of medicaments useful for the treatment and prevention of glucocorticoid assocd. disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid prodn., and by decreasing visceral adipose tissue formation.
IT 735344-54-4P 735344-55-5P 735344-56-6P
735344-57-7P 735344-58-8P 735344-59-9P
735344-60-2P 735344-61-3P 735344-62-4P
735344-63-5P 735344-64-6P 735344-65-7P
735344-66-8P 735344-67-9P 735344-68-0P
735344-69-1P 735344-70-4P 735344-71-5P
735344-72-6P 735344-73-7P 735344-74-8P
735344-75-9P 735344-76-0P 735344-77-1P
735344-78-2P 735344-79-3P 735344-80-6P
735344-81-7P 735344-82-8P 735344-83-9P
735344-84-0P 735344-85-1P 735344-86-2P
735344-87-3P 735344-88-4P 735344-89-5P
735344-90-8P 735344-91-9P 735344-92-0P
735344-93-1P 735344-94-2P 735344-95-3P
735344-96-4P 735344-97-5P 735344-98-6P
735344-99-7P 735345-00-3P 735345-01-4P
735345-02-5P 735345-03-6P 735345-04-7P
735345-05-8P 735345-06-9P 735345-07-0P
735345-08-1P 735345-09-2P 735345-10-5P
735345-11-6P 735345-12-7P 735345-13-8P
735345-14-9P 735345-15-0P 735345-16-1P
735345-17-2P 735345-18-3P 735345-19-4P
735345-20-7P 735345-21-8P 735345-22-9P
735345-23-0P 735345-24-1P 735345-25-2P
735345-26-3P 735345-27-4P 735345-28-5P
735345-29-6P 735345-30-9P 735345-31-0P
735345-32-1P 735345-33-2P 735345-34-3P
735345-35-4P 735345-36-5P 735345-37-6P
735345-38-7P 735345-39-8P 735345-40-1P
735345-41-2P 735345-42-3P 735345-43-4P
735345-44-5P 735345-45-6P 735345-46-7P
735345-47-8P 735345-48-9P 735345-49-0P
735345-50-3P 735345-51-4P 735345-52-5P
735345-53-6P 735345-54-7P 735345-55-8P
735345-56-9P 735345-57-0P 735345-58-1P
735345-59-2P 735345-60-5P 735345-61-6P
735345-62-7P 735345-63-8P 735345-64-9P
735345-65-0P 735345-66-1P 735345-67-2P
735345-68-3P 735345-69-4P 735345-70-7P
735345-71-8P 735345-72-9P 735345-73-0P
735345-74-1P 735345-75-2P 735345-76-3P
735345-77-4P 735345-78-5P 735345-79-6P
735345-80-9P 735345-81-0P 735345-82-1P
735345-83-2P 735345-84-3P 735345-85-4P
735345-86-5P 735345-87-6P 735345-88-7P
735345-89-8P 735345-90-1P 735345-91-2P
735345-92-3P 735345-93-4P 735345-94-5P
735345-95-6P 735345-96-7P 735345-97-8P
735345-98-9P 735345-99-0P 735346-00-6P
735346-01-7P 735346-02-8P 735346-03-9P
735346-04-0P 735346-05-1P 735346-06-2P
735346-07-3P 735346-08-4P 735346-09-5P
735346-10-8P 735346-11-9P 735346-12-0P
735346-13-1P 735346-14-2P 735346-15-3P

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
735346-16-4P 735346-17-5P 735346-18-6P
735346-19-7P 735346-20-0P 735346-21-1P
735346-22-2P 735346-23-3P 735346-24-4P
735346-25-5P 735346-26-6P 735346-27-7P
735346-28-8P 735346-29-9P 735346-30-2P
735346-31-3P 735346-32-4P 735346-33-5P
735346-34-6P 735346-35-7P 735346-36-8P
735346-37-9P 735346-38-0P 735346-39-1P
735346-40-4P 735346-41-5P 735346-42-6P
735346-43-7P 735346-44-8P 735346-45-9P
735346-46-0P 735346-47-1P 735346-48-2P
735346-49-3P 735346-50-6P 735346-51-7P
735346-52-8P 735346-53-9P 735346-54-0P
735346-55-1P 735346-56-2P 735346-57-3P
735346-58-4P 735346-59-5P 735346-60-8P
735346-61-9P 735346-62-0P 735346-63-1P
735346-64-2P 735346-65-3P 735346-66-4P
735346-67-5P 735346-68-6P 735346-69-7P
735346-70-0P 735346-71-1P 735346-72-2P
735346-73-3P 735346-74-4P 735346-75-5P
735346-76-6P 735346-77-7P 735346-78-8P
735346-79-9P 735346-80-2P 735346-81-3P
735346-82-4P 735346-83-5P 735346-84-6P
735346-85-7P 735346-86-8P 735346-87-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)
RN 735344-54-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-55-5 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-56-6 CAPLUS
CN Quinoline, decahydro-1-[4-[[(4-methoxyphenyl)sulfonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-57-7 CAPLUS
CN Benzamide, 3,5-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-58-8 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-59-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-60-2 CAPLUS
CN 1-Naphthalenecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-61-3 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-62-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-63-5 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-64-6 CAPLUS
CN Quinoline, 1-[4-[[(4-fluorophenyl)sulfonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-65-7 CAPLUS
CN Benzoic acid, 4-[[[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]amino]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-66-8 CAPLUS
CN Benzamide, 4-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-67-9 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-68-0 CAPLUS
CN Benzamide, 4-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-69-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-70-4 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-71-5 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-72-6 CAPLUS
CN Benzamide, 4-cyano-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-73-7 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-74-8 CAPLUS
CN Benzamide, 3,4-dimethoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-75-9 CAPLUS
CN Quinoline, 1-[4-[[[(2-cyanophenyl)amino]thioxomethyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-76-0 CAPLUS
CN Quinoline, decahydro-1-[4-[[[(3-nitrophenyl)amino]thioxomethyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-77-1 CAPLUS
CN Benzamide, 2-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-78-2 CAPLUS
CN Quinoline, decahydro-1-[4-[[[[2-(1-piperidinyl)ethyl]amino]thioxomethyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-79-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-80-6 CAPLUS
CN Benzoic acid, 4-[[[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]amino]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-81-7 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-82-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-83-9 CAPLUS
CN Quinoline, decahydro-1-[4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-84-0 CAPLUS
CN Quinoline, decahydro-1-[4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-85-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-86-2 CAPLUS
CN Quinoline, 1-[4-[[(4-fluorophenyl)methyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-87-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-88-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]amino]carbonyl]-, phenylmethyl ester, (2S)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-89-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-90-8 CAPLUS
CN Quinoline, 1-[4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735344-91-9 CAPLUS
CN Benzamide, 2-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-92-0 CAPLUS
CN Benzamide, 2,6-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-93-1 CAPLUS
CN Pentanamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-94-2 CAPLUS
CN Cyclopentanepropanamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-95-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-96-4 CAPLUS
CN Benzamide, 4-fluoro-N-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735344-97-5 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735344-98-6 CAPLUS
CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 735344-99-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-00-3 CAPLUS
CN Benzamide, 4-(methylsulfonyl)-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735345-01-4 CAPLUS
CN Benzamide, 2,4-difluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-02-5 CAPLUS
CN Benzamide, 4-chloro-2-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-03-6 CAPLUS
CN 1-Naphthalenecarboxamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-04-7 CAPLUS
CN Quinoline,
decahydro-1-[4-[[[(2-methoxyethyl)amino]carbonyl]amino]benzoyl]-
, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-05-8 CAPLUS
CN Quinoline,
decahydro-1-[4-[[[(3-hydroxypropyl)amino]carbonyl]amino]benzoyl
]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-08-1 CAPLUS
CN Quinoline,
1-[4-[[[(1-ethylpropyl)amino]carbonyl]amino]benzoyl]decahydro-,
(4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-09-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-06-9 CAPLUS
CN Quinoline, 1-[4-[[(hexylamino)carbonyl]amino]benzoyl]decahydro-,
(4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-07-0 CAPLUS
CN Quinoline, 1-[4-[[(cyclohexylamino)carbonyl]amino]benzoyl]decahydro-,
(4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-10-5 CAPLUS
CN Benzamide, 4-chloro-2-nitro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-11-6 CAPLUS
CN 3-Furancarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-12-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-13-8 CAPLUS
CN Benzamide, 3-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-14-9 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-15-0 CAPLUS
CN Benzamide, 2,4-dimethoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-16-1 CAPLUS
CN Benzamide, 4-methyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-17-2 CAPLUS
CN Benzamide, 2-chloro-4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-18-3 CAPLUS
CN Benzamide, 4-(4-methyl-2-oxo-3-oxazolidinyl)-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-19-4 CAPLUS
CN Benzamide, 4-chloro-2-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-20-7 CAPLUS
CN Benzamide, 4-(aminosulfonyl)-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-21-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-24-1 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-propyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-25-2 CAPLUS
CN Benzamide, 3-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-22-9 CAPLUS
CN Quinoline, 1-[4-[[[(2,6-diethylphenyl)amino]carbonyl]amino]benzoyl]decahydro- (9CI) (CA INDEX NAME)



RN 735345-23-0 CAPLUS
CN Quinoline, decahydro-1-[4-[[[(2-methylpropyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-26-3 CAPLUS
CN Benzeneacetamide, α-hydroxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (αR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-27-4 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 735345-28-5 CAPLUS
CN Benzeneacetamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-29-6 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-30-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-butyl-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-31-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-(hexyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-32-1 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[(propylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-33-2 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-34-3 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[(2-phenylethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-35-4 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]de
cahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-36-5 CAPLUS
CN Quinoline, 1-[4-[[(butylamino)carbonyl]amino]-2-chlorobenzoyl]decahydro-,
(4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-37-6 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[(pentylamino)carbonyl]amino]benzoyl]decahydro-,
(4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-38-7 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-4-hexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-39-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-40-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]-4-
(pentyloxy)- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-41-2 CAPLUS
CN Benzamide, 2-chloro-N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-42-3 CAPLUS
CN Cyclohexanecarboxamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-
quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-43-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-cyano-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-44-5 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[(cyclohexylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-47-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-48-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-45-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-46-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735345-49-0 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-50-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-51-4 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-52-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-53-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-54-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-chlorophenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-55-8 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(2-ethoxyphenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-56-9 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-57-0 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-58-1 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-59-2 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-60-5 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[(2,4-difluorophenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-61-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-fluorophenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-62-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-63-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-64-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-65-0 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-66-1 CAPLUS
CN Quinoline,
1-[2-chloro-4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-67-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-68-3 CAPLUS
CN Benzamide, 4-cyano-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-69-4 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-72-9 CAPLUS
CN Benzamide, 4-chloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-73-0 CAPLUS
CN Cyclopentaneacetamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-70-7 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-71-8 CAPLUS
CN Benzamide, 4-hexyl-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-74-1 CAPLUS
CN Butanamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-3,3-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-75-2 CAPLUS
CN Quinoline, 1-[4-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-2-methoxybenzoyl]decahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-76-3 CAPLUS
CN Quinoline,
decahydro-1-[2-methoxy-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-77-4 CAPLUS
CN Quinoline,
decahydro-1-[2-methoxy-4-[[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-80-9 CAPLUS
CN Quinoline, 1-[4-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-81-0 CAPLUS
CN Quinoline, 1-[4-[[[(2,4-difluorophenyl)amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-78-5 CAPLUS
CN Quinoline, 1-[4-[[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-79-6 CAPLUS
CN Quinoline, 1-[4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-82-1 CAPLUS
CN Quinoline,
decahydro-1-[2-methoxy-4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-83-2 CAPLUS
CN Quinoline, 1-[4-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-84-3 CAPLUS
CN Benzamide, 4-fluoro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-85-4 CAPLUS
CN Benzamide, 4-(dimethylamino)-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-88-7 CAPLUS
CN Cyclopentanepropanamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-89-8 CAPLUS
CN Benzamide, 4-butoxy-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-86-5 CAPLUS
CN Cyclohexanecarboxamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-87-6 CAPLUS
CN 2-Thiopheneacetamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-90-1 CAPLUS
CN Benzamide, 4-methoxy-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-91-2 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-92-3 CAPLUS
CN Benzamide, 3,4-difluoro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735345-93-4 CAPLUS
CN Quinoline, decahydro-1-[2-methoxy-4-[[[(2-phenylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-94-5 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-95-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735345-96-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-97-8 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735345-98-9 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735345-99-0 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-00-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-01-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (1R,2S,5S)-2-methyl-5-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-02-8 CAPLUS
CN Benzamide, 2,4-difluoro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-03-9 CAPLUS
CN Quinoline, decahydro-1-[2-methoxy-4-[[(propylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-04-0 CAPLUS
CN Quinoline, decahydro-1-[2-methoxy-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-05-1 CAPLUS
CN Quinoline, 1-[4-[[(butylamino)carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-06-2 CAPLUS
CN Quinoline, decahydro-1-[2-methoxy-4-[[(pentylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-07-3 CAPLUS
CN Quinoline, 1-[4-[[(cyclohexylamino)carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-08-4 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735346-09-5 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-10-8 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-11-9 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-14-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[2-methoxy-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-15-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]methyl-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-12-0 CAPLUS
CN Benzamide, 4-fluoro-N-[2-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-13-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[2-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-16-4 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[(3-methoxyphenyl)amino]carbonyl]methylamino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-17-5 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]methylamino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-18-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-19-7 CAPLUS
CN Benzamide,
4-methoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-22-2 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-23-3 CAPLUS
CN 2-Furancarboxamide,
N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-20-0 CAPLUS
CN Benzamide,
4-fluoro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-21-1 CAPLUS
CN Benzamide,
4-chloro-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-24-4 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-25-5 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735346-26-6 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-27-7 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-28-8 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-29-9 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-3-propoxyphenyl]-, 4-fluorophenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-30-2 CAPLUS
CN Benzamide, N-[2-(acetylamino)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-2,4-dichloro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-31-3 CAPLUS
CN Benzamide, N-[2-(benzoylamino)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-2,4-dichloro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-32-4 CAPLUS
CN Quinoline, decahydro-1-[4-(1-piperidinylcarbonyl)benzoyl]-, (4aR,8aS)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-33-5 CAPLUS
CN Benzamide, N-(4-methylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-34-6 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-35-7 CAPLUS
CN Benzamide, N-hexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-36-8 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(4-pyridinylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-37-9 CAPLUS
CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-38-0 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[1-(phenylmethyl)-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-39-1 CAPLUS
CN Benzamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-40-4 CAPLUS
CN Benzamide, N-methyl-N-(1-methyl-4-piperidinyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-41-5 CAPLUS
CN Benzamide, N-(2-hydroxy-2-phenylethyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-42-6 CAPLUS
CN Benzamide, N-cyclohexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-43-7 CAPLUS
CN Benzamide, N-[(4-methylphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-44-8 CAPLUS
CN Benzamide, N-(2,2-diphenylethyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-45-9 CAPLUS
CN Benzamide, N-(2-methylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-46-0 CAPLUS
CN Benzamide, N-(2-methylbutyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-47-1 CAPLUS
CN Benzamide, N-[2-(acetylamino)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-48-2 CAPLUS
CN Benzamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-49-3 CAPLUS
CN Benzamide, N-[2-(2-chlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-50-6 CAPLUS
CN Benzamide, N-[2-(3-methoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-51-7 CAPLUS
CN Benzamide,
N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-52-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]benzoyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-53-9 CAPLUS
CN Benzamide, N-methyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-54-0 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(3-pyridinylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-55-1 CAPLUS
CN Benzamide,
4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-56-2 CAPLUS
CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-57-3 CAPLUS
CN Benzamide, N-[3-(methylphenylamino)propyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-58-4 CAPLUS
CN Benzamide, N-(3,3-diphenylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-59-5 CAPLUS
CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-60-8 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-N-methyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-61-9 CAPLUS
CN Benzamide, N-(cyclohexylmethyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-62-0 CAPLUS
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-63-1 CAPLUS
CN Benzamide, N-[2-(2-fluorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-64-2 CAPLUS
CN Benzamide, N-[2-(2,5-dimethoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-65-3 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[2-(4-

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenoxyphenyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-66-4 CAPLUS
CN Benzamide, N-[2-(4-ethoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-67-5 CAPLUS
CN Benzamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-68-6 CAPLUS

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzamide, N-(1-methylethyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-69-7 CAPLUS
CN Benzamide, N-(2-chlorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-70-0 CAPLUS
CN Benzamide, N-(4-butylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-71-1 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-72-2 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[(tetrahydro-2-furanyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-73-3 CAPLUS
CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-74-4 CAPLUS
CN Benzamide, N-[(2-fluorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-75-5 CAPLUS
CN Benzamide, N-[(2,4-dichlorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-76-6 CAPLUS
CN Benzamide, N-[(2-methoxyphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-77-7 CAPLUS
CN Benzamide, N-[(2-ethoxyphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-78-8 CAPLUS
CN Benzamide, N-[(3-fluorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-79-9 CAPLUS
CN Benzamide, N-[(2-methylphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-80-2 CAPLUS
CN Benzamide, N-[(3,4-dichlorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-81-3 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-82-4 CAPLUS
CN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-85-7 CAPLUS
CN L-Proline, 1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 735346-86-8 CAPLUS
CN L-Proline, 1-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]benzoyl]- (CA INDEX
NAME)

Absolute stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-83-5 CAPLUS
CN Benzamide, N-[(3-methylphenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-84-6 CAPLUS
CN Benzamide, N-(4-cyanophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-87-9 CAPLUS
CN Quinoline,
1-[4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 735346-88-0P 735346-89-1P 735346-90-4P
735346-91-5P 735346-92-6P 735346-93-7P
735346-94-8P 735346-95-9P 735346-96-0P
735346-97-1P 735346-98-2P 735346-99-3P
735347-02-1P 735347-03-2P 735347-04-3P
735347-05-4P 735347-06-5P 735347-07-6P
735347-08-7P 735347-09-8P 735347-10-1P
735347-11-2P 735347-12-3P 735347-13-4P
735347-14-5P 735347-15-6P 735347-16-7P
735347-17-8P 735347-18-9P 735347-19-0P
735347-20-3P 735347-21-4P 735347-22-5P
735347-23-6P 735347-24-7P 735347-25-8P
735347-26-9P 735347-27-0P 735347-28-1P
735347-29-2P 735347-30-5P 735347-31-6P
735347-32-7P 735347-33-8P 735347-34-9P
735347-35-0P 735347-36-1P 735347-37-2P
735347-38-3P 735347-39-4P 735347-40-7P
735347-41-8P 735347-42-9P 735347-43-0P
735347-44-1P 735347-45-2P 735347-46-3P

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
735347-47-4P 735347-48-5P 735347-49-6P
735347-50-9P 735347-51-0P 735347-52-1P
735347-53-2P 735347-54-3P 735347-55-4P
735347-56-5P 735347-57-6P 735347-58-7P
735347-60-1P 735347-61-2P 735347-62-3P
735347-63-4P 735347-64-5P 735347-65-6P
735347-66-7P 735347-67-8P 735347-68-9P
735347-69-0P 735347-70-3P 735347-71-4P
735347-72-5P 735347-73-6P 735347-74-7P
735347-75-8P 735347-76-9P 735347-77-0P
735347-78-1P 735347-79-2P 735347-80-5P
735347-81-6P 735347-82-7P 735347-83-8P
735347-84-9P 735347-85-0P 735347-86-1P
735347-87-2P 735347-89-4P 735347-91-8P
735347-92-9P 735347-93-0P 735347-94-1P
735347-95-2P 735347-96-3P 735347-97-4P
735347-98-5P 735347-99-6P 735348-00-2P
735348-01-3P 735348-02-4P 735348-31-9P
735348-32-0P 735348-33-1P 735348-34-2P
735348-35-3P 735348-36-4P 735348-37-5P
735348-38-6P 735348-39-7P 735348-40-0P
735348-41-1P 735348-42-2P 735348-43-3P
735348-44-4P 735348-45-5P 735348-46-6P
735348-47-7P 735348-48-8P 735348-49-9P
735348-50-2P 736142-29-3P 736142-30-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)

RN 735346-88-0 CAPLUS
CN Benzamide, N-(cyclohexylmethyl)-N-methyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-89-1 CAPLUS

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-90-4 CAPLUS
CN Quinoline, decahydro-1-[4-(4-morpholinylcarbonyl)benzoyl]-, (4aR,8aS)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735346-91-5 CAPLUS
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-92-6 CAPLUS
CN Benzamide, N-(4-ethylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-93-7 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(4-propylphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-94-8 CAPLUS
CN Benzamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(4-pentylphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-95-9 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-96-0 CAPLUS
CN Benzamide, N-[(4-chlorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-97-1 CAPLUS
CN Benzamide, N-(4-heptylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735346-98-2 CAPLUS
CN Benzamide, N-(4-butyl-2-methylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735346-99-3 CAPLUS
CN Benzamide, 2-(acetylamino)-N-(2-methylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-02-1 CAPLUS
CN Benzamide, 3,4-dimethoxy-N-[4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-03-2 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-04-3 CAPLUS
CN Benzamide, 4-hexyl-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-05-4 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-06-5 CAPLUS
CN Benzamide, 2-chloro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-07-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-10-1 CAPLUS
CN Benzamide, 3,4-difluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-11-2 CAPLUS
CN Benzamide, 3-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-08-7 CAPLUS
CN Benzamide, 4-butyl-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-09-8 CAPLUS
CN Benzamide, 2,4-difluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-12-3 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 735347-13-4 CAPLUS
CN Benzamide, N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-pentyl- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-14-5 CAPLUS
CN Benzamide, 2-methoxy-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-15-6 CAPLUS
CN Benzamide, N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-phenoxy- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-16-7 CAPLUS
CN Benzamide, 4-methoxy-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-17-8 CAPLUS
CN 1-Naphthalenecarboxamide, N-(4-fluorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735347-18-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-(2-methylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-19-0 CAPLUS
CN 1-Naphthalenecarboxamide, N-cyclohexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-20-3 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(4-methoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-21-4 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[1-(phenylmethyl)-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-22-5 CAPLUS
CN 1-Naphthalenecarboxamide, N-decyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-23-6 CAPLUS
CN 1-Naphthalenecarboxamide, N-[(4-chlorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-26-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(4-ethoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-27-0 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[2-(4-phenoxyphenyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-24-7 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-25-8 CAPLUS
CN 1-Naphthalenecarboxamide, N-methyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-28-1 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-29-2 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[2-(4-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-30-5 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(3-chlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-31-6 CAPLUS
CN 1-Naphthalenecarboxamide, N-[(2-fluorophenyl)methyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-34-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(2-chlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-35-0 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-32-7 CAPLUS
CN 1-Naphthalenecarboxamide, N-(2-methylbutyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-33-8 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[2-(2-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-36-1 CAPLUS
CN 1-Naphthalenecarboxamide, N-(4-cyanophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-37-2 CAPLUS
CN 1-Naphthalenecarboxamide, N-(4-butylphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-38-3 CAPLUS
CN 1-Naphthalenecarboxamide, N-[1,1'-biphenyl]-4-yl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-39-4 CAPLUS
CN Quinoline, decahydro-1-[[4-(1-piperidinylcarbonyl)-1-naphthalenyl]carbonyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-42-9 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-(3-phenylpropyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-43-0 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(3-methoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-40-7 CAPLUS
CN 1-Naphthalenecarboxamide, N-(2,4-dichlorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-41-8 CAPLUS
CN 1-Naphthalenecarboxamide, N-hexyl-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-44-1 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(2-methoxyphenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-45-2 CAPLUS
CN 1-Naphthalenecarboxamide, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-[2-(3-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-46-3 CAPLUS
CN Quinoline, decahydro-1-[[4-[(4-phenyl-1-piperidinyl)carbonyl]-1-naphthalenyl]carbonyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-47-4 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-50-9 CAPLUS
CN 1-Naphthalenecarboxamide, N-(3,4-dimethoxyphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-51-0 CAPLUS
CN 1-Naphthalenecarboxamide, N-(4-methoxyphenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-48-5 CAPLUS
CN 1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)ethyl]-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-49-6 CAPLUS
CN 1-Naphthalenecarboxamide, N-(2-chlorophenyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-52-1 CAPLUS
CN Carbamic acid, (2-phenylethyl)-, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-53-2 CAPLUS
CN Quinoline, decahydro-1-[4-(1H-pyrrol-1-yl)benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-54-3 CAPLUS
CN Quinoline, 1-[[6-(acetyloxy)-2-naphthalenyl]carbonyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-55-4 CAPLUS
CN Quinoline, decahydro-1-[4-(1-methylethoxy)benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-56-5 CAPLUS
CN Quinoline, decahydro-1-(2-naphthalenylcarbonyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-57-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-methylpropyl)-6-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-58-7 CAPLUS
CN Quinoline, 1-[[6-(acetyloxy)-2-naphthalenyl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-60-1 CAPLUS
CN Quinoline, 1-[[1-(4-fluorobenzoyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735347-61-2 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(4-methoxybenzoyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-62-3 CAPLUS
CN Quinoline, 1-[(1-benzoyl-2,3-dihydro-1H-indol-5-yl)carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-63-4 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N,N-dimethyl-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-64-5 CAPLUS
CN Quinoline, 1-[[1-(2,4-dichlorobenzoyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-65-6 CAPLUS
CN Quinoline, 1-[[1-(4-chlorobenzoyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-66-7 CAPLUS
CN Quinoline, 1-[[1-[4-(hexyloxy)benzoyl]-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-67-8 CAPLUS
CN Quinoline, 1-[[1-(4-hexylbenzoyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-68-9 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-propyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-69-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, phenyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-70-3 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-methyl-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-71-4 CAPLUS
CN 1H-Indole-1-carboxamide, N-ethyl-2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-72-5 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-(3-methoxyphenyl)-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-73-6 CAPLUS
CN 1H-Indole-1-carboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-76-9 CAPLUS
CN Quinoline, 1-[[1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-77-0 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-(1-methylethyl)-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-74-7 CAPLUS
CN Quinoline, 1-[[1-(2-furanylcarbonyl)-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-75-8 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(2-thienylcarbonyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-78-1 CAPLUS
CN 1H-Indole-1-carboxamide, N-cyclohexyl-2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-79-2 CAPLUS
CN 1H-Indole-1-carboxamide, N-[(4-fluorophenyl)methyl]-2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-80-5 CAPLUS
CN 1H-Indole-1-carboxamide, N-(4-fluorophenyl)-2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-81-6 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-[(4-methoxyphenyl)methyl]-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-82-7 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-1-naphthalenyl-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-83-8 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, 2-methoxyethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-84-9 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, propyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-85-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-86-1 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-87-2 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(2-methoxybenzoyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-89-4 CAPLUS
CN Quinoline, 1-[[1-[(6-chloro-3-pyridinyl)carbonyl]-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-91-8 CAPLUS
CN Quinoline, 1-[[1-[(2-chloro-3-pyridinyl)carbonyl]-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-94-1 CAPLUS
CN 1H-Indole-1-carboxamide, 2,3-dihydro-N-methyl-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-N-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-95-2 CAPLUS
CN Quinoline, 1-[[1-[(4-fluorophenyl)sulfonyl]-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-92-9 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(4-pyridinylcarbonyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-93-0 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(2-pyridinylcarbonyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-96-3 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-97-4 CAPLUS
CN Quinoline, 1-[[1-[(2,4-dichlorophenyl)sulfonyl]-2,3-dihydro-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735347-98-5 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(methylsulfonyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735347-99-6 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, 2-methylpropyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-02-4 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, 4-(methoxycarbonyl)phenyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-31-9 CAPLUS
CN Quinoline, decahydro-1-[3-[[(phenylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-00-2 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, 2,2-dimethylpropyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-01-3 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-1-(2-thienylsulfonyl)-1H-indol-5-yl]carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-32-0 CAPLUS
CN Quinoline, 1-[3-[[(cyclohexylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-33-1 CAPLUS
CN Quinoline, 1-[3-[[[(3-chlorophenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-34-2 CAPLUS
CN Cyclohexanecarboxamide, N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-35-3 CAPLUS
CN Benzamide, 3,4-dimethoxy-N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-36-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-37-5 CAPLUS
CN Quinoline, 1-[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-38-6 CAPLUS
CN Quinoline, decahydro-1-[3-[[[[2-(1-piperidinyl)ethyl]amino]thioxomethyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-39-7 CAPLUS
CN Benzoic acid, 3-[[[[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]amino]thioxomethyl]amino]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-40-0 CAPLUS
CN Quinoline, 1-[3-[[[(2-cyanophenyl)amino]thioxomethyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-41-1 CAPLUS
CN Quinoline, decahydro-1-[3-[[[(3-nitrophenyl)amino]thioxomethyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-42-2 CAPLUS
CN Benzamide, 4-cyano-N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-43-3 CAPLUS
CN Benzamide, N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-44-4 CAPLUS
CN Benzamide, 4-chloro-N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-45-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735348-46-6 CAPLUS
CN Propanamide, 2-methyl-N-[3-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-47-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,6R,8aR)-octahydro-6-hydroxy-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-48-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,6S,8aR)-octahydro-6-hydroxy-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-49-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,6R,8aR)-octahydro-6-hydroxy-6-methyl-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-50-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aR)-octahydro-6,6-dimethyl-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 736142-29-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 736142-30-6 CAPLUS
CN Benzamide, N-(2-methylpropyl)-4-[[(4aR,8aR)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 735351-86-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)
RN 735351-86-7 CAPLUS
CN Quinoline, 1-(4-amino-2-chlorobenzoyl)decahydro- (9CI) (CA INDEX NAME)



IT 735351-41-4P 735351-42-5P 735351-43-6P
735351-44-7P 735351-45-8P 735351-46-9P
735351-49-2P 735351-50-5P 735351-51-6P
735351-52-7P 735351-53-8P 735351-54-9P
735351-55-0P 735351-58-3P 735351-59-4P
735351-65-2P 735351-66-3P 735351-67-4P
735351-68-5P 735351-79-8P 735351-80-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)
RN 735351-41-4 CAPLUS

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Quinoline, decahydro-1-(4-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-42-5 CAPLUS
CN Quinoline, decahydro-1-(4-nitrobenzoyl)-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-43-6 CAPLUS
CN Quinoline, 1-(4-aminobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735351-44-7 CAPLUS
CN Quinoline, 1-(4-aminobenzoyl)decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-45-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]methyl-, 2-propenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-46-9 CAPLUS
CN Quinoline, 1-[2-chloro-4-(methylamino)benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-49-2 CAPLUS
CN Quinoline, decahydro-1-[4-nitro-2-(2-propenyloxy)benzoyl]- (9CI) (CA INDEX NAME)



RN 735351-50-5 CAPLUS
CN Quinoline, 1-(4-amino-2-propoxybenzoyl)decahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-54-9 CAPLUS
CN Benzoic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-55-0 CAPLUS
CN Benzoic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735351-51-6 CAPLUS
CN Quinoline, 1-(4-amino-3-nitrobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-52-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[2-nitro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-53-8 CAPLUS
CN Benzamide, N-[2-amino-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]phenyl]-2,4-dichloro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-58-3 CAPLUS
CN Benzamide, N-(2-methylpropyl)-2-nitro-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-59-4 CAPLUS
CN Benzamide, 2-amino-N-(2-methylpropyl)-4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735351-65-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-66-3 CAPLUS
CN 1-Naphthalenecarboxylic acid, 4-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735351-67-4 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-80-1 CAPLUS
CN Quinoline, 1-(4-aminobenzoyl)decahydro-6,6-dimethyl-, (4aR,8aR)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735351-68-5 CAPLUS
CN Quinoline, 1-[(2,3-dihydro-1H-indol-5-yl)carbonyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735351-79-8 CAPLUS
CN Quinoline, decahydro-6,6-dimethyl-1-(4-nitrobenzoyl)-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:356930 CAPLUS
DOCUMENT NUMBER: 141:332023
TITLE: Angularly Substituted Octahydroindoles, Decahydroquinolines, Octahydropyrindines, and Octahydrocyclopenta[b]pyrroles by Bruylants Reaction
AUTHOR(S): Reimann, Eberhard; Ettmayr, Christian; Polborn, Kurt
CORPORATE SOURCE: Zentrum fuer Pharmaforschung, Department Pharmazie, Ludwig-Maximilians-Universitaet Muenchen, Muenich, D-81377, Germany
SOURCE: Monatshefte fuer Chemie (2004), 135(5), 557-579
CODEN: MOCMB7; ISSN: 0026-9247
PUBLISHER: Springer-Verlag Wien
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:332023
GI

AB The easily available cycloalkanoyl acetic- and propionic acid esters are transformed to the corresponding amines by standard procedures. These in turn provided an efficient access to cyclic α-aminonitriles, which were reacted with a series of Grignard reagents yielding stereoselectively the cis-configured title compds., such as I and II; the scope and limitation of this route were investigated. The stereochem. assignment was achieved by X-ray crystallog. and NMR spectroscopy.

IT 770714-02-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of angularly substituted octahydroindoles, decahydroquinolines, octahydropyrindines, and octahydrocyclopenta[b]pyrroles by Bruylants reaction)

RN 770714-02-8 CAPLUS
CN 8a(1H)-Quinolinecarbonitrile, 1-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:376830 CAPLUS
DOCUMENT NUMBER: 138:385441
TITLE: Preparation of quinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040108	A1	20030515	WO 2002-GB4931	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465068	A1	20030515	CA 2002-2465068	20021031
AU 2002341156	A1	20030519	AU 2002-341156	20021031
EP 1444210	A1	20040811	EP 2002-774960	20021031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013842	A	20040831	BR 2002-13842	20021031
HU 2004001646	A2	20041228	HU 2004-1646	20021031
CN 1585754	A	20050223	CN 2002-826384	20021031
JP 2005515176	T	20050526	JP 2003-542154	20021031
NZ 532524	A	20070223	NZ 2002-532524	20021031
IN 2004DN01092	A	20050401	IN 2004-DN1092	20040423
MX 2004PA04219	A	20040910	MX 2004-PA4219	20040503
NO 2004002279	A	20040602	NO 2004-2279	20040602
US 20050043336	A1	20050224	US 2004-494137	20041006
US 20070082921	A1	20070412	US 2006-443208	20060531

PRIORITY APPLN. INFO.:
GB 2001-26433 A 20011103
GB 2001-29059 A 20011205
WO 2002-GB4931 W 20021031
US 2004-494137 B1 20041006

OTHER SOURCE(S): MARPAT 138:385441
GI

L4 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II

AB Anilino-, indolylamino-, and benzopyrazolylamino-substituted quinazolines I [wherein R1, R2, R3, and R6 = independently H or alkyl; Z = a bond, O, S, or NR2; Q1 = (un)substituted cycloalkyl(alkyl), cycloalkyl(alkenyl), cycloalkyl(alkynyl), or heterocyclyl(alkyl); with the proviso that alkylene chains within Q1Z are optionally interrupted by O, S, SO, SO2, NR3, CO, CHOR3, CONR3, NR3CO, SO2NR3, NR3SO2, CH=CH, or C.tplbond.C; Q2 = (un)substituted C6H4-4-X2Q2, 1-(X3Q4)indol-5-yl, 1-(X3Q4)-indol-6-yl, 1-(X3Q4)-1H-benzopyrazol-5-yl, or 1-(X3Q4)-1H-benzopyrazol-6-yl; X2 = a bond, O, S, SO, SO2, NR6, CHOR6, CONR6, NR6CO, SO2NR6, NR6SO2, OC(R6)2, C(R6)2O, SC(R6)2, C(R6)2S, CO, C(R6)2NR6, or NR6C (R6)2; or X2Q3 = heterocyclylcarbonyl; X3 = a bond, SO2, CO, SO2NR7, or C(R7)2; Q3 and Q4 = independently (un)substituted (heteroaryl); and pharmaceutically acceptable salts thereof] were prepared for use in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 4-hydroxy-1-methylpiperidine with 5-fluoro-3,4-dihydroquinazolin-4-one using NaH in DMA gave the ether (91%). Reaction with POCl3 and di-isopropylethylamine in DCM provided 4-chloro-5-(1-methylpiperidin-4-yloxy)quinazoline (62%), which was coupled with 5-amino-1-benzylindole in the presence of IPA containing HCl in ether to afford II•HCl (46%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-containing polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 μM - 10 μM. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 μM - 20 μM. In addition, I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.

IT 524954-35-6P, 4-[3-Chloro-4-(decahydroquinolin-1-ylcarbonyl)anilino]-5-(1-methylpiperidin-4-yloxy)quinazoline
524954-41-4P, 4-[3-Ethynyl-4-(decahydroquinolin-1-ylcarbonyl)anilino]-5-(1-methylpiperidin-4-yloxy)quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(antitumor agent; prepn. of quinazolines as erbB receptor tyrosine kinase inhibitors for treatment of cancer)

RN 524954-35-6 CAPLUS
CN Quinoline, 1-[2-chloro-4-[[5-[(1-methyl-4-piperidinyl)oxy]-4-quinazolinyl]amino]benzoyl]decahydro- (9CI) (CA INDEX NAME)



RN 524954-41-4 CAPLUS
CN Quinoline, 1-[2-ethynyl-4-[[5-[(1-methyl-4-piperidinyl)oxy]-4-quinazolinyl]amino]benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:487553 CAPLUS
DOCUMENT NUMBER: 137:47200
TITLE: Aryl or heteroaryl fused imidazoles as selective GABAA receptor ligands
INVENTOR(S): Li, Guiying; Peterson, John M.; Albaugh, Pamela; Currie, Kevin S.; Cai, Guolin; Gustavson, Linda M.; Lee, Kyungae; Hutchison, Alan; Singh, Vinod; Maynard, George D.; Yuan, Jun; Ling, Hong Xie; Ghosh, Manuka; Liu, Nian; Luke, George P.; Mitchell, Scott; Allen, Martin Patrick; Liras, Spiros
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.
SOURCE: PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050062	A2	20020627	WO 2001-US50038	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431592	A1	20020627	CA 2001-2431592	20011221
AU 2002032768	A	20020701	AU 2002-32768	20011221
US 20030069257	A1	20030410	US 2001-38069	20011221
US 6916819	B2	20050712		
EP 1368342	A2	20031210	EP 2001-992307	20011221
EP 1368342	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300304	A	20031215	EE 2003-304	20011221
HU 2003003849	A2	20040301	HU 2003-3849	20011221
CN 1553909	A	20041208	CN 2001-822386	20011221
JP 2004536782	T	20041209	JP 2002-551558	20011221
AT 304008	T	20050915	AT 2001-992307	20011221
BR 2001016385	A	20051213	BR 2001-16385	20011221
AP 1503	A	20060228	AP 2003-2818	20011221
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW				
ES 2256325	T3	20060716	ES 2001-992307	20011221
NZ 526330	A	20060929	NZ 2001-526330	20011221
AU 2002232768	B2	20070906	AU 2002-232768	20011221
IN 2003KN00740	A	20060310	IN 2003-KN740	20030609
BG 107899	A	20040831	BG 2003-107899	20030611
ZA 2003004544	A	20050407	ZA 2003-4544	20030611
MX 2003PA05493	A	20040420	MX 2003-PA5493	20030618

L4 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NO 2003002834 A 20030808 NO 2003-2834 20030620
US 20060025425 A1 20060202 US 2005-179458 20050712
US 7300945 B2 20071127
PRIORITY APPLN. INFO.: US 2000-257492P P 20001221
US 2001-38069 A3 20011221
WO 2001-US50038 W 20011221

OTHER SOURCE(S): MARPAT 137:47200
GI



I



II

AB Title compds. I [W = N or CR3, X = N or CR4, Y = N or CR5, Z = N or CR6 with the provision that no more than two of W, X, Y and Z are N; Q = O or CR7R8; R1 = H, haloalkyl, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, etc.; R2 = nitrogen containing 5-7 membered (un)substituted heteroaryl or heterocycloalkyl ring with up to 4 heteroatoms independently selected from N, S, and O; R3, R4, R5 and R6 are independently selected from H, halo, OH, NO2, CN, (un)substituted alkyl, alkoxy, etc.] and there pharmaceutically acceptable salts are prepared and disclosed as selective GABAA receptor ligands. Thus, II was prepared in five steps from malonyl dichloride and Et vinyl ether with imidazole ring formation via cyclocondensation of 3-amino-4-ethylaminobenzonitrile with 1-(3-fluorophenyl)-5-carboxymethylpyrazole. The invention is particularly related to such compds. that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. Preferred compds. of the invention exhibit Ki values of < 100 nM for binding at the benzodiazepine site with more preferred compds. exhibiting Ki values of < 10 nM. This invention also relates to pharmaceutical compns. comprising such compds. and to the use of such compds. in treatment of certain central nervous system (CNS) diseases. This invention also relates to the use of I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Addnl. this invention relates to the use such compds. as probes for the localization of GABAA receptors in tissue sections.

IT 438556-40-2P 438556-41-3P 438557-66-5P
438557-67-6P 438557-68-7P 438557-69-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of aryl or heteroaryl fused imidazoles as selective GABAA receptor ligands)

RN 438556-40-2 CAPLUS
CN Quinoline, 1-[[1-ethyl-2-[(1-phenyl-1H-pyrazol-5-yl)methyl]-1H-benzimidazol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



RN 438556-41-3 CAPLUS
CN Quinoline, 1-[[2-[[1-(2,5-difluorophenyl)-1H-pyrazol-5-yl]methyl]-1-ethyl-1H-benzimidazol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



RN 438557-66-5 CAPLUS
CN Quinoline, decahydro-1-[[2-[(2-phenyl-1H-imidazol-1-yl)methyl]-1-propyl-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 438557-67-6 CAPLUS
CN Quinoline, 1-[[2-[[2-(3-fluorophenyl)-1H-imidazol-1-yl]methyl]-1-propyl-1H-benzimidazol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



RN 438557-68-7 CAPLUS
CN Quinoline, 1-[[2-[[2-(2,5-difluorophenyl)-1H-imidazol-1-yl]methyl]-1-propyl-1H-benzimidazol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



RN 438557-69-8 CAPLUS
CN Quinoline, 1-[[2-[[2-(3-chlorophenyl)-1H-imidazol-1-yl]methyl]-1-propyl-1H-benzimidazol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:417184 CAPLUS
DOCUMENT NUMBER: 137:137662
TITLE: Lepadins D-F: Antiplasmodial and antitrypanosomal decahydroquinoline derivatives from the tropical marine tunicate Didemnum sp.
AUTHOR(S): Wright, Anthony D.; Goclik, Eva; Koenig, Gabriele M.; Kaminsky, Ronald
CORPORATE SOURCE: Institute for Pharmaceutical Biology, Technical University of Braunschweig, Braunschweig, 38106, Germany
SOURCE: Journal of Medicinal Chemistry (2002), 45(14), 3067-3072
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB From a new tunicate species, belonging to the genus Didemnum, three alkaloids possessing an unusual and extremely rare decahydroquinoline skeleton and showing significant and selective antiplasmodial and antitrypanosomal activity were obtained as follows: (2R*,3S*,4aR*,5R*,8aS*)-decahydro-3-hydroxy-5-(5'-hydroxyoctyl)-2-methylquinoline (lepadin D, e.g. I), its quaternary nitrogen derivative (II), (2R*,2''E,3S*,4aR*,5R*,8aS*)-decahydro-3-hydroxy-5-(5'-hydroxyoctyl)-2-methyl-3-quinolinyl ester 2''-octenoic acid (lepadin E), and (2S*,2''E,3S*,4aR*,5R*,8aS*)-decahydro-3-hydroxy-5-(5'-hydroxyoctyl)-2-methyl-3-quinolinyl ester 2''-octenoic acid (lepadin F). These isolates may well serve as lead structures for the development of new antimalarial drugs.

IT 444914-23-2P, Lepadin E p-bromobenzoyl derivative
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties of)

L4 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 444914-23-2 CAPLUS
CN 2-Octenoic acid, (2R,3S,4aR,5R,8aS)-1-(4-bromobenzoyl)decahydro-5-(5-hydroxyoctyl)-2-methyl-3-quinolinyl ester, (2E)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:408648 CAPLUS
DOCUMENT NUMBER: 137:6176
TITLE: Preparation of aromatic acid derivatives useful as serine protease inhibitors
INVENTOR(S): Bisacchi, Gregory S.; Sutton, James C., Jr.; Slusarchyk, William A.; Treuner, Uwe D.; Zhao, Guohua; Cheney, Daniel L.; Wu, Shung C.; Shi, Yan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042273	A2	20020530	WO 2001-US46884	20011107
WO 2002042273	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428191	A1	20020530	CA 2001-2428191	20011107
AU 2002027269	A	20020603	AU 2002-27269	20011107
EP 1332131	A2	20030806	EP 2001-996145	20011107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514669	T	20040520	JP 2002-544409	20011107
HU 2004000651	A2	20040628	HU 2004-651	20011107
PRIORITY APPLN. INFO.:			US 2000-246392P P	20001107
			WO 2001-US46884 W	20011107

OTHER SOURCE(S): MARPAT 137:6176
GI

L4 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Aromatic compds. I, are useful as serine protease inhibitors, wherein ring B
is Ph or pyridyl; W is amide, alkyl, alkenyl, heterocycle, heteroaryl, aryl, cycloalkyl; L is a linker group; X is N, CH, or C, provided that X is C when R1 and R2 join to form a fully unsatd. ring; Z is an optionally-substituted monocyclic or bicyclic ring system; R is H, alkoxy,
amine, alkyl, alkenyl, halogen, haloalkyl, cyano, nitro, alkylthio, CHO, acyl, CO2H, alkoxycarbonyl, sulfonamido, sulfonyl, Ph; R1 and R2 (i) are independently selected from hydrogen, alkyl, alkenyl, heteroaryl, aryl, heterocycle, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocycle, provided that R1 and R2 do not together form pyrazole when W is methoxy and Z is biphenyl; and when R1 and R2 individually or together form a heteroaryl, aryl, heterocycle, cycloalkyl; R3 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocycle, cycloalkyl, or alkyl substituted with -OC(O)R4 or -OC(O)OR4, wherein R4 is alkyl, cycloalkyl, provided that R3 is not Ph when W is methoxy. Thus, II was prepared for treating a coagulation-associated disorder,
an inflammatory or immune disease, or metastases (no data). Included within the scope of the invention are pharmaceutical compns. for treating a serine protease disease, an inflammatory or immune condition, or cancer.

IT 431051-96-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU

L4 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. acid derivs. useful as anti-inflammatory, anticoagulant, antitumor, immunomodulator agents and serine protease inhibitors)

RN 431051-96-6 CAPLUS
CN Benzoic acid, 2-[2-[[(2-amino-1H-benzimidazol-5-yl)amino]carbonyl]-6-methoxy-3-pyridinyl]-5-[(octahydro-1(2H)-quinolinyl)carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:290437 CAPLUS
DOCUMENT NUMBER: 135:77002
TITLE: Total Synthesis of the Marine Alkaloids (-)-Lepadins A, B, and C Based on Stereocontrolled Intramolecular Acylnitroso-Diels-Alder Reaction
AUTHOR(S): Ozawa, Tetsuji; Aoyagi, Sakae; Kibayashi, Chihiro
CORPORATE SOURCE: School of Pharmacy, Tokyo University of Pharmacy & Life Science, Horinouchi Hachioji Tokyo, 192-0392, Japan
SOURCE: Journal of Organic Chemistry (2001), 66(10), 3338-3347
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:77002
GI



I

AB The first syntheses of (-)-lepadins A (I) and C, as well as a new synthesis of (-)-lepadin B, have been achieved from com. available (S)-malic acid. The methodol. is based on an intramol. hetero-Diels-Alder
reaction of the acylnitroso compound, affording the bicyclic oxazino lactam
with trans selectivity, which was converted to the cis-decahydroquinoline via asym. enolate hydroxylation followed by intramol. aldol cyclization. The total syntheses proceed by employing cis-decahydroquinoline bearing the (E)-iodoalkenyl group as the common key intermediate, which underwent a convergent coupling with the (E)-hexenyl unit via a palladium-catalyzed Suzuki cross-coupling reaction for the elaboration of the octadienyl side chain at the C5 position.

IT 303191-09-5P 303191-10-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total synthesis of marine alkaloids (-)-lepadins A, B, and C based on stereocontrolled intramol. acylnitroso-Diels-alder reaction)

RN 303191-09-5 CAPLUS
CN 5-Quinolinecarboxaldehyde, 1-benzoyl-3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]decahydro-4a-hydroxy-2-methyl-, (2S,3S,4aR,5S,8aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L4 ANSWER 26 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 303191-10-8 CAPLUS
CN 5-Quinolinecarboxylic acid, 1-benzoyl-3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]decahydro-4a-hydroxy-2-methyl-, methyl ester, (2S,3S,4aR,5S,8aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:597905 CAPLUS
DOCUMENT NUMBER: 133:335363
TITLE: Total Synthesis of the Marine Alkaloid (-)-Lepadin B
AUTHOR(S): Ozawa, Tetsuji; Aoyagi, Sakae; Kibayashi, Chihiro
CORPORATE SOURCE: School of Pharmacy, Tokyo University of Pharmacy Life Science, Tokyo, 192-0392, Japan
SOURCE: Organic Letters (2000), 2(19), 2955-2958
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:335363
GI



I

AB An enantioselective total synthesis of (-)-lepadin B was developed starting from (2S,4S)-2,4-O-benzylidene-2,4-dihydroxybutanal. The key steps in the synthesis include the use of an aqueous intramol. acylnitroso
Diels-Alder reaction to afford the trans-1,2-oxazinolactam I and the Suzuki cross-coupling reaction to elaborate the (E,E)-octadienyl unit.
IT 303191-09-5P 303191-10-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of the alkaloid (-)-lepadin B)
RN 303191-09-5 CAPLUS
CN 5-Quinolinecarboxaldehyde, 1-benzoyl-3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]decahydro-4a-hydroxy-2-methyl-, (2S,3S,4aR,5S,8aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L4 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 303191-10-8 CAPLUS
CN 5-Quinolinecarboxylic acid, 1-benzoyl-3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]decahydro-4a-hydroxy-2-methyl-, methyl ester, (2S,3S,4aR,5S,8aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:468059 CAPLUS
DOCUMENT NUMBER: 131:116160
TITLE: Decahydroquinoline-based anticholinergic agents
INVENTOR(S): Efange, S. Mbua Ngale; Parsons, Stanley M.
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA
SOURCE: U.S., 13 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5929087	A	19990727	US 1997-826830	19970408
PRIORITY APPLN. INFO.:			US 1997-826830	19970408

OTHER SOURCE(S): MARPAT 131:116160
GI



I II

AB Decahydroquinolines such as I were prepared as anticholinergic agents. Thus, I was prepared in 30% yield by refluxing epoxide II with 4-phenylpiperidine and Na2CO3 in EtOH for 48 h. In tests with vesicular acetylcholine transporter, the decahydroquinolines exhibited Ki values of 0.26-96 nM, compared to 2.0 nM for (-)-vesamicol.
IT 232278-88-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PEP (Physical, engineering or chemical process); RCT
(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(decahydroquinoline-based anticholinergic agents)
RN 232278-88-5 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 232279-03-7P 232279-05-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PUR (Purification or recovery); RCT (Reactant); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent)
(decahydroquinoline-based anticholinergic agents)
RN 232279-03-7 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 232279-05-9 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 232278-93-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(decahydroquinoline-based anticholinergic agents)
RN 232278-93-2 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-6-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 232279-02-6P 232279-04-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(decahydroquinoline-based anticholinergic agents)
RN 232279-02-6 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, dihydrochloride, (4aR,6R,7R,8aR)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



●2 HCl

RN 232279-04-8 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, dihydrochloride, (4aR,6R,7R,8aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L4 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●2 HCl

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:465814 CAPLUS
DOCUMENT NUMBER: 131:214164
TITLE: Hydroxylated Decahydroquinolines as Ligands for the Vesicular Acetylcholine Transporter: Synthesis and Biological Evaluation
AUTHOR(S): Efange, Simon M. N.; Khare, Anil B.; Mach, Robert H.; Parsons, Stanley M.
CORPORATE SOURCE: University of Minnesota, Minneapolis, MN, 55455, USA
SOURCE: Journal of Medicinal Chemistry (1999), 42(15), 2862-2869
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Analogs of the potent anticholinergic 2-(4-phenylpiperidino)cyclohexanol (vesamicol) in which the cyclohexyl fragment was replaced with an N-acyl- or N-alkyl-trans-decahydroquinolyl moiety were synthesized and evaluated as potential ligands for the vesicular acetylcholine transporter (VAChT). The binding of compds., such as I [R = Bz, H, 3-IC6H4CH2], was both stereospecific and of comparable magnitude to that of the closely related vesamicol analog 2,3-trans-4a,8a-trans-3-hydroxy-2-(4-phenylpiperidino)-1,2,3,4,5,6,7,8-decahydronaphthalene which displays subnanomolar affinity for this transporter. However, these compds. also demonstrated high affinities for σ1 and σ2 receptors and thus failed to show significantly improved selectivity over previously reported vesamicol analogs.
IT 232279-03-7P 232279-05-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of phenylpiperidinodecahydroquinolines as vesicular acetylcholine transporter ligands)
RN 232279-03-7 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

L4 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 232279-05-9 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 232278-88-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylpiperidinodecahydroquinolines as vesicular acetylcholine transporter ligands)
RN 232278-88-5 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-7-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 232278-93-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of phenylpiperidinodecahydroquinolines as vesicular acetylcholine transporter ligands)
RN 232278-93-2 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-6-(4-phenyl-1-piperidinyl)-, (4aR,6R,7R,8aR)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:479019 CAPLUS
DOCUMENT NUMBER: 129:109094
TITLE: Antagonists of gonadotropin releasing hormone
INVENTOR(S): Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 47 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780437	A	19980714	US 1996-760816	19961205
US 6200957	B1	20010313	US 1998-115497	19980714
PRIORITY APPLN. INFO.:			US 1995-8633P	P 19951214
			US 1996-760816	A2 19961205

OTHER SOURCE(S): MARPAT 129:109094
GI



I



II

L4 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. [I; A = (un)substituted C1-6 alkyl, C3-7 cycloalkyl, alkenyl, etc.; R0 = H, (un)substituted C1-6 alkyl, aryl, etc.; R1 = aromatic heterocyclyl; R2 = H, (un)substituted C1-6 alkyl, aralkyl, etc.; R3-R5 = H, (un)substituted C1-6 alkyl, alkenyl, etc.; R6 = H, (un)substituted C1-6 alkyl, aryl, etc.; R7 = H, (un)substituted C1-6 alkyl, etc.; R8 =CO2R20, CONR20R21, etc.; R20, R21 = H, (un)substituted C1-6 alkyl, aryl, etc.; R9, R9a = H, (un)substituted C1-6 alkyl or aryl, etc.; R10, R10a = H, (un)substituted C1-6 alkyl or aryl, aralkyl, etc.; X = N, O, CO, etc.; m = 0-3] and pharmaceutically acceptable salts thereof are prepared I are useful as antagonists of gonadotropin-releasing hormone (GnRH) and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women (no data). Thus, [2-[2-(3,5-dimethylphenyl)-5-(morpholine-4-carbonyl)-1H-indol-3-yl]ethyl]-(4-pyridin-4-ylbutyl)carbamic acid benzyl ester (preparation given) was hydrogenated over Pd/C to give 60% the title compound (II).

IT 192643-20-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of indole derivs. as antagonists of gonadotropin releasing hormone)

RN 192643-20-2 CAPLUS
CN Quinoline, 1-[[2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-indol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:511777 CAPLUS
DOCUMENT NUMBER: 127:121742
TITLE: Preparation of heterocyclic compounds as antagonists of gonadotropin releasing hormone
INVENTOR(S): Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721704	A1	19970619	WO 1996-US19444	19961210
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2240108	A1	19970619	CA 1996-2240108	19961210
AU 9714106	A	19970703	AU 1997-14106	19961210
AU 707641	B2	19990715		
EP 873336	A1	19981028	EP 1996-944249	19961210
EP 873336	B1	20020327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1208412	A	19990217	CN 1996-199872	19961210
JP 11506471	T	19990608	JP 1997-522124	19961210
JP 3230818	B2	20011119		
JP 2001106685	A	20010417	JP 2000-257791	19961210
HU 9903671	A2	20011028	HU 1999-3671	19961210
HU 9903671	A3	20011128		
AT 215081	T	20020415	AT 1996-944249	19961210
ES 2174129	T3	20021101	ES 1996-944249	19961210
ZA 9610536	A	19970814	ZA 1996-10536	19961213
NO 9802729	A	19980813	NO 1998-2729	19980612

PRIORITY APPLN. INFO.:	US 1995-8633P	P	19951214
	GB 1996-3242	A	19960216
	JP 1997-522124	A3	19961210
	WO 1996-US19444	W	19961210

OTHER SOURCE(S): MARPAT 127:121742
GI

L4 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. I [A = alkyl, etc.; R = H, alkyl, etc.; R1 = heterocyclic ring (generic structures given); R2 = H, alkyl, etc.; or R2A = ring; R3, R4, R5 = H, (un)substituted alkyl, alkenyl, etc.; or R3R4 = ring; R6 = H, (un)substituted alkyl, etc.; R7 = H, (un)substituted alkyl; unless X is hydrogen or halo, then R7 is absent; R8 = heterocyclic ring, etc.; or R7R8 = heterocyclic ring; R9, R19 = H, (un)substituted alkyl; further details on R9R19 and R9A are given; R20, R10 = H, (un)substituted alkyl, etc.; further details on R20R10, and R9R20, R9R2, R20R2, R20A are given; m = 0 to 3; X = N, etc.], useful as antagonists of gonadotropin releasing hormone (no data), are prepared I may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. The title compound II was prepared in a multistep process.

IT 192643-20-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as antagonists of gonadotropin releasing hormone)

RN 192643-20-2 CAPLUS
CN Quinoline, 1-[[2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-1H-indol-5-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 32 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:539424 CAPLUS
DOCUMENT NUMBER: 125:248179
TITLE: Stereoselective total synthesis of (-)-pumiliotoxin C by an aqueous intramolecular acylnitroso Diels-Alder approach. [Erratum to document cited in CA125:86951]
AUTHOR(S): Naruse, Masaichi; Aoyagi, Sakae; Kibayashi, Chihiro
CORPORATE SOURCE: School Pharmacy, Tokyo University Pharmacy and Life Science, Hachioji, 192-03, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1996), (16), 2077
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The errors were not reflected in the abstract or the index entries.

IT 178740-05-1P 178740-08-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective total synthesis of (-)-pumiliotoxin C by an aqueous intramol. acylnitroso Diels-Alder approach (Erratum))

RN 178740-05-1 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, [2S-(2α,4aβ,5β,8aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178740-08-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, [2S-(2α,4aβ,5α,8aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 32 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:358175 CAPLUS
DOCUMENT NUMBER: 125:86951
TITLE: Stereoselective total synthesis of (-)-pumiliotoxin C by an aqueous intramolecular acylnitroso Diels-Alder approach
AUTHOR(S): Naruse, Masaichi; Aoyagi, Sakae; Kibayashi, Chihiro
CORPORATE SOURCE: School Pharmacy, Tokyo University Pharmacy & Life Science, Hachioji, 192-03, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1996), (11), 1113-1124
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:86951
GI



AB A chiral approach to (-)-pumiliotoxin C based on an aqueous intramol. acylnitroso Diels-Alder reaction was described. Upon treatment of the hydroxamic acid (4S,5E,7E)-H3CCH2CH:CH:CH:CHCH(OCH2Ph)(CH2)2CONHOH (I) with Pr4NIO4 under the aqueous conditions, the in situ generated acylnitroso compound was subjected to intramol. [4 + 2] cycloaddn. to yield the trans-1,2-oxazino lactam (II) with significantly increased diastereoselectivity in comparison with the same cycloaddn. conducted in a chloroform solution (-)-Pumiliotoxin C and its C-5 epimer III (5β-Me and 5α-Me, resp.) were subsequently prepared from the intermediate intramol. Diels-Alder product II by different synthetic routes.
IT 178740-05-1P 178740-08-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective total synthesis of (-)-pumiliotoxin C by an aqueous intramol. acylnitroso Diels-Alder approach)
RN 178740-05-1 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, [2S-(2α,4aβ,5β,8aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 178740-08-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, [2S-(2α,4aβ,5α,8aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:290828 CAPLUS
DOCUMENT NUMBER: 120:290828
TITLE: Carbostyril derivatives and benzoheterocyclic compounds as oxytocin antagonists for treating oxytocin-related diseases
INVENTOR(S): Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Tanaka, Michinori; Kitano, Kazuyoshi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9401113	A1	19940120	WO 1993-JP835	19930622
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9343569	A	19940131	AU 1993-43569	19930622
AU 657424	B2	19950309		
EP 602209	A1	19940622	EP 1993-913553	19930622
R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, NL, SE				
JP 06087747	A	19940329	JP 1993-161715	19930630
JP 2969206	B2	19991102		
JP 06092854	A	19940405	JP 1993-161716	19930630
JP 2969207	B2	19991102		
CN 1091288	A	19940831	CN 1993-109876	19930702
PRIORITY APPLN. INFO.:			JP 1992-175563 A	19920702
			JP 1992-175566 A	19920702
			WO 1993-JP835 A	19930622

OTHER SOURCE(S): MARPAT 120:290828
GI



AB Oxytocin antagonists comprise, as active ingredients, carbostyril derivs. I [R1 = H, NO2, lower alkyl, lower alkoxy, lower alkoxycarbonsyl, halo, etc.; q = 1-3; R = substituted Ph, (substituted) 5-6-membered ring containing

L4 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NR2; R2 = H, lower alkoxycarbonyl, (substituted) phenoxycarbonyl, naphthylcarbonyl, etc.] or benzoheterocyclic compds. II [R16 = H, halo, lower alkyl, (lower alkyl substituted) amino, lower alkoxy; R17 = H, halo, lower alkoxy, phenyl(lower)alkoxy, HO, lower alkyl, etc.; R18 = NR19R20, CONR26R27; R19 = H, lower alkyl, (halo substituted) benzoyl; R20 = (substituted) COC6H4, lower alkanoyl, phenyl-lower alkoxycarbonyl, cycloalkylcarbonyl, etc.; R26 = H, lower alkyl; R27 = cycloalkyl, (substituted) Ph; W = (CH2)t, CH=CH(CH2)v, etc.; t = 3-5; v = 1-3] or their pharmaceutically acceptable salts,. These compds. show excellent oxytocin antagonist activity and hence are useful in the protection or treatment of oxytocin-related diseases, esp. for treatment of premature delivery, dysmenorrhea, endometritis, or for stopping labor preparatory to cesarean delivery. IC50 values were detd. for I and II compds. in a rat oxytocin receptor binding assay. Coated tablet and injection formulations are given.
IT 154890-26-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(oxytocin antagonist)
RN 154890-26-3 CAPLUS
CN Benzamide, 3-methyl-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]phenyl]- (CA INDEX NAME)



L4 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:207078 CAPLUS
DOCUMENT NUMBER: 114:207078
TITLE: Synthesis of cis- and trans-1-substituted 1,2,3,4,4a,5,11,11a-octahydro-6H-pyrido[3,2-b]carbazoles, 4-substituted 1,2,3,4,4a,5,6,11c-octahydro-7H-pyrido[2,3-c]carbazoles, cis-4-methyl-1,2,3,4,4a,5,6,12b-octahydro-7H-pyrido[2,3-c]acridine and cis-1-methyl-1,2,3,4,4a,5,12,12a-octahydro-6H-pyrido[3,2-b]acridine- a new class of potential antiparkinsonian agents
AUTHOR(S): Mehta, P.; Kumar, Yatendra; Saxena, Anil K.; Gulati, Anil K.; Singh, H. K.; Anand, Nitya
CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(2), 213-21
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:207078
GI



AB The preparation of title compds., e.g., cis- and trans-I (R = H, Me, Et, Pr) and II from 6-hydroxyquinoline is reported. Most of the prepared compds. show good dopaminergic activity in reserpine-induced rigidity tests and displaced 3H-dopamine in receptor binding studies, cis-I (R = H, Me) were the most potent of the compds. prepared
IT 16878-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Jones oxidation of)
RN 16878-38-9 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:23699 CAPLUS
DOCUMENT NUMBER: 110:23699
TITLE: Stereochemistry of nitrogen-containing heterocycles. 70. Conformation of 1-benzoyl-t-2-methyl-t-5-benzoyloxy-r-9-H-cis-decahydroquinoline and the nature of its benzoic acid complex
AUTHOR(S): Espenbetov, A. A.; Struchkov, Yu. T.; Kuz'mina, N. Yu.; Litvinenko, G. S.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1988), (5), 1056-60
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 110:23699
GI



AB Benzoylation of decahydroquinolinol derivative I by BzCl gave the H-bonded complex II, which was subjected to x-ray anal. The substituents in the α and α' positions of the piperidine ring of II have the axial orientation.
IT 118115-72-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and x-ray anal. of)
RN 118115-72-3 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-2-methyl-, benzoate (ester), (2α,4aβ,5α,8aβ)-, benzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 118115-71-2
CMF C24 H27 N O3

L4 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 65-85-0
CMF C7 H6 O2



IT 118115-71-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 118115-71-2 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-2-methyl-, benzoate (ester), (2α,4aβ,5α,8aβ)- (9CI) (CA INDEX NAME)



L4 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 111575-05-4 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aβ,8a. beta.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:636477 CAPLUS
DOCUMENT NUMBER: 107:236477
ORIGINAL REFERENCE NO.: 107:37985a,37988a
TITLE: Stereochemistry of nitrogen heterocycles. 61. Synthesis and configuration of the eighth isomer of 2-methyl-4-hydroxydecahydroquinoline
AUTHOR(S): Litvinenko, G. S.; Voronenko, L. A.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, 480100, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1987), (2), 238-43
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 107:236477
AB 1-Benzoyl-2α-methyl-4β-hydroxy-cis-decahydroquinoline (I) existing in a steroid conformation with diaxial α,α'-substituents in the piperidine ring and an equatorial hydroxyl group, was prepared by reducing 1-benzoyl-2α-methyl-4-oxo-cis-decahydroquinoline with NaBH4 and with Na-EtOH. Subsequent dibenzylation gave 2α-methyl-4β-hydroxy-cis-decahydroquinoline which exists in a non-steroidal conformation with an axial hydroxyl group.
IT 54375-41-6P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in reduction of benzoylmethyldecahydroquinolinone by sodium
borohydride)
RN 54375-41-6 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aβ,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 36041-62-0P 111575-05-4P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in reduction of benzoylmethyldecahydroquinolinone by sodium
borohydride and sodium-methanol)
RN 36041-62-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:68738 CAPLUS
DOCUMENT NUMBER: 104:68738
ORIGINAL REFERENCE NO.: 104:11000h,11001a
TITLE: Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of γ-aminobutyric acid-related biological properties in vitro and in vivo
AUTHOR(S): Witiak, Donald T.; Patch, Raymond J.; Enna, S. J.; Fung, Yiu K.
CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
SOURCE: Journal of Medicinal Chemistry (1986), 29(1), 1-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:68738
GI



AB The syntheses of the 5β and 5α epimers of trans-(4aα,8aβ)-decahydroquinoline-5-carboxylic acids I and II from vinylogous bicyclic imide III are described. The reduction of trans-5-(1,3-dithian-2-ylidene)octahydro-2(1H)-quinolinone to afford the 5α-(1,3-dithian-2-yl) compound IV was a key step in the synthesis of II while hydroboration-H2O2 treatment of phenylmethyl trans-octahydro-5-methylene-1(2H)-quinolinecarboxylate to afford the 5β-hydroxymethyl compound V was a key step in the synthesis of I. I and II and the previously prepared cis analogs were investigated for their ability to interact with GABAA and GABAB receptors and picrotoxin binding sites as well as with neuronal GABA transport systems in brain tissue. Like the cis analogs, tonic-clonic seizures were induced when I or II were

L4 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
administered to mice intracerebroventricularly. Only II weakly inhibited [3H]GABA binding to GABAA and GABAB receptors in vitro. Large doses (10 mg/kg) of diazepam reversed the convulsant activity of both I and II. Although I is the more potent convulsant, II may have GABA antagonist activity in vivo. Results obtained in vivo lead us to propose that these diastereoisomers may serve as unique conformational probes relating certain zwitterionic topogs. to stimulatory activity in the central nervous system.
IT 98761-73-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 98761-73-0 CAPLUS
CN 5-Quinolinecarboxylic acid, 1-(3,5-dinitrobenzoyl)decahydro-, methyl ester, (4aα,5β,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 98761-74-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 98761-74-1 CAPLUS
CN 5-Quinolinecarboxylic acid, 1-(3,5-dinitrobenzoyl)decahydro-, methyl ester, (4aα,5α,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:612018 CAPLUS
DOCUMENT NUMBER: 99:212018
ORIGINAL REFERENCE NO.: 99:32615a,32618a
TITLE: Electron impact induced water elimination from hydroxy
amides. 2. N-Acetyl- and N-benzoyl-4a-hydroxydecahydroquinoline and N-methyl-4a-hydroxy-2-oxodecahydroquinoline
AUTHOR(S): Steiner, B.; Schumann, D.; Naumann, A.
CORPORATE SOURCE: Inst. Org. Chem. Tech., Univ. Berlin, Berlin, D-1000, Fed. Rep. Ger.
SOURCE: Organic Mass Spectrometry (1983), 18(8), 350-4
CODEN: ORMSBG; ISSN: 0030-493X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Electron impact-induced H2O elimination from the metastable mol. ions of N-acetyl- and N-benzoyl-4a-hydroxydecahydroquinoline follows a formal [1,2]elimination. The initiating and rate-determining step in the reaction is
the rearrangement of H from C-8a onto the CO group. The transferred H is subsequently lost, together with the OH group. The almost complete absence of H2O loss from both diastereomers of N-methyl-4a-hydroxy-2-oxodecahydroquinoline confirms that the reaction only proceeds when the CO
group can act as a H carrier by occupying positions near both a H and the OH function.
IT 87931-03-1P 87931-04-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and mass spectrum of, mechanism of electron impact-induced
elimination of water in)
RN 87931-03-1 CAPLUS
CN 4a(2H)-Quinolinol, 1-benzoyloctahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 87931-04-2 CAPLUS
CN 4a(2H)-Quinolinol, 1-benzoyloctahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 87931-05-3P 87931-06-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87931-05-3 CAPLUS
CN 4a(2H)-Quinolinol, 1-benzoyloctahydro-8a-d-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 87931-06-4 CAPLUS
CN 4a(2H)-Quinolinol, 1-benzoyloctahydro-8a-d-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:558205 CAPLUS
DOCUMENT NUMBER: 99:158205
ORIGINAL REFERENCE NO.: 99:24249a,24252a
TITLE: Intramolecular Diels-Alder reactions of 2-alkenyl-1,2-dihydropyridines. An approach to the synthesis of the cis-decahydroquinoline ring system
AUTHOR(S): Comins, Daniel L.; Abdullah, Abdul H.; Smith, Roy K.
CORPORATE SOURCE: Dep. Chem. Biochem., Utah State Univ., Logan, UT, 84322, USA
SOURCE: Tetrahedron Letters (1983), 24(27), 2711-14
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:158205
GI


I


II


III


IV

AB In refluxing decalin alkenyldihydropyridines I (n = 1, 2) undergo an intramol. Diels-Alder reaction to give novel polycyclic compds. II. cis-Decahydroquinoline ring system III was prepared from Diels-Alder product IV by a ring-opening reverse Mannich reaction.
IT 87288-13-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87288-13-9 CAPLUS
CN 5-Quinolineacetic acid, 1-(4-chlorobenzoyl)decahydro-, ethyl ester, (4aα,5β,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:19927 CAPLUS
DOCUMENT NUMBER: 96:19927
ORIGINAL REFERENCE NO.: 96:3311a,3314a
TITLE: Stereochemistry of nitrogen heterocycles. XLY. Configuration of 2-methyldecahydro-5-quinolinol and the ketones corresponding to it
AUTHOR(S): Sokolov, D. V.; Kuz'mina, N. Yu.; Isin, Zh. I.; Litvinenko, G. S.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1981), (4), 59-62
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 96:19927
GI


I


II


III


IV

AB Several title compds. were prepared,e. g., ketone I, was prepared by successive benzoylation and oxidation of the resp. alc. I was hydrogenated to give alcs. II and III. Ketone IV was also obtained by successive benzoylation and oxidation The configuration of I and IV was determined
IT 80197-73-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cleavage of)
RN 80197-73-5 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4aα,5β,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 80197-68-8P 80197-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)
RN 80197-68-8 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4aα,5α,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 80197-69-9 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4aβ,5α,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:533499 CAPLUS
DOCUMENT NUMBER: 87:133499
ORIGINAL REFERENCE NO.: 87:21229a,21232a
TITLE: Octahydro-7(1H)-quinolones. I. Stereochemistries of the catalytic hydrogenation of 7-hydroxyquinoline
AUTHOR(S): Momose, Takefumi; Uchida, Shuji; Yamaashi, Noriko; Imanishi, Takeshi
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Osaka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(6), 1436-42
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 7-Hydroxyquinoline was hydrogenated over 5% Rh on alumina to give the trans-aminoalcohol (I) as a main product along with other possible diastereomeric isomers. Configurations were assigned from chemical and phys.
evidence.
IT 34513-24-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)
RN 34513-24-1 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-, (4aα,7α,8aβ)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



IT 64416-66-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 64416-66-6 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-, benzoate (ester), (4aα,7α,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 43 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:29969 CAPLUS
DOCUMENT NUMBER: 86:29969
ORIGINAL REFERENCE NO.: 86:4807a,4810a
TITLE: Synthesis of pumiliotoxin C
AUTHOR(S): Habermehl, Gerhard; Andres, Hendrik; Miyahara, Kazumoto; Witkop, Bernhard; Daly, John W.
CORPORATE SOURCE: Inst. Org. Chem., Tech. Hochsch. Darmstadt, Darmstadt,
Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1976), (9), 1577-83
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB (±)-Pumiliotoxin C [(±)-I] was stereoselectively prepared in 25% yield by cyclizing cyclohexene II with BrCH2CH2CHPrNH2·HBr, hydrolyzing and decarboxylating the quinoline (±)-III (R = CO2Et) thus formed, and hydrogenating the product (±)-III (R = H) to give (±)-I and (±)-IV, which were separated by precipitating (±)-IV·HCl or chromatog. of the N-Bz derivs. Using (1R)-(-)-BrCH2CH2CHPrNH2 similarly gave I identical with the natural material.
IT 61424-99-5P 61425-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzoylation of)
RN 61424-99-5 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, (2α,4aα,5α,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 43 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 61425-00-1 CAPLUS
CN Quinoline, 1-benzoyldecahydro-5-methyl-2-propyl-, (2α,4aβ,5β,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 44 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:563963 CAPLUS
DOCUMENT NUMBER: 83:163963
ORIGINAL REFERENCE NO.: 83:25718h,25719a
TITLE: Reduction of 5,6,7,8-tetrahydroquinolines and 2,3,4,5,6,7,8,10-octahydroquinolines to trans-decahydroquinolines
AUTHOR(S): Vierhapper, Friedrich W.; Eliel, Ernest L.
CORPORATE SOURCE: William R. Kenan, Jr.-Lab. Chem., Univ. North Carolina, Chapel Hill, NC, USA
SOURCE: Journal of Organic Chemistry (1975), 40(19), 2734-42
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 83:163963
AB The reduction of the title compds. with Na in EtOH gives largely (.apprx.90%) trans-decahydroquinolines. When alkyl substituents or fused rings are present in the starting materials, the decahydroquinoline juncture of the product is still largely trans, but two (or more) epimers at the point of alkyl substitution (or fused ring juncture) result; they are separated readily by preparative gas chromatog. Similar reduction of 5,6,7,8-tetrahydroisoquinoline gives mainly Δ9,10-octahydroisoquinoline (58%) with lesser amts. of cis- (20%) and trans-decahydroisoquinoline (22%). Reduction of 5,6,7,8-tetrahydroquinoline with Na in EtOD gives mainly 2,3,3,4,9,10-hexadeuterio-trans-decahydroquinoline with some deuteration also occurring at position 8. Evidently exchange at an intermediate reduction stage is involved. Similar reduction of pyridine gives 2,3,3,4,5,5,6-heptadeuteriopiperidine. Reduction of Δ1,9-octahydroquinolines with Na in EtOH provides an alternative path for the synthesis of trans-decahydroquinolines, including compds. with Me substituents at C-10. The synthesis of certain deuterated analogs is also described. The 1H NMR spectra of the compds. synthesized (including the deuterated analogs) as well as of their N-methyl, N-ethyl, and N-isopropyl derivs. are described in some detail.
IT 55905-29-8P 55905-32-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55905-29-8 CAPLUS
CN Quinoline, 1-benzoyldecahydro-8-methyl-, (4aα,8α,8aβ)-(9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 44 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 55905-32-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-8-methyl-, (4aα,8β,8aβ)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:72454 CAPLUS
DOCUMENT NUMBER: 82:72454
ORIGINAL REFERENCE NO.: 82:11563a,11566a
TITLE: Stereochemistry of nitrogen heterocycles. XL. Chromatographic behavior of stereoisomers of decahydroquinoline (piperidine) derivatives on aluminum oxide. Relation of Rf to the nature of the substituents
AUTHOR(S): Litvinenko, G. S.; Sosnova, V. V.; Sokolov, D. V.; Artyukhin, V. I.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1974), 24(6), 33-7
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The adsorption of N-benzoyldecahydro-2-methylquinolines on Al2O3 decreases in the following order of substituent at the 4-position: OH > oxo> H. Adsorption of the N-unsubstituted and N-Me derivs. is determined by the basicity of the N atom and decreases in the following order of 4-substituent: H > MeCO > Cl > oxo. Adsorption of the 4-OH derivs. is the strongest and depends on the intrinsic adsorbability of the OH group, rather than its effect on N basicity.
IT 963-78-0 28289-85-2
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, on aluminum oxide)
RN 963-78-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 28289-85-2 CAPLUS
CN Quinoline, 1-benzoyldecahydro-2-methyl- (8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:72277 CAPLUS
DOCUMENT NUMBER: 82:72277
ORIGINAL REFERENCE NO.: 82:11539a,11542a
TITLE: Configuration and reactivity of saturated cyclic and heterocyclic compounds. XII. Mass spectra of tertiary alcohols of decahydroquinoline derivatives
AUTHOR(S): Matamarov, N.; Lyuts, A. E.; Praliev, K. D.; Sokolov, D. V.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1974), 24(5), 74-9
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Mass spectra of 20 stereoisomers of 2-methyl-4-ethynyl-, 1,2-dimethyl-4-ethynyl-, 2-methyl-4-vinyl-, 2-methyl-4-ethyl-, and 1-benzoyl-2-methyl-4-ethynyldecahydro-4-quinolinol were determined and correlated with structure.
IT 54099-30-8 54099-31-9 54099-32-0
54162-66-2
RL: PRP (Properties)
(mass spectrum of)
RN 54099-30-8 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethyldecahydro-2-methyl-, (2α,4α,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 54099-31-9 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethyldecahydro-2-methyl-, (2α,4β,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 54099-32-0 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethyldecahydro-2-methyl-, (2α,4α,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 54162-66-2 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethyldecahydro-2-methyl-, (2α,4α,4aβ,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 47 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:72259 CAPLUS
DOCUMENT NUMBER: 82:72259
ORIGINAL REFERENCE NO.: 82:11539a,11542a
TITLE: Stereochemistry of nitrogen heterocycles. XXXIX. Chromatographic behavior of stereoisomers of decahydroquinoline (piperidine) derivatives on aluminum oxide. Relation of Rf to the acid-base properties of the adsorbent
AUTHOR(S): Litvinenko, G. S.; Sosnova, V. V.; Sokolov, D. V.; Khludneva, K. I.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1974), 24(6), 22-32
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The thin-layer chromatog. behavior of decahydro-2-methylquinoline, decahydro-2-methyl-4-quinolinol, decahydro-2-methyl-4-quinolinone, and their N-Me derivs. on Al2O3 depends on the activity and on the acid-base properties of the adsorbent. Adsorption is decreased as the basicity of the Al2O3 is increased. Adsorption of the N-Bz derivs. depends only on the activity of the Al2O3.
IT 36041-59-5 36041-60-8 36041-61-9
36041-62-0 54375-39-2 54375-40-5
54375-41-6
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, on aluminum oxide)
RN 36041-59-5 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36041-60-8 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 47 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36041-61-9 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aβ,8a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36041-62-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 54375-39-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aα,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 47 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 54375-40-5 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aα,8a α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 54375-41-6 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aβ,8a β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 48 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 48 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:16202 CAPLUS
DOCUMENT NUMBER: 82:16202
ORIGINAL REFERENCE NO.: 82:2585a,2588a
TITLE: Observable magnetic nonequivalence of diastereotopic protons as a stereochemical probe
AUTHOR(S): Walsh, David A.; Smissman, Edward E.
CORPORATE SOURCE: Sch. Pharm., Univ. Kansas, Lawrence, KS, USA
SOURCE: Journal of Organic Chemistry (1974), 39(25), 3705-7 CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The N-benzyl derivs. of cis- and trans-decahydroquinoline and trans-octahydrobenzo [g] quinoline were prepared to determine the stereochem. of the ring juncture. The diastereotopic benzylic protons for the cis stereochem. appear as an AB quartet in the NMR spectrum with a chemical shift difference of .apprx.24 Hz, while the benzylic protons for the trans stereochem. appear as an AB quartet with a chemical shift difference of .apprx.60 Hz.
IT 5710-04-3 22218-33-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:59338 CAPLUS
DOCUMENT NUMBER: 80:59338
ORIGINAL REFERENCE NO.: 80:9625a,9628a
TITLE: Stereochemistry of nitrogenous heterocycles. XXXV. Stereochemistry of the ethynylation of trans ismers of 2-methyldecahydroquinol-4-one
AUTHOR(S): Sokolov, D. V.; Praliev, K. D.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1973), 23(5), 54-60 CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Condensation of C2H2 with the cis-2-methyldecahydroquinol-4-one having an axial Me group gave quinolols I and II in 96.4 and 1.6% yields, resp. Condensation of C2H2 with the epimeric quinolone having an equatorial Me group gave quinolols III, IV, and V, the yield of III decreasing and that of IV increasing as the temperature was raised from -10 to +10°. V, isolated in .apprx.2% yield, was formed by isomerization of the starting cis-fused quinolone to its trans isomer under the reaction conditions. The configurations and conformations of the 5 quinolols and their N-methyl derivs. were determined from ir, NMR, and basicity data.
IT 51075-13-9P 51211-41-7P 51776-60-4P
51776-61-5P 51776-62-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51075-13-9 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethynyldecahydro-2-methyl-, (2α,4β,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 51211-41-7 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethynyldecahydro-2-methyl-, (2α,4α,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 51776-60-4 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethynyldecahydro-2-methyl-, (2α,4α,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 51776-61-5 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethynyldecahydro-2-methyl-, (2α,4β,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 51776-62-6 CAPLUS
CN 4-Quinolinol, 1-benzoyl-4-ethynyldecahydro-2-methyl-, (2α,4α,4aβ,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 50 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:126263 CAPLUS
DOCUMENT NUMBER: 76:126263
ORIGINAL REFERENCE NO.: 76:20441a,20444a
TITLE: Proton magnetic resonance of cyclic compounds. VIII. Conformations of cis- and trans-decahydroquinolines and their acyl derivatives
AUTHOR(S): Booth, H.; Bostock, A. H.
CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1972), (5), 615-21
CODEN: JCPKBH; ISSN: 0300-9580
DOCUMENT TYPE: Journal
LANGUAGE: English
AB PMR spectra indicated a twin-chair conformation for trans-decahydroquinoline and its NSO2Ph, -CONHPh, -NO, and -CS2- derivs. The N lone pair prefers to occupy the hindered, inside position in the twin-chair conformation of cis-decahydroquinoline (I); the N-Bz, -SO2Ph, -CONHPh, and -NO derivs. of I adopt the alternative twin-chair confirmation which avoids repulsive interaction between the N-substituent and the C-8 CH2 group.
IT 22218-33-3
RL: PRP (Properties)
(NMR of)
RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 5710-04-3
RL: PRP (Properties)
(conformation of, NMR in relation to)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 50 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 51 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:126261 CAPLUS
DOCUMENT NUMBER: 76:126261
ORIGINAL REFERENCE NO.: 76:20441a,20444a
TITLE: Dipole moments of stereoisomers of some trans-decahydroquinoline derivatives
AUTHOR(S): Vladul, A. T.; Sokolov, D. V.; Litvinenko, G. S.; Khludneva, K. A.; Artyukhin, V. I.; Vladul, N. I.; Agashkin, O. V.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1971), 21(6), 36-40
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Dipole moments μ of trans-decahydroquinolines (I, II, III, IV, V, VI) were determined at 20° with an error <0.05 D by measuring the permittivity by the zero-beat method. The μ for I (axial 2-Me) was higher than for I (equatorial 2-Me). The μ for III (equatorial 4-OH) was higher than μ for other III isomers. The μ for equatorial isomers did not change after a transition from secondary to tertiary amines, but those for axial isomers changed by 20-5%. The μ for II, III, or IV, calculated by assuming 3 orientations (cis, trans, and free rotation) of the H atom of OH with respect to C-4 H, agreed with experiment
The validity of the vector-addition approximation for the μ calcn. was not
determined
IT 36041-59-5 36041-60-8 36041-61-9
36041-62-0
RL: PRP (Properties)
(dipole moment of)
RN 36041-59-5 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36041-60-8 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aα,8aβ)- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



RN 36041-61-9 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4β,4aβ,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36041-62-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, (2α,4α,4aα,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 52 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:21059 CAPLUS
DOCUMENT NUMBER: 76:21059
ORIGINAL REFERENCE NO.: 76:3381a,3384a
TITLE: Structure-activity studies of new potential depressants 3,4,5-trimethoxybenzamides. II
AUTHOR(S): Luts, Heino A.
CORPORATE SOURCE: Dep. Chem., East. Kentucky Univ., Richmond, KY, USA
SOURCE: Journal of Pharmaceutical Sciences (1971), 60(9), 1409-11
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Of several 3,4,5-trimethoxybenzamides (I) which were synthesized by adding
to the acid chloride in benzene solution, 0.1 mole of the appropriate amine,
N-cyclooctyl-N-methyl-3,4,5-trimethoxybenzamide [33522-73-5], N-cyclohexyl-N-isopropyl-3,4,5-trimethoxybenzamide [33522-74-6], N,N-dicyclopentyl-3,4,5-trimethoxybenzamide [33522-75-7] and N-cyclohexyl-N-phenyl-3,4,5-trimethoxybenzamide [33522-76-8], were strong depressants in tests with Na hexobarbital [50-09-9] potentiation, Randall-Sellito pressure paw, phenylquinone [106-51-4] writhing, and in pyresis, but were ineffective in antagonizing reserpine [50-55-5] effects in rats.
IT 34897-73-9
RL: BIOL (Biological study)
(depressant, structure in relation to)
RN 34897-73-9 CAPLUS
CN Quinoline, decahydro-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 53 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:529233 CAPLUS
DOCUMENT NUMBER: 75:129233
ORIGINAL REFERENCE NO.: 75:20391a,20394a
TITLE: Circular dichroism and electronic absorption studies on some N-monosubstituted and N,N-disubstituted benzamides
AUTHOR(S): Krueger, W. C.; Johnson, Roy A.; Pschigoda, L. M.
CORPORATE SOURCE: Res. Lab., Upjohn Co., Kalamazoo, MI, USA
SOURCE: Journal of the American Chemical Society (1971), 93(19), 4865-72
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The absorption and CD spectra of some N-monosubstituted and N,N-disubstituted benzamides are reported. The principle features and solvent effects in the CD spectra can be best explained by assuming that the n → π* transition of the benzamido chromophore is responsible for a Cotton effect between the two aromatic transitions.
The
signs of the Cotton effects are correlated with absolute configuration.
IT 16878-35-6 16915-92-7 22218-33-3
34513-24-1 34513-25-2
RL: PRP (Properties)
(circular dichroism of)
RN 16878-35-6 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-, (S,S,S)-(+)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 16915-92-7 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-, (4aS,5R,8aR)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 22218-33-3 CAPLUS

L4 ANSWER 53 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 34513-24-1 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-, (4aα,7α,8aβ)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



RN 34513-25-2 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-, stereoisomer (8CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 54 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 54 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:99147 CAPLUS
DOCUMENT NUMBER: 74:99147
ORIGINAL REFERENCE NO.: 74:16137a,16140a
TITLE: Mass spectra of decahydroquinolines
AUTHOR(S): Yu, Chi-Kuen; Oldfield, Dane; MacLean, David B.
CORPORATE SOURCE: Dep. Chem., McMaster Univ., Hamilton, ON, Can.
SOURCE: Organic Mass Spectrometry (1970), 4(Suppl.), 147-55
CODEN: ORMSBG; ISSN: 0030-493X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The mass spectra of cis-and trans-decahydroquinoline, their N-Me and their
N-Bz derivs. were examined Several deuterated derivs. of the N-Me compds.
and one C-Me derivative were prepared and a study of their spectra has aided in
the interpretation of the mechanism of fragmentation. The major fragment ions are formed by loss of 2, 3 and 4 C fragments from the homocyclic ring.
IT 5710-04-3 22218-33-3
RL: PRP (Properties)
(mass spectrum of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 55 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:115851 CAPLUS
DOCUMENT NUMBER: 72:115851
ORIGINAL REFERENCE NO.: 72:20891a,20894a
TITLE: Configuration and reactivity of saturated cyclic and heterocyclic compounds. VIII. Mass spectra of N-benzoyl derivatives of 2-methyldecahydroquinoline stereoisomers
AUTHOR(S): Lyuts, A. E.; Agashkin, O. V.; Artyukhin, V. I.; Sokolov, D. V.; Litvinenko, G. S.
CORPORATE SOURCE: Inst. Khim. Nauk, Alma-Ata, USSR
SOURCE: Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya (1970), 20(1), 74-81
CODEN: IKAKAK; ISSN: 0002-3205
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Mass spectra of 4 isomers of 1-benzoyl-2-methyldecahydroquino-line at ionization voltages of 20 and 70 V were obtained. The distribution of pos. charge between N and fragments containing benzoyl is affected by the structure
and configuration of the mol. In the case of isolated benzoyl and amino groups, pos. ions containing N prev ailed. In the case of amides, the pos.
charge was localized in fragments containing c6H6 and the degree of localization increased with increased efficiency o f conjugation.
IT 28289-85-2
RL: USES (Uses)
(mass spectra of conformational isomers of)
RN 28289-85-2 CAPLUS
CN Quinoline, 1-benzoyldecahydro-2-methyl- (8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 56 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:466766 CAPLUS
DOCUMENT NUMBER: 69:66766
ORIGINAL REFERENCE NO.: 69:12447a,12450a
TITLE: Conformations of alkylpiperidine amides
AUTHOR(S): Johnson, Roy A.
CORPORATE SOURCE: Biochem. Res. Div., Upjohn Co., Kalamazoo, MI, USA
SOURCE: Journal of Organic Chemistry (1968), 33(9), 3627-32
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The N.M.R. signals of the C-2 and C-6 protons of a series of alkylpiperidine benzamides coalesce at a temperature lower than that for the same protons in similar alkylpiperidine acetamides. The energy barrier to rotation about the C-N amide bonds is lower in the benzamides than in the acetamides as a result of increased steric interactions between the phenyl ring and the C-2 and C-6 substituents in the planar benzamide conformation. Such steric interactions between the amide and C-2 and C-6 alkyl substituents in both acetamides and benzamides are sufficient to cause conformational bias in the piperidine ring, resulting in the preference for axial configurations for the alkyl groups. These examples are a special case of the general concept of A(1,3) strain. The piperidine-containing mol. 3-benzoyl-3-azabicyclo[3.3.1]nonane was found to have a chair-chair conformation. The N.M.R. spectrum of 1-benzoyl-trans-decahydroquinoline shows no variation with temperature change, suggesting that the amide group in this mol. has no preferred conformation.
IT 5681-50-5
RL: PROC (Process)
(conformational inversion of, N.M.R. in relation to)
RN 5681-50-5 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, (4aS,8aR)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:451960 CAPLUS
DOCUMENT NUMBER: 69:51960
ORIGINAL REFERENCE NO.: 69:9698h,9699a
TITLE: Microbiological hydroxylation of 1-benzoyl-trans-decahydroquinoline. Determination of structure, stereochemistry, and absolute configuration of the products
AUTHOR(S): Johnson, Roy A.; Murray, Herbert C.; Reineke, Lester M.; Fonken, Gunther S.
CORPORATE SOURCE: Biochem. Res. Div., Upjohn Co., Kalamazoo, MI, USA
SOURCE: Journal of Organic Chemistry (1968), 33(8), 3207-17
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Microbiol. hydroxylation of (±)-1-benzoyl-trans-decahydroquinoline [(±)-I] with Sporotrichum sulfurescens gave (4aS,5S,8aR)-1-benzoyl-trans-decahydroquinolin-5-ol [(-)-II], (±)-1-benzoyl-trans-decahydroquinolin-6-ol [(±)-III], and (4aS,7S,8aS)-1-benzoyl-trans-decahydroquinolin-7-ol [(+)-IV] in a total yield of 80-90%. Under the same conditions hydroxylation of (+)-I gave optically pure (+)-IV and (+)-III in a 7:13 ratio. Hydroxylation of (-)-I gave optically pure (-)-II and (-)-III in a 87:13 ratio. Various chemical modifications of these products were carried out in order to determine their structures and stereochemistry and included the conversions of (-)-II, (+)-IV, and (+)-III to (4aS,8aR)-trans-decahydroquinolin-5-one (V), (4aS,8aS)-trans-decahydroquinolin-7-one (VI), and (4aS,8aS)-trans-decahydroquinolin-6-one (VII), resp. Application of the octant rule to the O.R.D. curves of V-VII allowed assignment of absolute configurations to the II-IV. The absolute configurations of the parent mols., (-)- and (+)-trans-decahydroquinoline, can be assigned as (4aR,8aS)-trans-decahydroquinoline and (4aS,8aR)-trans-decahydroquinoline, resp. 26 references.
IT 5681-50-5 16878-36-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxylation of)
RN 5681-50-5 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, (4aS,8aR)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 16878-36-7 CAPLUS

L4 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Quinoline, 1-benzoyldecahydro-, (4aR,8aS)-(+)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 16878-16-3P 16878-18-5P 16878-34-5P
16878-35-6P 16878-38-9P 16878-39-0P
16915-92-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16878-16-3 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-, (4aS,5S,8aR)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 16878-18-5 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-, cis-(±)- (8CI) (CA INDEX NAME)



RN 16878-34-5 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-, (R,R,R)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 16878-35-6 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro-, (S,S,S)-(+)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 16878-38-9 CAPLUS
CN 6-Quinolinol, 1-benzoyldecahydro- (9CI) (CA INDEX NAME)



RN 16878-39-0 CAPLUS
CN 7-Quinolinol, 1-benzoyldecahydro-, (S,S,S)-(+)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 16915-92-7 CAPLUS
CN 5-Quinolinol, 1-benzoyldecahydro-, (4aS,5R,8aR)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1967:75926 CAPLUS
DOCUMENT NUMBER: 66:75926
ORIGINAL REFERENCE NO.: 66:14235a,14238a
TITLE: Naphthyridines. III. Tetrahydro- and decahydro-1,5-,
-1,6-, -1,7-, and -1,7-, and -1,8-naphthyridines
AUTHOR(S): Armarego, Wilfred L. F.
CORPORATE SOURCE: Australian Natl. Univ., Canberra, Australia
SOURCE: Journal of the Chemical Society [Section] C: Organic (1967), (5), 377-83
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
AB cf. CA 59, 7504g. Decahydro-1,5-, -1,6-, -1,7-, and -1,8-naphthyridines were prepared by reduction of the resp. naphthyridines with Na and EtOH. Reduction
of 1,5-naphthyridine over PtO2 in acid solution gave a separable mixture of
trans- and cis-decahydro-1,5-naphthyridine. It was possible to distinguish between these isomers, and those of trans- and cis-decahydroquinolines and decahydroisoquinolines, by proton N.M.R. spectroscopy. Catalytic reduction of 1,5-, 1,6-, and 1,8-naphthyridine over
Pd-C in EtOH gave the corresponding 1,2,3,4-tetrahydro derivs. but 1,7-naphthyridine gave a separable mixture 57% 1,2,3,4-tetrahydro- and 43%
5,6,7,8-tetrahydro-1,7-naphthyridine. The structures of the tetrahydronaphthyridines were established by ionization measurements and by uv and proton N.M.R. spectroscopy.
IT 13623-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 13623-73-9 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, hydrochloride, cis- (8CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 59 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:35215 CAPLUS
DOCUMENT NUMBER: 64:35215
ORIGINAL REFERENCE NO.: 64:6459h,6460a-b
TITLE: Reaction of debenzoylation and configuration of isomeric N-benzoyloctahydro-1-pyrindenes and decahydroquinolines
AUTHOR(S): Mistryukov, E. A.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1965), (11), 2006-9
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB N-Benzoyl-trans-octahydro-1-pyrindene refluxed 40 min. in dioxane saturated
with dry HCl, evaporated in vacuo, and washed with Et2O gave 96% trans-octahydro-1-pyrindene-HCl, m. 238.5-9.5°. The cis isomer similarly gave the cis form, m. 186-6.5°, but the yield under these conditions was but 15%. The difference in reaction rates was explained by
the close proximity of the amide group O atom and the H atoms at C8 position; in cis forms this proximity is avoided by passage of the C-N bond into axial conformation. The ir spectra of N-benzoyl-cis-decahydroquinoline and -cis-octahydro-1-pyrindene differ from those of trans isomers in 1630-50 cm.-1 region (shown), proving that the cis forms have the conformations shown above. Ir spectra of the above amides in complexes with iodine and the uv spectra of these amides (containing benzoyl
or acetyl groups) complexed with concentrated H2SO4 were quite similar for the
N-acetyl members of the corresponding cis and trans isomers in each group,
as well as for N-benzoyl analogs in each group.
IT 5681-50-5 5710-04-3 94673-00-4
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 5681-50-5 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, (4aS,8aR)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 59 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



IT 22218-33-3, Quinoline, 1-benzoyldecahydro-, trans-
(spectra of)
RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 60 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



L4 ANSWER 60 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:35214 CAPLUS
DOCUMENT NUMBER: 64:35214
ORIGINAL REFERENCE NO.: 64:6459f-h
TITLE: Steric configuration of molecules in charge-transfer complexes of ferrocene with nitrobenzene derivatives
AUTHOR(S): Hetnarski, B.
SOURCE: Bulletin de l'Academie Polonaise des Sciences, Serie des Sciences Chimiques (1965), 13(9), 563-9
CODEN: BAPCAQ; ISSN: 0001-4095
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The structure (I) of the charge-transfer complex of ferrocene with 1,3,5(O2N)3C6H3 was suggested as probable. The acceptor mol. is situated sym. with respect to the ferrocene mol., shields the Fe atom surrounded by the π-electrons, and overlaps the orbitals between the cyclopentadienyl rings. The ferrocene ionization potential was associated with an electron situated between the cyclopentadienyl rings, and the ionization potential was connected with the position of the charge-transfer band. 21 references.
IT 5681-50-5 5710-04-3 94673-00-4
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 5681-50-5 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, (4aS,8aR)-(-)- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 61 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:867 CAPLUS
DOCUMENT NUMBER: 62:867
ORIGINAL REFERENCE NO.: 62:132g-h
TITLE: Intensities and frequencies of amide I bands in tertiary stereoisomeric amides
AUTHOR(S): Chasnikova, S. S.; Agashkin, O. V.; Litvinenko, G. S.; Sokolov, D. V.
SOURCE: Spektroskopiya, Metody i Primenenie, Akad. Nauk SSSR, Sibirsk. Otd. (1964) 124-6
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The ir spectra of 4 stereoisomers of N-benzoyl-2-methyl-4-oxo-decahydroquinoline and the N-benzoyl-2-methyl-4-hydroxy-decahydroquinoline obtained from them by reduction were investigated. The effect of the steric arrangement around the C:O bond on the frequency, integral intensity, and half-width of the stretching band was emphasized.
IT 963-78-0P, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-
RL: PREP (Preparation)
(spectrum of, conformation and stereochemistry in relation to)
RN 963-78-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 62 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:441605 CAPLUS
DOCUMENT NUMBER: 59:41605
ORIGINAL REFERENCE NO.: 59:7486d-f
TITLE: Configuration of isomeric N-benzoyl-cis-decahydro-4-quinolols and the relative stability of cis-trans isomers in the decahydro-4quinolone series
AUTHOR(S): Mistryukov, E. A.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1963) 929-32
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. Hardegger and Ott, CA 48, 10033b. The cis junction is the more stable in cis-trans forms of N-benzovldeca- hydro-4-quinolone. 4-Decahydroquinolol-HCl treated with K2CO3 gave the free base which, refluxed 2 hrs. in PHCl with pO2NC6H4CHO with slow removal of the solvent gave much unreacted material and after 2 hrs. further heating gave 32% tetrahydro-m-oxazine (I), m. 116-17°, which, refluxed briefly with 1:5 HCl gave 67% initial amino alc., m. 260°; thus the isomeric amino alc. whose N-benzoyl derivative m. 109°, forms the oxazine I with a double-boat configuration, and this amino alc. is in the trans series. The isomeric cis amino alc. reacts with the aldehyde very much more slowly. Therefore N-benzoyl-decahydro-4-quinolol, m. 222°, has an axial OH group, while the isomer m. 139° has the equatorial OH group. The results also prove the cis juncture of the rings in N-benzoyldecahydro-cisquinoline formed by reduction of the corresponding 4-oxo derivative
IT 93025-24-2, 4-Quinolinol, 1-benzoyldecahydro- (stereoisomers)
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 63 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:418273 CAPLUS
DOCUMENT NUMBER: 59:18273
ORIGINAL REFERENCE NO.: 59:3295b-c
TITLE: Thin-layer chromatography of some strongly adsorbed amines on nonbound alumina plates
AUTHOR(S): Mistryukov, E. A.
CORPORATE SOURCE: Acad. Sci. U.S.S.R., Moscow
SOURCE: Journal of Chromatography (1962), 9, 314-15
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. preceding abstract Rf values are tabulated for 34 primary and secondary amines chromatographed on Al2O3 (loc. cir.) with the solvent systems Me2CO-MeOH-H2O (8:2:1), MeCOEt-H2O (15:1), Me2CO-C7H16 (1:1), CHCl3-NH, (saturated at 22°), CHCl3/NH3-96% EtOH (30: 1), and CHCl3/NH3-C6H6 (1:1).
IT 93025-24-2, 4-Quinolinol, 1-benzoyldecahydro- (stereoisomers, chromatography of)
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 64 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:418272 CAPLUS
DOCUMENT NUMBER: 59:18272
ORIGINAL REFERENCE NO.: 59:3295a-b
TITLE: Thin-layer chromatography using the descending technique with nonbound alumina plates
AUTHOR(S): Mistryukov, E. A.
CORPORATE SOURCE: Acad. Sci. U.S.S.R., Moscow
SOURCE: Journal of Chromatography (1962), 9, 311-13
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. CA 56, 2867a. A mixture of isomeric compds. on Al2O3 is spread in a uniform layer at the upper end of a plate and chromatography is carried out by the descending technique with CHCl3. After drying, the zones are extracted with a solvent to give the separated isomers. The chromatography may be carried out on a preparative scale. The separation of 2 isomeric N-benzoyl-4-hydroxydecahydroquinolines (m. 104 and 140°, resp.) is used as an example.
IT 93025-24-2, 4-Quinolinol, 1-benzoyldecahydro- (stereoisomers, chromatography of)
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 65 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:27173 CAPLUS
DOCUMENT NUMBER: 58:27173
ORIGINAL REFERENCE NO.: 58:4514f-h,4515a
TITLE: Stereochemistry of heterocyclic compounds. XI. Effects of substitution at the nitrogen atom on configuration of 4-decahydroquinolones and the stereochemistry of some nucleophilic reactions at the oxo group
AUTHOR(S): Mistryukov, E. A.; Aronova, N. I.; Kucherov, V. F.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1962) 1599-604
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. CA 57, 12421h. Replacement of H by Me at the N atom of 4-decahydroquinolone does not change the predominant stability of the trans juncture of the 2 rings. 1-Methyldecahydro-4-quinolone and MeI in Me2CO gave the methiodide (I), m. 209-9.5° (λ 226 mμ). 4-Decahydroquinolone-HCl and NaBH4 in aqueous KOH gave in 1 hr. 86% 4-decahydroquinolol-HCl (II), m. 272-4°, after chromatography on Al2O3 and elution with CHCl3, followed by treatment with concentrated HCl and EtOCH2CH2OHMeOH-EtOAc. I treated similarly with NaBH4 gave 82.5% N-methyldecahydro-4-quinolol-MeI (III), m. 260-60.5° (Ac derivative m. 198-9°), also formed by 1 hr. treatment of II with paraformaldehyde and 85% HCO2H or after heating II (HBr salt) with paraformaldehyde and hydrogenating the product over Pt. NaBH4 converted N-benzoyl-trans-4-decahydroquinolone (IV) into a mixture of isomers of N-benzoyl-4-decahydroquinolols (loc. cit.). IV and PhLi in Et2O overnight gave after an aqueous treatment some Ph3COH and 4-phenyl-trans-4-decahydroquinolol, m. 148-50°. Treatment of the residue with HCO2HCH2O gave some α-isomer of 1-methyl-4-phenyl-trans-4-decahydroquinolol, m. 126°, and the γ-isomer, m. 148°, separated by chromatography on Al2O3. PhLi treated with N-benzoyl-cis-decahydro-4-quinolone similarly gave the β-isomer of 1-methyl-4-phenyldecahydro-4-quinolol, m. 113°. This alc. evidently has the cis junction of the rings and an equatorial Ph group. The alc. formed from the trans ketone evidently has the trans ring junction and axial OH and equatorial Ph groups.
IT 93025-24-2, 4-Quinolinol, 1-benzoyldecahydro- (isomers)
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 65 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 66 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:60548 CAPLUS
DOCUMENT NUMBER: 56:60548
ORIGINAL REFERENCE NO.: 56:11566g-i,11567a-d
TITLE: Stereochemistry of heterocyclic compounds. IX. Synthesis of O-acetates of isomeric decahydro-4-quinolols and a study of the possibility of O → N acyl migrations in decahydroquinolone series
AUTHOR(S): Mistryukov, E. A.; Kucherov, V. F.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1961) 2044-50
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB O-Ac derivs. of 4 isomers of 4-decahydroquinolol were prepared and on the basis of inability of these to isomerize to N-Ac analogs it was suggested that the O-N acyl migration method is inapplicable in the group of 4 decahydroquinolol derivs. PhLi in Et2O-tetrahydrofuran treated with N-benzoyl-trans-decahydro-4-quinolol gave 54% trans-4-decahydroquinolol-HCl, m. 199.5-201°, if the original benzoyl derivative m. 139°; if the isomer m. 222° was used in this reaction, the product, trans-decahydro-4-quinololHCl, m. 260.5-1.5°, was identical with the specimen reported earlier (cf. part VIII). Some Ph3COH was recovered from the residual mixts. cis-Decahydro-4-quinolol-HCl (I), m. 275°, refluxed briefly with AcCl-Ac2O gave the O-acetate HCl salt (II), decomposed at 269-71°; similarly, isomeric I, m. 230°, gave an isomer (III) of II which decomposed at 248-9.5°. trans-Decahydro-4-quinolol-HCl, m. 260.5°, treated similarly gave trans-decahydro-4-quinolol O-acetate HCl salt, m. 255-8°; similarly, its isomer, m. 199.5° gave the isomeric product, m. 192-3°. II and K2CO3 solution warmed briefly and extracted with CHCl3 gave, after purification on Al2O3, the free base, m. 85.5-6.5° (picrate m. 244-5°). III similarly treated gave the free base (picrate m. 147-9°) and none of the HCl salts showed evidence of migration of the O-acyl group. O-Benzoyl-cis-decahydro-4-quinolol-HCl and aqueous K2CO3 gave the free base O-benzoate, m. 217.518.5°. 4-Decahydroquinolol-HCl, m. 230°, refluxed 2 hrs. in Ac2O-NaOAc gave the O, N-diacetyl derivative, identified only chromatographically, and the crude product refluxed with MeOH-KOH 1.5 hrs. gave N-acetyl-cis-4-decahydroquinolol, an oil. trans-Decahydro-4-quinolol (HCl salt m. 260.5°) treated with Ac2O in MeOH gave a mixture of N and N,O-acetylated products; this heated with Ac2O in pyridine 3 hrs. and saponified as above gave the oily N-acetyltrans-4-decahydroquinolol. Refluxing trans-4-decahydroquinolol-HCl, m. 200°, with AcCl-Ac2O 1 hr. gave after saponification as above oily N-acetyl-trans-2-decahydroquinolol. PC15 and cis-4-decahydroquinolol-HCl, m. 275° gave 4chloro-cis-decahydroquinoline-HCl (IV), m. 228-8.5°. NBenzoyl-cis-4-decahydroquinolol, m. 104°, and SOCl2 in CHCl3 gave N-benzoyl-4-chloro-cis-decahydroquinoline, m.

L4 ANSWER 66 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
110.5-11°, also formed from IV and BzCl in pyridine. This with LiAlH4 gave after an aq. treatment N-benzyl-4-chlorocis-decahydroquinoline, m. 82.5-83°. Attempts to effect the redn. with Li in liquid NH3 failed as it did in a similar treatment of IV. Hydrogenation over Pt also was ineffec- tive. N-Benzoyl-trans-4-decahydroquinolol and SOCl2 gave N-benzoyl-Δ4-octahydroquinoline, m. 78-9°, after the usual treatment.

IT 94539-22-7P, Quinoline, 1-benzoyl-4-chlorodecahydro-
RL: PREP (Preparation)
(preparation of)

RN 94539-22-7 CAPLUS

CN Quinoline, 1-benzoyl-4-chlorodecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 67 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:60546 CAPLUS
DOCUMENT NUMBER: 56:60546
ORIGINAL REFERENCE NO.: 56:11565f-i,11566a-e
TITLE: Stereochemistry of heterocyclic compounds. VII. Spatial structure of decahydro-4-quinolone derivatives and configuration of isomeric decahydroquinolines
AUTHOR(S): Mistryukov, E. A.; Kucherov, V. F.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1961) 1816-25
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. CA 52, 20159c; 55, 27304q. -Decahydro-4-quinolone and BzCl in pyridine gave the N-benzoyl derivative (I), m. 145°, which had the cis configuration and whose 2,4-dinitrophenylhydrazone m. 231-3°; the same benzoyl derivative was formed from the ketone-HCl and BzCl (excess) in pyridine. I kept in dioxane in the presence of HCl overnight, then treated with C6H6 and aqueous Na2CO3, gave the trans isomer of I, m. 109-10.5°; the same formed when I was kept 3 days in MeONa-MeOH; refluxing with aqueous AcOH-HCl 8 hrs. gave decahydro-4-quinolone-HCl, m. 219-21°. trans-I and (CH2SH)2 in AcOH in the presence of BF3-Et2O (overnight) gave the ethylene thioketal (II), m. 121.5-3°; cis-I gave the analogous thioketal in the form of an oil. II refluxed with Raney Ni in dioxane 8 hrs. gave N-benzoyl-trans-decahydroquinoline, m. 99-100; the cis analog, prepared similarly, m. 54-6° and was identical with the substance that had been reported earlier as the trans isomer (Hueckel and Stepf, CA 29, 2903). Hydrogenation of decahydro-4-quinolone-HCl over Pt in aqueous medium gave 80% decahydro-4-quinolol-HCl, m. 274.5-6°; the mother liquors gave a crude material which (after benzoylation and chromatographic separation on alumina plates deposited on glass) contained 60% cis-N-benzoyldecahydro-4-quinolol (III), m. 104-4.5°, and 40% isomeric quinolol (IV), m. 138.5-40°. Hydrogenation of I over Pt in dioxane gave III and less than 5% IV. Refluxing decahydro-4-quinolone 2.75 hrs. with Na and iso-PrOH in MePh under N, adding more iso-PrOH, and refluxing 0.5 hr. longer gave, after an aqueous treatment, 60% cis-decahydro-4-quinolol, m. 124-30°; HCl salt m. 273-5° (identical with that formed by hydrogenation of decahydro-4quinolone-HCl). The mother liquor from this product was benzoylated to give 7.5% trans-N-benzoyldecahydro-4quinolol, m. 220°, and a small amount of mol. complex (m. 116-17°) of III and IV; chromatography of the residue indicated the presence of a mixture of 20% III and 60% IV. Refluxing of decahydro-4-quinolone with (iso-PrO)3Al in isoPrOH 2.75 hrs. and treatment with HCl gave 70.5% decahydro-4-quinolol-HCl, m. 230.5-1°; free base (IVa) m. 170-1°, whose benzoyl derivative, m. 138.5-40°, was identical with IV above. Hydrogenation of N-benzoyl-trans-deca-hydro-4-quinolone over Pt in dry dioxane gave 77% N-benzoyl-trans-decahydro-4-quinolol (V), m. 222.5-3.5° (chromatography of the residue indicated that some starting ketone was left unchanged), trans-I refluxed with (iso-PrO)3Al in iso-PrOH 2.5 hrs. gave 86.5% V; the residue (shown chromatographically) contained 5% isomeric N-benzoyltrans-decahydro-4-quinolol (VI), m. 139.5-40.5°. trans-I and NaBH4 in aqueous NaOH and MeOH gave in 50 min.

L4 ANSWER 67 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
53% VI. Hydrogenation of decahydro-4-quinolone in MeOH over Raney Ni at 50° and 50 atm. gave in 1 hr. pure IVa, m. 170-1°, and a residue contg. some mixed isomers of the trans series and the cis isomer, m. 124-30°, described above. The configurations of the above products are discussed at length. The results indicate that decahydro-4-quinolone probably has the conformation which avoids the interaction of NH bond with that of C5-C10 positions; the H atom on N in this substance is probably axially placed, since such forms are more prone to associate. In view of previously erroneous identification of isomeric decahydroquinolols (H. and S., loc. cit.), it is suggested that the criteria for assignment of structures to isomers relative to configuration of the two rings at their juncture should be reexamined.
IT 94539-22-7 94673-00-4
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 94539-22-7 CAPLUS
CN Quinoline, 1-benzoyl-4-chlorodecahydro- (7CI) (CA INDEX NAME)



RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



IT 5710-04-3P, Quinoline, 1-benzoyldecahydro-, cis-
22218-33-3P, Quinoline, 1-benzoyldecahydro-, trans-
RL: PREP (Preparation)
(preparation of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 67 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 93025-24-2, 4-Quinolinol, 1-benzoyldecahydro-
(stereoisomers)
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



L4 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:12938 CAPLUS
DOCUMENT NUMBER: 56:12938
ORIGINAL REFERENCE NO.: 56:2423e-g
TITLE: The reverse Schotten-Baumann reaction and the stereochemistry of decahydroquinoline and its derivatives
AUTHOR(S): Mistryukov, E. A.; Kucherov, V. F.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1961) 134-6
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Benzamides were cleaved stereospecifically by dry HCl in dioxane. Thus, N-benzoylcis-decahydroquinoline heated briefly in dioxane with dry HCl gave BzCl and cis-decahydroquinoline-HCl; the Bz derivative of the trans isomer was unchanged after such treatment. Both isomers of N-benzoyl-cis-decahydroquinolol (m. 104 and 140°) were readily cleaved by this reaction to yield the HCl salts of the free alcs. (m. 275 and 230°, resp.). The trans isomers were unchanged. Thus, the N-benzoyl group was selectively removed from O,N-dibenzoyl derivs. This route was used to prepare 4-benzoxydecahydroquinolineHCl, m. 278°, which could not be prepared by any other route. N-Benzoylpiperidine was unaffected by this treatment.
IT 93025-24-2 94673-00-4 96370-40-0
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)



RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



RN 96370-40-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate (ester) (9CI) (CA INDEX NAME)

L4 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 820985-98-6P, 4-Quinolinol, 1-benzoyldecahydro-, benzoate, trans-
877375-62-7P, 4-Quinolinol, 1-benzoyldecahydro-, benzoate, cis-
877604-54-1P, 4-Quinolinol, 1-benzoyldecahydro-, trans-
RL: PREP (Preparation)
(preparation of)
RN 820985-98-6 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate, trans- (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 877375-62-7 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, cis- (7CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 877604-54-1 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, trans- (7CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1962:12937 CAPLUS
DOCUMENT NUMBER: 56:12937
ORIGINAL REFERENCE NO.: 56:2423a-e
TITLE: Effect of the nitrogen function in 4-oxodecahydroquinoline on the relative stability of cis- and trans-isomers
AUTHOR(S): Mistryukov, E. A.; Kucherov, V. F.
CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1961) 1343-4
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 56:12937

AB cf. CA 52, 20159i.--The most stable isomers of decahydro-4-quinolone or its HCl salt and their N-benzoyl derivs. belong to different series relative to the ring junction orientation. Decahydro-4-quinolone (I) yields the N-benzoyl derivative, which is catalytically hydrogenated to N-benzoyldecahydro-4-quinolol (II), m. 104°, and I.HCl on hydrogenation yields decahydro-4-quinolol-HCl, m. 275°, which benzoylates to II. I and HCl yield I.HCl, also formed from the N-benzoyl derivative by heating with HCl, this fact being explained by formation of a common enol cation which undergoes ketonization. Reduction of the stereoisomeric Nbenzoyl derivs. of I (through desulfurization of their thioketals) yields N-benzoyldecahydroquinolines, m. 57° and m. 97°. The above results indicate that the former is the cis isomer and the latter the trans isomer (at the ring junction). Hydrogenation of the N-benzoyl derivative of I, m. 145°, in dioxane or hydrogenation of I.HCl in aqueous medium yields the corresponding quinolols, m. 275° (as HCl salt) and m. 104°. The isomeric N-benzoyl derivative of I, m. 140°, shows the axial disposition of the HO group in its spectrum. Reduction of I with Na-ROH gives 80% quinolol isomer corresponding to II. Hence I is the cis isomer (making possible the conversion of the axial to equatorial position of its HO group). The isomer of I which m. 109° reduced catalytically or with (iso-PrO)3Al gives isomeric N-benzoyldecahydro-4-quinolol, m. 222°, with an axial HO group. The other isomer of the trans series (m. 139°) is formed (53% yield) by reduction of the above ketone with NaBH4. Spectra of the products are reported for structural proof.

IT 93025-24-2 94673-00-4 96370-40-0
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 93025-24-2 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro- (7CI) (CA INDEX NAME)

L4 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



RN 96370-40-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, benzoate (ester) (9CI) (CA INDEX NAME)



IT 22218-33-3, Quinoline, 1-benzoyldecahydro-, trans-
(chemistry of)
RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 5710-04-3P, Quinoline, 1-benzoyldecahydro-, cis-
22218-33-3P, Quinoline, 1-benzoyldecahydro-, trans-
877375-62-7P, 4-Quinolinol, 1-benzoyldecahydro-, cis-
877604-54-1P, 4-Quinolinol, 1-benzoyldecahydro-, trans-
905825-82-3P, 4-Quinolinol, 1-benzoyldecahydro-, cis-, hydrochloride 905825-85-6P, 4-Quinolinol, 1-benzoyldecahydro-, trans-, hydrochloride
RL: PREP (Preparation)
(preparation of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 877375-62-7 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, cis- (7CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 877604-54-1 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-, trans- (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 905825-82-3 CAPLUS
CN Methanone, [(4aR,8aS)-octahydro-4-hydroxy-1(2H)-quinolinyl]phenyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 905825-85-6 CAPLUS
CN Methanone, [(4aR,8aR)-octahydro-4-hydroxy-1(2H)-quinolinyl]phenyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

L4 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



● HCl

L4 ANSWER 70 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:144166 CAPLUS
DOCUMENT NUMBER: 55:144166
ORIGINAL REFERENCE NO.: 55:27304a-d
TITLE: Stereochemistry of nitrogen heterocycles. X. Steric control in the hydrogenation of the isomers of 2-methyl-4-oxodecahydroquinoline. Reduction of the isomers of 1-benzoyl-2-methyl-4-oxodecahydroquinoline by aluminum isopropoxide
AUTHOR(S): Sokolov, D. V.; Litvinenko, G. S.; Artyukhin, V. I.
SOURCE: Izvest. Akad. Nauk Kazakh. S.S.R., Ser. Khim. (1961), (No. 1), 75-82
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. CA 54, 19677d; preceding abstract Each of the 4 isomers of 1-benzoyl-2-methyl-4-oxodecahydroquinoline (I) was refluxed with 2-5% excess M Al isopropoxide (in iso-PrOH) until no more acetone distilled After solvent removal, washing with dilute NaOH or HCl, H2O, and drying, the product was fractionally crystallized from alc. or Me2CO to sep. the mixture of isomers of 1-benzoyl-2-methyl-4-hydroxydecahydroquinoline (II). When isomer separation was incomplete after crystallization, the mixture was refluxed with 0.2M HCl in dry dioxane and the HCl salts of the benzoyl esters recrystd. Material still unresolved was further separated by fractional crystallization of the picrates. The α-isomer of I, m. 137-8°, gave 78% II, m. 151-2° (axial Me, OH), 1.3% II, m. 138-9° (axial Me, equatorial OH), and 19% unsepd. mixture, m. 125-30°. The β-isomer, m. 131-2°, gave 2% unchanged I (extraction of crude product with petr. ether), a total of 61.3% of various derivs. of II, m. 148-9° (axial Me, OH), 10.4% derivs. of II, m. 208-9° (axial Me, equatorial OH), and 20% unresolved mixture The γ-isomer, m. 138-9°, gave 57.7% derivs. of II, m. 131-2° (equatorial Me, OH), and 11.5% derivs. of II (equatorial Me, axial OH). The δ-isomer, m. 117-18°, gave 99% II, m. 183-4° (equatorial Me, OH), and none of the isomer with an axial OH. These results were compared with those from hydrogenation over a Ni catalyst.

IT 963-78-0, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-
857016-68-3, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, picrate (stereoisomers)

RN 963-78-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 70 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 857016-68-3 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, picrate (6CI) (CA INDEX NAME)

CM 1

CRN 963-78-0
CMF C17 H23 N O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L4 ANSWER 71 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1960:103439 CAPLUS
DOCUMENT NUMBER: 54:103439
ORIGINAL REFERENCE NO.: 54:19677d-h
TITLE: Stereochemistry of nitrogenous heterocycles. V. Stereoisomerism of 2-methyl-4-hydroxydecahydroquinoline
AUTHOR(S): Sokolov, D. V.; Litvinenko, G. S.; Khludneva, K. I.
SOURCE: Zhurnal Obshchei Khimii (1959), 29, 3555-64
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 54:103439
AB cf. CA 54, 13124i. Hydrogenation of the γ-isomer of 2-methyl-4-oxodecahydroquinoline (I) (m. 41-2°) in EtOH over Raney Ni gave 2-methyl-4-hydroxydecahydroquinoline (II), m. 143-4°; HCl salt m. 311-12°. The free base formed a trihydrate, m. 91-2°; picrate m. 207-7.5°. Treatment with BzCl in C6H6 gave 73% 1-benzoyl-2-methyl-4-hydroxydecahydroquinoline, m. 131-2°. The material remaining after the original isolation of II HCl salt gave the stereoisomer of II, m. 157-8° (dioxane); picrate m. 195-6°; HCl salt m. 247-8°; 1-benzoyl derivative (III), m. 133-4°. In all, 64.3% II and 22.7% of the latter isomer were isolated. If the hydrogenation was run as above but in petr. ether, the yields were 43.6% and 35.9%, resp. If the reduction was done with Na-EtOH (completed on a steam bath, the yields were 73.9% and 2.7%, resp. Hydrogenation of I hydrate in H2O over Raney Ni gave 48.2% and 32.6% of the above isomers, resp. Hydrogenation of I.HCl in H2O over Raney Ni gave 38.8% and 59% of the two isomers, resp. Hydrogenation of 1-Bz derivative of I in EtOH over Raney Ni gave 45.7% III and a smaller amount of H, isolated after hydrolysis of the Bz group with 10% HCl. Hydrogenation of δ-isomer of III (m. 117-18°) in EtOH over Raney Ni gave 92.3% 1-benzoyl-2-methyl-4-hydroxydecahydroquinoline, m. 182-3°, derived from the alc. (IV), m. 114-15°; heating this Bz derivative with BzCl at 135-40° gave 50.2% 2-methyl-4-benzoxydecahydroquinoline HCl salt (V), m. 303-5°; free ester m. 75-6°; picrate m. 216-7°. The residue after the isolation of V yielded an isomer of V, m. 123-5°. Refluxing free base of V with alc. KOH 1 hr. gave IV, m. 114-15°; HCl salt m. 278-9°; picrate m. 160-1°. The alc. II evidently had an equatorial HO group, while its isomer, m. 157-8°, had an axial HO group. The 3rd alc. isomer, IV, evidently was in the cis series and had an equatorial HO group. The probable conformations of these alcs. were shown diagrammatically.
IT 113750-72-4P, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, benzoate
RL: PREP (Preparation)
(preparation of)
RN 113750-72-4 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, benzoate (6CI) (CA INDEX NAME)

L4 ANSWER 71 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 963-78-0, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-
(stereoisomers)
RN 963-78-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 72 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1960:68220 CAPLUS
DOCUMENT NUMBER: 54:68220
ORIGINAL REFERENCE NO.: 54:13124i,13125a-e
TITLE: Stereochemistry of nitrogenous heterocycles. IV. Stereochemistry of 2-methyl-4-hydroxydecahydroquinoline
AUTHOR(S): Sokolov, D. V.; Litvinenko, G. S.; Khludneva, K. I.
SOURCE: Zhurnal Obshchei Khimii (1959), 29, 3204-14
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. CA 54, 1519e. Catalytic hydrogenation of α- and β-isomers of 2-methyl-4-oxodecahydroquinoline (I) resulted in mutual isomerization of the isomers; the Bz derivs. were hydrogenated without such isomerization. Hydrogenation of I α-isomer over Raney Ni gave 50.7% 2-methyl-4-hydroxydecahydroquinoline (II) isomer m. 127-8°; HCl salt m. 196-7°; picrate m. 174-6°. The residual material gave a mixture of isomers which with HCl gave 10% hydrochloride of II isomer, m. 270-1°, which with K2CO3 gave II isomer, m. 133-4°; picrate m. 177-8°; Bz derivative (III) m. 138-9°. The residue gave a 3rd II isomer, m. 188-9°. The low-melting II isomer formed a Bz derivative, m. 151-2°. Reduction of α-I (m. 127-8°) with Na in EtOH gave a little II, m. 188-9°; HCl salt m. 264-5°; picrate m. 223-4°; Bz derivative m. 210-11°. The residue gave low yields of the II isomers, m. 127-8° and 133-4° (HCl salt m. 270-1°). Hydrogenation over Raney Ni of α-I HCl salt gave II isomers, m. 127-8° and 133-4°, the former predominating. Hydrogenation of III over Raney Ni gave 74% 1-benzoyl-2-methyl-4-hydroxydecahydroquinoline, m. 151-2°, identical with above described material and 7.5% isomer, m. 138-9°, also shown above. Hydrogenation of β-I over Raney Ni gave 59.5% II, m. 127-8°, 4.9% isomer, m. 188-9°, 10% isomer with HCl salt, m. 270-1°, and 1% impure isomer, m. 125-6°. Reduction with Na-EtOH gave II isomer, m. 127-8°, along with isomer, m. 188-9°, and one whose HCl salt, m. 270-1°. Hydrogenation of Bz derivative of β-I gave 10% Bz derivative of II, m. 132-3°; 5.2% isomer, m. 210-11°; and 47.7% isomer, m. 147-9°. A mixture of benzoyl derivs., m. 143-7°, which remained, treated with dry HCl gave 2-methyl-4-benzoxydecahydroquinoline isomer as HCl salt (IV), m. 250-1°, while the residue yielded some II, m. 188-9° and 125-7°. IV gave the free ester, m. 94-5° (picrate m. 233-4°). Saponification of this ester with alc. KOH gave free 2-methyl-4-hydroxydecahydroquinoline, m. 131-2°; HCl salt m. 191-3°; picrate m. 204-5°. This isomer was believed to have a possibly inverted conformation with an equatorial Me group and equatorial HO group.
IT 963-78-0, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-
857015-64-6, 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, hydrochloride
(stereoisomers)
RN 963-78-0 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 72 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 857015-64-6 CAPLUS
CN 4-Quinolinol, 1-benzoyldecahydro-2-methyl-, hydrochloride (6CI) (CA INDEX NAME)



● HCl

L4 ANSWER 73 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1951:3533 CAPLUS
DOCUMENT NUMBER: 45:3533
ORIGINAL REFERENCE NO.: 45:592d-h
TITLE: Catalytic dehydrogenation of hydroaromatic compounds in benzene. V. Application to pyrrolidines and piperidines
AUTHOR(S): Adkins, Homer; Lundsted, Lester G.
CORPORATE SOURCE: Univ. of Wisconsin, Madison
SOURCE: Journal of the American Chemical Society (1949), 71, 2964-5
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 45:3533
AB The dehydrogenations were performed as described in the preceding abstrs. The compound being dehydrogenated, temperature (°C.), time (hrs.), yield (%), and product formed are given below: 1-amylpyrrolidine, 300°, 1.5, 79, 1-amylpyrrole (I); 250°, 3, 79, I; 1-ethyl-2,3,4,5-tetramethylpyrrolidine, 300°, 1.5, 70, 1-ethyl-2,3,4,5-tetramethylpyrrole (II); 2-ethyl-3,4,5-trimethylpyrrolidine, 300°, 1.5, 56, 2-ethyl-3,4,5-trimethylpyrrole (III); 1-cyclohexylpyrrolidine, 350°, 5, 56, 1-cyclohexylpyrrole (IV); 1-phenylpyrrolidine, 350°, 5, 53, 1-phenylpyrrole; indoline, 200°, 1, 75, indole; 1,2,3,4-tetrahydrocarbazole (V) 300°, 3, 95, carbazole (VI); perhydrocarbazole, 350°, 4, 82, VI; 9-ethylperhydrocarbazole, 250°, 1.5, 98, 9-ethylcarbazole; 2-phenylpyrrolidine (VII), 300°, 1.5, 46, 2-phenylpyrrole (VIII); 2-cyclohexylpyrrolidine (IX), 300°, 3, 16, VIII; piperidine, 350°, 5, 48, pyridine; 2-pipecoline (X), 350°, 5, 62, 2-picoline; 3-pipecoline (XI) 350°, 5, 53, 3-picoline; 4-pipecoline (XII), 350°, 5, 64, 4-picoline; 2,6-lupetidine (XIII), 250°, 5, 45, 2,6-lutidine; trans-decahydroquinoline, 350°, 5, 42, quinoline (XIV); cis-decahydroquinoline, 350°, 5, 47, XIV; 1-benzoyl-cis-decahydroquinoline, 350°, 5, 57, XIV. The phys. consts. of some of these compds. are (compound, b.p./mm., d, n25D, MD calculated, MD found, resp.):
IV, 114°/19, d20 0.953, 1.5140, -, -; I, 80-2°/15, d20 0.859, 1.4694, 44.33, 44.52; II, 84-90°/9, d25 0.899, 1.4930, 49.15, 48.77; III, 81-6°/10, d25 0.895, 1.4890, 44.18, 44.04.
There is more tendency for the heterocyclic compds., especially the piperidines, to go to compds. of higher mol. weight during dehydrogenations.
The yields of 8 compds. containing the pyridine nucleus averaged 50%; those
for 10 compds. containing the pyrrole nucleus averaged 73%. The yields for
compds. with the carbazole nucleus were almost quant. The yields of I, II, and III are attractive for preparing these compds. 1-Benzoylpyrrolidine,
1-carbethoxypyrrolidine, nicotine, or 4-phenylpiperidine could not be dehydrogenated. X, XI, XII, and XIII were prepared by hydrogenation of the
corresponding pyridine derivs. V, m. 118-20°, was made by the Fischer indole synthesis from cyclohexanone phenylhydrazone.

L4 ANSWER 73 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 94673-00-4P, Quinoline, 1-benzoyldecahydro-
RL: PREP (Preparation)
(preparation of)
RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



L4 ANSWER 74 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1949:6475 CAPLUS
DOCUMENT NUMBER: 43:6475
ORIGINAL REFERENCE NO.: 43:1414f-i,1415a-b
TITLE: Synthetical and stereochemical investigations of reduced cyclic bases. II. cis- and trans-Decahydroquinolines
AUTHOR(S): King, F. E.; Henshall, T.; Whitehead, R. L. St.D.
SOURCE: Journal of the Chemical Society (1948) 1373-5
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C.A. 39, 4324.6. The following synthesis is analogous to that described in part I for the preparation of the isomeric 2-ethylcyclohexylamines. Et 2-oxocyclohexanecarboxylate (63.5 g.) in 10 cc.
EtOH containing 8.9 g. Na, treated with 63.5 g. EtO(CH2)3 Br and refluxed 4
hrs., gives 66% Et 1-(3-ethoxypropyl)-2-oxocyclohexanecarboxylate (I), b11
167-8° (2,4-dinitrophenylhydrazone, deep yellow, m. 76°). I (97 g.) and 208 g. Ba(OH)2 in 560 cc. H2O, refluxed 6 hrs., give 42% 2-(3-ethoxypropyl)cyclohexanone (II), b12 128-9° (2,4-dinitrophenylhydrazone, orange, m. 77°; semicarbazone, m. 96°), and 32% α-(3-ethoxypropyl)pimelic acid (III), b8 243-8°; 10 g. III and 35 g. Ac2O, heated 6 hrs., 15 g. Ac2O added, and the mixture refluxed an addnl. 3 hrs., give 23% II. II yields 87% of the oxime (IV), b12 163-4°, m. 47°. Reduction of IV with Na in EtOH gives 77% trans-2-(3-ethoxypropyl)cyclohexylamine, b8 114° [Bz derivative (V), m. 119°]. V (2 g.) and 50 cc. 50% HBr, refluxed 8 hrs. and the residue kept overnight with NH4OH and ether, give trans-N-[2-(3-bromopropyl)cyclohexyl]-benzamide (?), m. 127°, and 41% trans-decahydroquinoline-HCl, m. 278° (decomposition); the free trans-base (VI) b15, 78-80°, m. 48°. IV (10.4 g.) in 75 cc. EtOH saturated with NH3, hydrogenated over Raney Ni at 130°/37 atmospheric,
yields 7 g. of a mixture of the cis and trans isomers, b13-14 119°; through the Bz derivative, some V can be isolated; 6.1 g. of the mixture, refluxed 5 hrs. with 122 cc. 50% HBr and the product treated with NH4OH and ether, gives 0.4 g. of the HBr salt of VI; the ether solution yields some
cis- VI. II (4.3 g.) and 7.2 g. HCO2NH4, heated 10 hrs. at 200° and the product shaken with H2O and ether, give 78% of the mixed formamides, b7 187-91°; on standing, 18% trans-N-(ethoxypropylcyclohexyl)formamide (VII), m. 84°, seps.; hydrolysis and reaction with BzCl give V; the oily portion (3.2 g.), refluxed 1.5 hrs. with 9 cc. concentrated HCl and 9 cc. EtOH and the fraction (1 g.) b11
117° treated with BzCl, gives cis-N-[2-(3-ethoxypropyl)cyclohexyl]benzamide (VIII), m. 54°. The oily cis isomer of VII (2 g.) yields 0.5 g. cis-VI.HCl, m. 218° (decomposition); it also results from VIII. No evidence was detected of the isomerization of cis- to trans-VI.HCl on heating the former with concentrated HCl.
IT 5710-04-3P, Quinoline, 1-benzoyldecahydro-, cis-
RL: PREP (Preparation)
(preparation of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 74 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



L4 ANSWER 75 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1946:10034 CAPLUS
DOCUMENT NUMBER: 40:10034
ORIGINAL REFERENCE NO.: 40:1835c-i,1836a
TITLE: Cycloalkenopyridines. III. Pyrindan and bz-tetrahydroquinoline
AUTHOR(S): Prelog, V.; Szpilfogel, S.
CORPORATE SOURCE: Tech. Hochschule, Zurich
SOURCE: Helvetica Chimica Acta (1945), 28, 1684-92
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Pyrindan (cyclopenteno-2,3-pyridine) (I) and bz-tetrahydroquinoline (cyclohexeno-2,3-pyridine) (II) are prepared by the method applied for the preparation of cyclohepteno-2,3-pyridine (III) (cf. P. and Hinden, C.A. 40, 1510.6). Dry NH3 is passed into 60 g. Et cyclopentan-2-one-1-carboxylate containing 33 g. NH4NO3 for 48 hrs., giving 70% Et 2-amino-1-cyclopentene-1-carboxylate (IV), m. 57-8°. Condensation of IV with CH2(CO2Et)2 in the presence of EtONa at 110° for 30 hrs. gives 76.5% Et 4,6-dihydroxycyclopenteno-2,3-pyridine-5-carboxylate, m. 221° (decomposition), which when refluxed for 24 hrs. with dilute HCl gives in quant. yield 4,6-dihydroxycyclopenteno-2,3-pyridine (V) which chars above 305°. When 7.9 g. V is heated with 30 g. POCl3 for 6 hrs. at 180°, 8 g. 4,6-dichlorocyclopenteno-2,3-pyridine (VI), b11 126-8°, is obtained. Reduction of 7.9 g. VI in a solution of 8 g. Na in 200 cc. MeOH in the presence of 16 g. Raney Ni and conversion of the reaction product into the picrate gives the picrate (VII) of I, m. 181-2°. I, regenerated from VII, b11 90°, d420 1.0359, nα20 1.53962, nD20 1.54446, nβ20 1.55692, mol. refraction 45.68, (styphnate, yellow needles from MeOH, m. 178-9° (decomposition); picrolonate, orange prisms from MeOH, m. 235-6° (decomposition)). Dehydrogenation expts. with I with Pd-charcoal or with Se failed. Reduction of I with Na in boiling EtOH gives 76% trans(?)-cyclopentano-2,3-piperidine, b13 64-6°; picrolonate, m. 241°. Et cyclohexan-2-one-1-carboxylate and NH3 in the presence of NH4NO3 give 77% Et 2-amino-1-cyclohexene-1-carboxylate, m. 72-3.5°, which when condensed with NaHC(CO2Et)2 gives 71.5% Et 2,4-dihydroxy-bz-tetrahydro-3-quinolinecarboxylate (VIII), m. 234° (carbonization). Saponification and decarboxylation of VIII give 2,4-dihydroxy-bz-tetrahydroquinoline (IX), decomposing above 310° without melting. IX and POCl3 give 86% 2,4-dichloro-bz-tetrahydroquinoline, b14 149-50°, which when reduced gives II, isolated as the picrate (X) m. 158°. II, regenerated from X, b12 92-5°, d420 1.0304, nα20 1.53887, nD20 1.54257, nβ20 1.55503, nγ20 1.56481, mol. refraction 40.69. Dehydrogenation of II by heating 150 mg. with 300 mg. 18% Pd-charcoal for 3 hrs. at 300° in a sealed tube gives 85% quinoline, isolated as the picrate, m. 197°. Reduction of II with Na in boiling EtOH, conversion of the reduction product into the N-Bz derivative, and chromatographic fractionation of the latter give the low-melting 1-benzoyl-trans-decahydroquinoline. Saponification of the latter with

L4 ANSWER 75 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
HCl gives trans-decahydroquinoline-HCl, m. 286-7.5° (Huckel and Stepf, C.A. 21, 2903, found 275°). Probably other piperidine derivs. obtained by reduction of cycloalkeno-2,3-pyridines with Na and EtOH also have the trans configuration in accord with the rule of Skita (C.A. 16, 2321; 17, 1787). cis-Decahydroquinoline, when heated with concd. HCl at 160°, is recovered unchanged. III has d420 1.013, nD20 1.4504, mol. refraction 45.68. The mol. dispersions and the ultraviolet absorption spectra of these cycloalkeno-2,3-pyridines are detd. All m. ps. are cor.

IT 22218-33-3P, Quinoline, 1-benzoyldecahydro-, trans-
RL: PREP (Preparation)
(preparation of)
RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 76 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1936:45186 CAPLUS
DOCUMENT NUMBER: 30:45186
ORIGINAL REFERENCE NO.: 30:5990d-g
TITLE: Stereoisomerism of 6-methyldecahydroquinoline. Preliminary note
AUTHOR(S): Fujise, Shin-ichiro; Iwakiri, Mitsuo
SOURCE: Bulletin of the Chemical Society of Japan (1936), 11, 293-4
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Hydrogenation of 6-methylquinoline (I) in AcOH with PtO2 at 60° gave a quant. yield of completely hydrogenated I, b. 213-15°. On strong cooling about 3/7 of the distillate crystallized The crystals (II) were filtered, and, after recrystn. from petr. ether, m. 68-9°. The remaining liquid base was further purified over the HBr salt, and remained liquid (III). II, b. 211.5-12°, d474 0.8694, nD74 1.46005, EMD 0.69, (HCl salt, m. 265°; HBr salt, m. 244-5°; HAuCl4 salt, m. 117-19°; H2PtCl6 salt, m. 171.5-2.5°; p-nitrobenzoyl derivative, m. 124.5-25°; Bz derivative, m. 95-9°), is trans-6-methyldecahydroquinoline, and III, b. 212-12.5°, d474 0.8843, nD74 1.46514, EMD 0.33 (HCl salt, m. 263-4°; HBr salt, m. 252-3°; HAuCl4 salt, m. 152-3°; H2PtCl6 salt, m. 230° (decomposition); p-nitrobenzoyl derivative, m. 138-9°), is the cis-form. II was resolved, using d-bromocamphorsulfonic acid, giving pure d-II, m. 92-3°, [α]D14.5 4.8° (in EtOH).

IT 856089-42-4, Quinoline, decahydro-6-methyl-1-p-nitrobenzoyl-
(isomers)
RN 856089-42-4 CAPLUS
CN Quinoline, decahydro-6-methyl-1-p-nitrobenzoyl- (3CI) (CA INDEX NAME)



IT 856089-80-0P, Quinoline, 1-benzoyldecahydro-6-methyl-
RL: PREP (Preparation)
(preparation of)
RN 856089-80-0 CAPLUS
CN Quinoline, 1-benzoyldecahydro-6-methyl- (3CI) (CA INDEX NAME)

L4 ANSWER 76 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 77 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1928:33048 CAPLUS
DOCUMENT NUMBER: 22:33048
ORIGINAL REFERENCE NO.: 22:3890h-i,3891a-d
TITLE: Stereoisomerism of 8-hydroxydecahydroquinoline and its derivatives
AUTHOR(S): Fujise, Shinichiro
SOURCE: Scientific Papers of the Institute of Physical and Chemical Research (Japan) (1928), 8, 161-71
CODEN: SPIPAG; ISSN: 0020-3092
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The hydrogenation of 8-hydroxyquinoline (I) in AcOH, with Pt black as a catalyst, gives 10% of decahydroquinoline (II) and a mixture of two stereoisomers (A and B) of 8-hydroxydecahydroquinoline (III). A as isolated by crystallization of the base from petroleum ether, m. 111-2°, b20 136-46°; HCl salt, m. 201-2°; HBr salt, m. 202-3°; chloroaurate, m. 191-2°; d-bromocamphorsulfonate, m. 250-3°. The 8-Bz derivative of A, prepared by the Schotten-Baumann reaction and crystallized from aqueous acetone, m. 130-1°; the HCl salt m. 255-6°. N-O-Di-Bz derivative of A, prepared by treating A with an excess of BzCl and pyridine, m. 81-3°. B, m. 92-3°, is obtained by crystallization of its HBr salt, m. 251°, from absolute alc.; HCl salt, m. 247-8°; chloroaurate, m. 188-9°. The 8-Bz derivative of B m. 93-5°; HCl salt, m. 251°. A or B, when converted to the alcoholate by Na, heated to 140°, and treated with HCl, gives another isomer (C) of III, m. 101-2°; HCl salt (IV) of C m. 245-6°; chloroaurate, m. 152-3°. The 8-Bz derivative of C m. 99-100°; HCl salt, decomps. 302°. N-O-Di-Bz derivative of C, obtained as with A, m. 92-3°. N-Me derivative of C (V), prepared by treating IV with 40% CH2O at 130-40°, b8 125-6°; picrate m. 123-4°; MeI addition compound, m. 285-6° (gas evolution). The 8-benzoyl-N-methyl derivative of C, obtained by treating V with Bz2O and then crystallizing from petroleum ether, m. 91-2°; chloroplatinate, m. 231°; picrate, m. 193-5°. C treated with Me2SO4 and alkali, followed by treatment with KI, gives the corresponding quinolinium iodide, m. 285-6°, but none of the corresponding MeO derivative; picrate of the quaternary base, m. 173-4°. The d-bromocamphorsulfonate (VI) of the d-form of C m. 294-5°, [α]D25 84.9°. The impure free base obtained from VI shows [α]D23 47.6°; HBr salt m. 213-4°, [α]D25 29.6°. The corresponding sulfonate of the l-form of C m. 262-3°, [α]D23 41.8°; impure, free base, [α]D22 -53.1°; HBr salt, m. 211-3°, [α]D23-31.6°. Catalytic hydrogenation of quinoline (VII) with Pt-black gives II, m. 48-48.5°, b. 201°; HBr salt, m. 277-9°; chloroaurate, m. 124-5°; chloroplatinate, m. 228° (decomposition); and also a liquid isomer of II, whose N-Bz derivative m. 96-7°. The N-Bz derivative (VIII) of II m. 53-4°. Oxidation of VIII with KMnO4 gives o-benzoylaminohexahydrophenylpropionic acid (IX),

L4 ANSWER 77 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
m. 199- 200°, which on warming with concd. HCl gives octahydrocarbostyril, m. 152-3°. Hydrogenation of VII by the Sabatier method gives 80% of II, m. 48-48.5°, and a liquid material (X) (purified by crystn. of the HBr salt, m. 232°) that is a stereoisomer of II, b. 205-6°, b19-21 89-91°, d420 0.9426, nD20 1.4926; HCl salt, m. 223-4°; chloroaurate m. 157-8°; picrate, m. 135-6°. The N-Bz deriv. of X m. 96-7°, and on oxidation with KMnO4 gives an acid, IX, m. 156-7°. As to the explanation of the foregoing isomerism, F. believes A and B to be cis-forms, but reserves further comments on this for a future publication.
IT 94673-00-4, Quinoline, 1-benzoyldecahydro- (isomers)
RN 94673-00-4 CAPLUS
CN Quinoline, 1-benzoyldecahydro- (7CI, 9CI) (CA INDEX NAME)



IT 876491-85-9P, 8-Quinolinol, 1-benzoyldecahydro-
RL: PREP (Preparation)
(preparation of)
RN 876491-85-9 CAPLUS
CN 8-Quinolinol, 1-benzoyldecahydro- (3CI) (CA INDEX NAME)



L4 ANSWER 78 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1927:23594 CAPLUS
DOCUMENT NUMBER: 21:23594
ORIGINAL REFERENCE NO.: 21:2903b-d
TITLE: Stereochemistry of bicyclic ring systems. IV. Stereoisomerism of decahydroquinoline
AUTHOR(S): Huckel, Walter; Stepf, Friedrich
SOURCE: Justus Liebigs Annalen der Chemie (1927), 453, 163-76
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 21:23594
AB cf. C. A. 21, 1112. Attempts to prepare 2-ketodecahydroquinoline by the reduction of o-O2NC6H4CH:CHCO2H or its cyclohexyl ester, m. 55-6°. gave principally 2-keto-1-2,3,4-tetrahydroquinoline. Hydrogenation of quinoline H oxalate in the presence of colloidal Pt gives the trans-decahydroquinoline, b735, 203° m. 48° d456.5 0.9021, n 1.46917,1.47190,1.47827 and 1.48347 for α, He, β and γ at 55.8° (Bz derivative, m. 56°) and a liquid cis-isomer (10%), m. about -40°, b735 205°, d456 0.9191, n 1.47409, 1.47681, 1.48318 and 1.48873 at 55.7° (HCl salt, m. 226°; picrate, m. 142-5°; dithiocarbamate, m. 143°; phenylurethan, m. 163-5°; B2 derivative, m. 96°). In the presence of HCl 65% of the cis-isomer is formed, while in neutral solution only the tetrahydro derivative results. Certain corrections to the terminology of Bamberger's compds. (Ber. 23, 1138; 27, 1458) are made.
IT 5710-04-3P, Quinoline, 1-benzoyldecahydro-, cis-
22218-33-3P, Quinoline, 1-benzoyldecahydro-, trans-
RL: PREP (Preparation)
(preparation of)
RN 5710-04-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, cis- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 22218-33-3 CAPLUS
CN Quinoline, 1-benzoyldecahydro-, trans- (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 78 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 79 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1923:21828 CAPLUS
DOCUMENT NUMBER: 17:21828
ORIGINAL REFERENCE NO.: 17:3342c-i,3343a
TITLE: bz-Tetrahydroquinolines and their derivatives. II
AUTHOR(S): v. Braun, Julius; Gmelin, Walter; Schultheiss, Adam
SOURCE: Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1923), 56B, 1338-47
CODEN: BDCBAD; ISSN: 0365-9488
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C. A. 17, 1965. Below are given the relative % of bz- and py-tetrahydro derivs., resp., obtained in the catalytic hydrogenation of methylated quinolines: 8-Me, 0, 100; 7-Me, 0, 100; 6-Me, 0, 100; 5-Me, not studied; 4-Me, 33, 66; 3-Me, 33, 66; 2-Me, 4, 96; 2,3-Me2, 44, 56; 2,4-Me2, 80, 20; 2,3,4-Me3, > 80, -. These results, in connection with those reported in the earlier paper, show that substitution in the C6H6 nucleus prevents hydrogenation of that nucleus while loading of the C5H5N nucleus with substituents favors hydrogenation of the C6H6 nucleus. Thus, by suitable substitution of the quinoline it is possible to obtain any desired relative hydrogenation of the 2 nuclei, and as the bz-tetrahydro compds. are smoothly reduced in the C5H5N nucleus by Na and alc. the way is now open for the preparation of an extensive series of decahydroquinolines.
To the reduced Ni salt in tetra- or decahydronaphthalene suspension in the pressure hydrogenation apparatus described in earlier papers was added the methylated quinoline, in the same solvent, and the temperature was raised until the absorption of H began (110-90°); when the reaction was ended, the mixture was diluted with Et2O, filtered from the Ni, shaken out with acid, the extract made alkaline and the tertiary bz-tetrahydro bases were separated from the isomeric secondary py-compds. by treatment with BzCl. py-8-Methyltetrahydroquinoline; N-NO derivative, m. 51°; Bz derivative, m. 108°. 7-Me isomer, b12 130-2°; Bz derivative, m: 70-2°; picrate, m. 173-4°; HCl salt, m. 175°. py-Tetrahydrolepidine, b12 130°; Bz derivative, m. 129°. bz-Isomer (4-methyl-5,6-tetramethylenepyridine), b11 122°, does not react with HNO2; HCl salt, m. 203-4°; picrate, m. 170°; methiodide, darkens 179°, m. 183°. With 3 times the calculated amount of Na in alc. the base gives the decahydro compound, b11 105°; HCl salt, m. 205°; picrate, m. 159°; phenylthiourea, m. 105°; with MeI and alkali the decahydro base gives a compound C12H24NI, m. 235°. py-Tetrahydro-3-methylquinoline, b10 116-8°; Bz derivative, m. 84°; HCl salt, m. 207°; picrate, m. 155°; NO derivative, oil. bz-Isomer, b11 126-7°; HCl salt, oil; chloroplatinate, decomps. 219°; picrate, m. 171°; methiodide, m. 162°. Decahydro compound, b15 125-7°, m. 70-1°; NO and Bz derivs., oils; picrate, m. 75°, HCl salt, sinters about 210°, m. 218°. bz-Tetrahydroquinaldine, b12 101-4°, d416 1.0000; picrate, lemon-yellow, m. 154°; HCl salt, slightly hygroscopic, m. 164°; methodide, quite hygroscopic, m. 118°. py-Isomer, b12 115-6°; Bz deriv., m. 116°; HCl salt, m. 128-30°. The 2,3-dimethylquinoline (I), m. 68-9°, was prepd. by Pfitzinger's method by decarboxylation of the 2,3-dimethylcinchoninic acid (II) obtained from isatin and MeCOEt (J. prakt. Chem. 56, 314(1897)); it crysts. slowly and incompletely from the oily crude product and is freed from the accompanying oil by pressing on clay. To det. whether the I thus obtained is really pure, the crude II was converted into the Ag salt and heated several hrs. on the H2O bath with an excess of MeI; the resulting Me ester, warmed a short time at 40° on clay, can be sepd. into a fraction, m. 120-1°, hydrolyzed by aq. alc. KOH to the pure II, the latter on decarboxylation yielding I, while the part of the ester which goes into the clay and is extd. with Et2O b13 176-8°, m. 38°, and is hydrolyzed to 2-ethylcinchoninic acid. As the I obtained from the ester mixt. agrees completely in its properties with that isolated from the base mixt. it can with all probability be assumed to be homogeneous. py-Tetrahydro-2,3-dimethylquinoline, b13 127-8° d415 1.0048; Bz deriv., m. 94-5°; HCl salt, m. 154°; picrate, m. 161°; NO deriv., yellow 56°. bz-Isomer, b14 125-6°, m. 38°; HCl salt, very hygroscopic, m. 192°; picrate, m. 169°; methiodide, m. 117°. Decahydro compd., b11 95-7°, d415 0.9152; picrate and NO deriv., oils; HCl salt, does not m. 280°; methiodide, m. 199°. py-Tetrahydro-2,4-dimethylquinoline, b12 125-7°; Bz deriv., m. 110°. bz-Isomer, b12 122-3°; picrate, m. 141-5°; HCl salt; NO deriv., yellow oil; quaternary methiodide, sinters about 200°, m. 210°.

IT 861385-97-9P, Quinoline, 1-benzoyldecahydro-3-methyl-
RL: PREP (Preparation)
(preparation of)

RN 861385-97-9 CAPLUS
CN Quinoline, 1-benzoyldecahydro-3-methyl- (2CI) (CA INDEX NAME)



```
=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   433.43     612.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -63.20     -63.20

FILE 'REGISTRY' ENTERED AT 16:53:59 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 APR 2008  HIGHEST RN 1011757-08-6
DICTIONARY FILE UPDATES:   2 APR 2008  HIGHEST RN 1011757-08-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-542,759-1 - isoquinoline.str
```





chain nodes :
11 18 20 21 22 23 24 25 27 28 29 30 31 32 34 35 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
1-22 1-23 2-20 2-21 3-11 4-37 4-38 5-35 6-24 7-32 7-34 8-30 8-31 9-28
9-29 10-25 10-27 11-18 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 1-22 1-23 2-3 2-20 2-21 3-4 3-11 4-5 4-37 4-38 5-6 5-7 5-35
6-10 6-24 7-8 7-32 7-34 8-9 8-30 8-31 9-10 9-28 9-29 10-25 10-27 11-18

exact bonds :
11-12
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 :

G1:H,Ak,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,Ak,O

Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss sam
SAMPLE SEARCH INITIATED 16:54:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 32968 TO ITERATE

6.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 648504 TO 670216
PROJECTED ANSWERS: 86 TO 572

L6 1 SEA SSS SAM L5

```
=> s l5 sss full
FULL SEARCH INITIATED 16:54:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   658492 TO ITERATE

100.0% PROCESSED   658492 ITERATIONS                              407 ANSWERS
SEARCH TIME: 00.00.07

L7          407 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.82     791.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -63.20

FILE 'CAPLUS' ENTERED AT 16:55:08 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Apr 2008  VOL 148 ISS 14
FILE LAST UPDATED: 2 Apr 2008  (20080402/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8          32 L7

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 32 ANSWERS - CONTINUE? Y/(N):y
```

L8 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1454483 CAPLUS
DOCUMENT NUMBER: 148:79076
TITLE: Preparation of benzamide compounds containing heterocycle moiety as PARP inhibitors
INVENTOR(S): Javaid, Muhammad Hashim; Gomez, Sylvie; Cockcroft, Xiao-Ling Fan; Menear, Keith Allan; Martin, Niall Morrison Barr
PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007144652	A2	20071221	WO 2007-GB2247	20070615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-804848P P 20060615

OTHER SOURCE(S): MARPAT 148:79076
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2-R5 = H, alkoxy, amino, etc.; Y = -CR11R12-(CH2)m-; m = 0 or 1; R11 = CH3 or CF3; R12 = H or CH3; or R11 and R12 together with the carbon atom to which they are attached form 1,1-cyclopropylene group; R21, R22 = H or R; R = (un)substituted alkyl, heterocyclyl or aryl; or R21 and R22 together with the carbon atom to which they are attached form a (un)substituted nitrogen containing heterocyclic ring; Het = Q1, etc.; Y1, Y3 = CH or N; Y2 = CX or N; X = H, Cl or F] and their pharmaceutically acceptable salts were prepared Thus, a multi-step synthesis of compound II, starting from 2-fluoro-5-formylbenzonitrile, was given. In PARP

L8 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Poly(ADP-ribose) polymerase) inhibition assays, compd. II exhibited the IC50 value of less than 1 μM. Compds. I are claimed useful for the treatment of vascular diseases, septic shock, etc.
IT 960244-72-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide compds. containing heterocycle moiety as PARP
inhibitors for treatment of vascular diseases, septic shock)
RN 960244-72-8 CAPLUS
CN Benzamide, 2-[1-[4-fluoro-3-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]ethoxy]- (CA INDEX NAME)



L8 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1454122 CAPLUS
DOCUMENT NUMBER: 148:79062
TITLE: Preparation of heterocyclylcarbonylphenylalkoxybenzamides as poly(ADP-ribose) polymerase (PARP) inhibitors.
INVENTOR(S): Javaid, Muhammad Hashim; Gomez, Sylvie; Cockcroft, Xiao-Ling Fan; Menear, Keith Allan; Martin, Niall Morrison Barr
PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 56pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007144639	A1	20071221	WO 2007-GB2232	20070615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-804849P P 20060615

OTHER SOURCE(S): MARPAT 148:79062
GI



AB Title compds. [I; R2-R5 = H, alkoxy, amino, halo, OH; Y = CR21R22(CH2)m; m = 0, 1; R21 = H, Me, CF3; R22 = H, Me; R21R22C = 1,1-cyclopropylene; R11, R12 = H, R; R = (substituted) alkyl, heterocyclyl, aryl; R11R12N = (substituted) 5-7 membered heterocyclyl; Y1, Y3 = CH, N; Y2 = CX, N; X = H, Cl, F], were prepared Thus, 2-[2-[3-fluoro-4-[4-(2-

L8 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenoxypropionyl)piperazine-1-carbonyl]phenyl]ethoxy]benzamide [multistep prepn. from 2-(3-fluorophenyl)ethan-1-ol, salicylamide, Boc-piperazine, and 2-phenoxypropionyl chloride given] and other I inhibited mammalian PARP with IC50 values of <10 μM.
IT 960250-15-1P 960250-28-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylcarbonylphenylalkoxybenzamides as PARP inhibitors)
RN 960250-15-1 CAPLUS
CN Benzamide, 2-[2-[3-fluoro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]ethoxy]- (CA INDEX NAME)



RN 960250-28-6 CAPLUS
CN Benzamide, 5-fluoro-2-[[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1051323 CAPLUS
DOCUMENT NUMBER: 147:534024
TITLE: 2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists
AUTHOR(S): Clark, Robin D.; Ray, Nicholas C.; Blaney, Paul; Crackett, Peter H.; Hurley, Christopher; Williams, Karen; Dyke, Hazel J.; Clark, David E.; Lockey, Peter M.; Devos, Rene; Wong, Melanie; White, Anne; Belanoff, Joseph K.
CORPORATE SOURCE: Corcept Therapeutics, Menlo Park, CA, 94025, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(20), 5704-5708
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:534024

AB The 2-azadecalin ring system was evaluated as a scaffold for the preparation of glucocorticoid receptor (GR) antagonists. High affinity, selective GR antagonists were discovered based on a hypothetical binding mode related to the steroidal GR antagonist RU-43044. 2-Benzenesulfonyl substituted 8a-benzyl-hexahydro-2H-isoquinolin-6-ones exemplified by (R)-37 had low nanomolar affinity for GR with moderate functional activity (200 nM) in a reporter gene assay. These compds. were devoid of affinity for other steroidal receptors (ER, AR, MR, and PR). Analogs based on an alternative putative binding mode (CP-like) were found to be inactive.

IT 956912-48-4P 956912-50-8P 956912-53-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(2-benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists)

RN 956912-48-4 CAPLUS
CN Methanone, 1H-indol-6-yl[(4aR,6R,8aS)-octahydro-6-hydroxy-8a-(phenylmethyl)-6-(1-propyn-1-yl)-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 956912-50-8 CAPLUS
CN Acetamide, N-[4-[[(4aR,6R,8aS)-octahydro-6-hydroxy-8a-(phenylmethyl)-6-(1-

L8 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
propyn-1-yl)-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 956912-53-1 CAPLUS
CN Acetamide, N-[3-[[(4aR,6R,8aS)-octahydro-6-hydroxy-8a-(phenylmethyl)-6-(1-propyn-1-yl)-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:874154 CAPLUS
DOCUMENT NUMBER: 147:257665
TITLE: Spirochromane derivatives as histamine H3 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Butler, Todd William; Howard, Harry Ralph, Jr.; Wager, Travis T.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007088462	A1	20070809	WO 2007-IB235	20070122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-764230P P 20060201

OTHER SOURCE(S): MARPAT 147:257665
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to spirochromane derivs. of formula I, which are histamine H3 receptor antagonists. In compds. I, R1 is selected from (un)substituted Ph, (un)substituted naphthyl, (un)substituted 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, and (un)substituted carbamoyl; and R2 is C1-4 alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I, and optionally a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of disorders or conditions that respond to H3 receptor antagonism, such as depression, anxiety disorders, and attention-deficit disorders. Cyclocondensation of 5'-bromo-2'-hydroxyacetophenone with N-Boc-piperidin-4-one followed by hydride reduction and deoxygenation yielded

L8 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
spirochromane II, which underwent alkylation with Et iodide and Suzuki coupling with 2-methoxypyridine-5-boronic acid to give spirochromane III. The compds. of the invention, e.g., III, are antagonists of histamine H3 receptors (no data).

IT 945723-21-7P 945723-25-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of spirochromane derivs. as histamine H3 receptor antagonists)

RN 945723-21-7 CAPLUS
CN Methanone, (1'-ethyl-3,4-dihydrospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl)[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 945723-25-1 CAPLUS
CN Methanone, (1'-ethyl-3,4-dihydrospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl)(octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



L8 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:817925 CAPLUS
DOCUMENT NUMBER: 147:211730
TITLE: Isoindole derivatives as cannabinoid receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Chackalamannil, Samuel; Chelliah, Mariappan V.; Clasby, Martin C.; Eagen, Keith A.; Scott, Jack D.; Wang, Yuguang; Xia, Yan; Greenlee, William J.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: PCT Int. Appl., 406pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007084450	A2	20070726	WO 2007-US1024	20070116
WO 2007084450	A3	20071108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070197628	A1	20070823	US 2007-653558	20070116
PRIORITY APPLN. INFO.:			US 2006-760007P P	20060118
			US 2006-846965P P	20060925

OTHER SOURCE(S): MARPAT 147:211730
GI

L8 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB A compound having the general structure of formula I or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders. Compds. of formula I wherein m is 0 and 1; n is 1 and 2; and m + n is 1 and 2; dashed lines is single and double bonds; R1 is CONH2 and derivs., CO2-alkyl, and acyl; R2 is H, (un)substituted alkyl, and alkylene-NH2 and derivs.; R1R2 taken together fo form a (un)substituted 5-membered heterocyclic ring; R15 is H, N3, halo, alkenyl, (un)substituted alkylene, OH, CN, etc.; Ar1 and Ar2 are independently (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, solvates and esters thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their cannabinoid receptor modulatory activity. From the assay, it was determined that compound II exhibited Ki value in the range of 10 to 1 nM.

IT 944815-64-9P 944818-07-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoindole derivs. as cannabinoid receptor modulators useful in the treatment of diseases or conditions mediated by cannabinoid receptors)

RN 944815-64-9 CAPLUS
CN 1H-Isoindol-1-one, 5-[2-chloro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(4-chlorophenyl)octahydro-3,7a-dimethyl-, (3R,3aS,4S,5R,7aR)- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 944818-07-9 CAPLUS
CN 1H-Isoindol-1-one, 5-[2-chloro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(4-chlorophenyl)octahydro-3,7a-dimethyl-, (3R,3aS,4S,5R,7aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:512058 CAPLUS
DOCUMENT NUMBER: 146:481830
TITLE: Substituted benzamide and 11β-hydroxysteroid dehydrogenase type 1 and their preparation and pharmaceutical use
INVENTOR(S): Andersen, Henrik Sune; Joergensen, Anker Steen; Kilburn, John Paul; Kampen, Gita Camilla Tejlgaard; Ebdrup, Soeren
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 185pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051810	A2	20070510	WO 2006-EP68015	20061101
WO 2007051810	A3	20080124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			EP 2005-110228 A	20051101
			EP 2006-116808 A	20060707

OTHER SOURCE(S): MARPAT 146:481830
GI

L8 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The use of substituted amides of formula I for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compds. as pharmaceutical compns., are described. Also a class of substituted amides of formula I, their use in therapy, pharmaceutical compns. comprising the compds., as well as their use in the manufacture of medicaments are described. Compound of formula I wherein R1 is H, acyl, (amino)sulfonyl, (amino)sulfinyl, etc.; R2 is H, C1-6 alkyl, and C3-6 cycloalkyl; R1R2 taken together with N to form (un)substituted (un)saturated 3- to 12-membered (mono/bi)heterocyclic ring; A is (un)substituted (un)saturated 5- to 12-membered (bi/tri)heterocyclic; R5 is H, C1-6 alkyl, C3-6 cycloalkyl, halo, OH, and CN; R6 and R7 is H, C1-6 alkyl, F, trihalomethyl, and trihalomethoxy; R6R7 taken together to give (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic; and their prodrugs, pharmaceutically acceptable acid and base salts, optical isomers, mixts. of optical isomers, racemic mixts., tautomeric forms thereof, are claimed. The compds. are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. Example compound II was prepared by amidation ot 4-(tert-butoxycarbonylaminomethyl)benzoic acid with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride; the resulting [4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester underwent methylation with Me iodide to give methyl-[4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester, which underwent hydrolysis to give (4-methylaminomethylphenyl)-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methanone, which underwent acetylation with acetyl chloride to give compd. II. All the invention compds. were evaluated for their 11βHSD1 inhibitory activity. From the assay, it was detd. that compd. II exhibited an IC50 value of 19 nM.

IT 936019-82-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzamide derivs. as 11β-hydroxysteroid dehydrogenase type 1 inhibitors useful in the treatment of diseases)

RN 936019-82-8 CAPLUS

CN Methanone, [4-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



L8 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:143519 CAPLUS

DOCUMENT NUMBER: 146:229382

TITLE: Preparation of dipiperazinyl ketones and related analogues as modulators of histamine H3 receptor binding

INVENTOR(S): Xie, Linghong; Ochterski, Joseph W.; Gao, Yang; Han, Bingsong; Caldwell, Timothy M.; Xu, Yuelian; Peterson, John M.; Ge, Ping; Ohliger, Robert

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 279pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016496	A2	20070208	WO 2006-US29761	20060728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2606004	A1	20070208	CA 2006-2606004	20060728
US 20070049571	A1	20070301	US 2006-495986	20060728
PRIORITY APPLN. INFO.:			US 2005-704722P P	20050802
			WO 2006-US29761 W	20060728

OTHER SOURCE(S): MARPAT 146:229382

GI

L8 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [Z1 and Z2 independently = N or CRa wherein Ra = H, OH, halo, alkyl, etc.; Z3 = N or CRb wherein Rb = absent, H, OH, alkyl, etc.; bonds a and b independently represent single or double bond such that if Z3 = N, then bond a is single bond and at least on oe bond a or bond b = single bond; W = CR3R4, NR5, COCR3R4, CO2R3R4; R3 and R4 independently = H, alkyl, haloalkyl, etc.; R5 = H, alkyl, haloalkyl, etc.; each m independently = 0-2, such that neither m = 0 if both Z2 and Z3 = N; n = 0-2; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge; R6 = (un)substituted alkanoyl, alkoxycarbonyl, alkenyl, etc.; R7 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge], and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of histamine H3 receptor binding. Thus, e.g., II was prepared by acetylation of 1-cyclopentylpiperazine with bromoacetyl bromide followed by N-alkylation of 1-(4-piperazin-1-ylphenyl)ethanone. Details for bioassays are described (no data). I may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

IT 923934-89-8P 923934-90-1P 923934-91-2P 923934-92-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipiperazinyl ketones and related analogs as histamine H3 receptor modulators)

RN 923934-89-8 CAPLUS

CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[3-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 923934-90-1 CAPLUS
CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 923934-91-2 CAPLUS
CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[3-[[(4aS,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 923934-92-3 CAPLUS
CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[4-[[(4aS,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1206741 CAPLUS
DOCUMENT NUMBER: 145:489228
TITLE: Preparation of thiazole compounds for treating Hepatitis C virus infections
INVENTOR(S): Zhang, Suoming; Phadke, Avinash; Liu, Cuixian; Wang, Xiangzhu; Quinn, Jesse; Chen, Dawei; Gadhachanda, Venkat; Li, Shouming; Deshpande, Milind
PATENT ASSIGNEE(S): Achillion Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 254pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122011	A2	20061116	WO 2006-US17692	20060509
WO 2006122011	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006244203	A1	20061116	AU 2006-244203	20060509
CA 2607617	A1	20061116	CA 2006-2607617	20060509
US 20070004711	A1	20070104	US 2006-431155	20060509
EP 1879575	A2	20080123	EP 2006-770077	20060509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
KR 2008019213	A	20080303	KR 2007-728496	20071206
PRIORITY APPLN. INFO.:			US 2005-679133P	P 20050509
			WO 2006-US17692	W 20060509

OTHER SOURCE(S): MARPAT 145:489228
GI

L8 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. I [Ar1 = fluorenyl, Ph, naphthyl, etc.; R2 = halo, CO2H, CONH2, etc.; R3 = H, alkyl, C(O)R5 (wherein R5 = alkyl, Ph, 5-6 membered heteroaryl); R4 = H, halo, OH, etc.; or R2 and R4 are taken together with the carbon atoms of the thiazole ring to which they are attached to form 5-7 membered carbocyclic ring which is aromatic or partially unsatd.; r = 0-2; q = 0-1; t = 0-1] that are potent and/ or selective inhibitors of Hepatitis C virus replication, were prepared Thus, bromination of 3-acetylpyridine with Br2 followed by reacting 2-bromo-1-(pyridin-3-yl)ethanone with N-(4-pentyloxy-3-trifluoromethylphenyl)thiourea afforded II which showed EC50 of < 1 μM when tested in a replicon based assay of HCV replication inhibition. Certain compds. I inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compns. containing one or more compds. I , or a salt, solvate, or acylated prodrug of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with on or more other therapeutic agent.

IT 914667-43-9P 914668-24-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole compds. for treating Hepatitis C virus infections)

L8 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 914667-43-9 CAPLUS
CN Methanone, [4-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-2-(trifluoromethyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 914668-24-9 CAPLUS
CN Methanone, [4-[[4-(2-methoxy-5-pyrimidinyl)-2-thiazolyl]amino]-2-(trifluoromethyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



L8 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:213433 CAPLUS
DOCUMENT NUMBER: 144:274294
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Bishoff, Francois Paul; Bracken, Mirielle; Pieters, Serge Marie Aloysius; Mercken, Marc Hubert; De Winter, Hans Louis Jos; Berthelot, Dieder Jean-Claude
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N. V., Belg.
SOURCE: PCT Int. Appl., 369 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006024932	A1	20060309	WO 2005-IB2595	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1789398	A1	20070530	EP 2005-780525	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035772	A	20070912	CN 2005-80034228	20050808
JP 2008509129	T	20080327	JP 2007-524423	20050808
IN 2007KN00752	A	20070713	IN 2007-KN752	20070301

PRIORITY APPLN. INFO.: US 2004-599810P P 20040806
US 2004-599317P P 20040806
US 2004-599811P P 20040806
WO 2005-IB2595 W 20050808

OTHER SOURCE(S): MARPAT 144:274294
GI

L8 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; A1 = (un)substituted alkyl; Q1= O, S, CO, CS, NHCO, CONH, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; R3 = (un)substituted alk(en)yl, aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.
IT 876766-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)
RN 876766-27-7 CAPLUS
CN Isoquinoline, 2-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]decahydro- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:152738 CAPLUS
DOCUMENT NUMBER: 144:254142
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Baxter, Ellen; Bischoff, Francois Paul; Boyd, Robert; Braeken, Mirielle; Coats, Steven; Huang, Yifang; Jordan, Alfonzo; Luo, Chi; Mercken, Marc Hubert; Reynolds, Charles H.; Ross, Tina Morgan; Tounge, Brett A.; Schulz, Mark; De Winte, Hans Louis Jos; Pieters, Serge Maria Aloysius; Reitz, Allen B.
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017836	A2	20060216	WO 2005-US28191	20050808
WO 2006017836	A3	20060629		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1776349	A2	20070425	EP 2005-785256	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035771	A	20070912	CN 2005-80034122	20050808
JP 2008509165	T	20080327	JP 2007-525074	20050808
IN 2007KN00762	A	20070713	IN 2007-KN762	20070301

PRIORITY APPLN. INFO.: US 2004-599811P P 20040806
US 2004-599317P P 20040806
US 2004-599810P P 20040806
WO 2005-US28191 W 20050808

L8 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 144:254142
GI



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; A1 = (un)substituted alkyl; Q1 = O, S, CO, CS, NHCO, CONH, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl; m = 0-1; L1 = O, S, SO, SO2, etc.; R3 = (un)substituted alk(en)yl, aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.
IT 876766-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)
RN 876766-27-7 CAPLUS
CN Isoquinoline, 2-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]decahydro- (9CI) (CA INDEX NAME)

L8 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:149827 CAPLUS
DOCUMENT NUMBER: 144:254141
TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders
INVENTOR(S): Baxter, Ellen; Boyd, Robert; Coats, Steve; Jordan, Alfonzo; Reitz, Allen; Reynolds, Charles H.; Scott, Malcolm; Schulz, Mark; De Winter, Hans Louis Jos
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 382 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017844	A1	20060216	WO 2005-US28340	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060079686	A1	20060413	US 2005-197608	20050804
US 20060079687	A1	20060413	US 2005-197669	20050804
US 20060178383	A1	20060810	US 2005-197615	20050804
EP 1776350	A1	20070425	EP 2005-786778	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101035770	A	20070912	CN 2005-80034011	20050808
JP 2008509167	T	20080327	JP 2007-525078	20050808
IN 2007KN00792	A	20070713	IN 2007-KN792	20070306

PRIORITY APPLN. INFO.: US 2004-599317P P 20040806
US 2004-599810P P 20040806
US 2004-599811P P 20040806
WO 2005-US28340 W 20050808

OTHER SOURCE(S): MARPAT 144:254141
GI

L8 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; q = 0-1; A2 = (un)substituted alkyl; R = (un)substituted hetero/aryl, arylalkyl, hetero/cycloalkyl, partially unsatd. carbocyclyl, spiroheterocyclyl; provided that when q = 0; R is other than hetero/aryl; Q3 = O, S, CO, CS, OCO, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; L1 = O, S, SO, SO2, CO, NH and derivs., etc.; R3 = (un)substituted cyclo/alkyl, alkenyl, hetero/aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β-secretase in 3 different assays.

IT 876766-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-aminoquinazolines as β-secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-27-7 CAPLUS

CN Isoquinoline, 2-[3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]benzoyl]decahydro- (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1012143 CAPLUS
DOCUMENT NUMBER: 143:398877
TITLE: Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
AUTHOR(S): Coppola, Gary M.; Kukkola, Paivi J.; Stanton, James L.; Neubert, Alan D.; Marcopulos, Nicholas; Bilci, Natalie A.; Wang, Hua; Tomaselli, Hollis C.; Tan, Jenny; Aicher, Thomas D.; Knorr, Douglas C.; Jeng, Arco Y.; Dardik, Beatriz; Chatelain, Ricardo E.
CORPORATE SOURCE: Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6696-6712
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:398877

AB Hiqh-throughput screening identified 5 as a weak inhibitor of 11β-HSD1. Optimization of the structure led to a series of perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A tertiary benzamide is required for biol. activity and substitution of the terminal benzamide with either electron-donating or -withdrawing groups is tolerated. The majority of the compds. show selectivity of >20 to >700-fold over 11β-HSD2. Analogs which showed >50% inhibition of 11β-HSD1 at 1 μM in an cellular assay were screened in an ADX mouse model. A maximal response of >70% reduction of liver corticosterone levels was observed for three compds.; 9m, 25 and 49.

IT 735348-72-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)

RN 735348-72-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 867288-62-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)

RN 867288-62-8 CAPLUS

CN Isoquinoline, decahydro-2-(4-nitrobenzoyl)-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 867288-63-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)

RN 867288-63-9 CAPLUS

CN Isoquinoline, 2-(4-aminobenzoyl)decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:800492 CAPLUS
DOCUMENT NUMBER: 143:386895
TITLE: A phase-switch purification approach for the expedient removal of tagged reagents and scavengers following their application in organic synthesis
AUTHOR(S): Siu, Jason; Baxendale, Ian R.; Lewthwaite, Russell A.; Ley, Steven V.
CORPORATE SOURCE: Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
SOURCE: Organic & Biomolecular Chemistry (2005), 3(17), 3140-3160
CODEN: OBCRAK; ISSN: 1477-0520
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:386895
AB In this paper a variety of expedient chemical transformations and purifications achieved via a generic catch and release methodol., based on a synthetically inert bipyridyl chelating tag that can be selectively captured with a resin-bound copper(II) species, were reported. Utilizing this approach it was possible to derive many of the same benefits associated with both solid phase synthesis and supported reagent methods.
IT 866789-74-4P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of amides using amines and carboxylic acid as reactants and N-(cyclohexylcarbonimidoyl)bipyridine amine as coupling agent and study of phase-switch purification approach for expedient removal of tagged reagents and scavengers)
RN 866789-74-4 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(6-quinoxalinylcarbonyl)-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS

L8 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:347016 CAPLUS
DOCUMENT NUMBER: 142:411252
TITLE: Preparation of azabicyclooctane derivatives as CXCR3 antagonists
INVENTOR(S): Habashita, Hiromu; Suzuki, Ryo; Shibayama, Shiro; Tanihiro, Tatsuya; Kaneko, Yousuke; Egashira, Hiromu; Nishiyama, Eiji; Yamatsuta, Katsura; Fujita, Setsuko
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035534	A1	20050421	WO 2004-JP14864	20041007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2007015927	A	20070125	JP 2003-349033	20031008
JP 2007015930	A	20070125	JP 2004-266040	20040913
PRIORITY APPLN. INFO.:			JP 2003-349033 A	20031008
			JP 2004-266040 A	20040913

OTHER SOURCE(S): MARPAT 142:411252
GI



I

AB Title compds. I [ring A = (un)substituted heterobicycle, heterotricycle; ring B = (un)substituted cycle; Y = bond, spacer] were prepared For example, 1,3,3-trimethyl-6-(2-naphthoyl)-6-azabicyclo[3.2.1]octane (II) was prepared from 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane. In 11β-HSD1 inhibition assays, the IC50 value of compound II was 29 nM. Compds. I are claimed useful for the treatment of inflammation, allergy, etc. Formulations are given.
IT 850366-88-0P 850367-02-1P 850367-07-6P 850367-80-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azabicyclooctane derivs. as CXCR3 antagonists for treatment of inflammation, allery, etc.)
RN 850366-88-0 CAPLUS
CN Isoquinoline, decahydro-2-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 850367-02-1 CAPLUS
CN Isoquinoline, decahydro-2-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]benzoyl]-, (4aR,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850367-07-6 CAPLUS
CN Isoquinoline, decahydro-2-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]benzoyl]-, (4aS,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850367-80-5 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]benzoyl]-, (3S,4aS,8aS)-(CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4-[(4-piperidin-1-yl)piperidin-1-yl]benzoic acid hydrochloride, e.g., prepd. from 4-fluorobenzonitrile in 2 steps, afforded compd. III in 44% yield. In histamine analog binding inhibition assays, the IC50 value of compd. III was 7.5 (sic). Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.

IT 848822-88-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine compds. as histamine H3 antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 848822-88-8 CAPLUS
CN Isoquinoline, 2-(4-[1,4'-bipiperidin]-1'-ylbenzoyl)decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:283466 CAPLUS
DOCUMENT NUMBER: 142:355171
TITLE: Preparation of piperidine compounds as histamine H3 antagonists or inverse agonists
INVENTOR(S): Ohtake, Norikazu; Mizutani, Sayaka; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028438	A1	20050331	WO 2004-JP13768	20040921
WO 2005028438	A9	20050526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004274309	A1	20050331	AU 2004-274309	20040921
CA 2551037	A1	20050331	CA 2004-2551037	20040921
EP 1669350	A1	20060614	EP 2004-787951	20040921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1902177	A	20070124	CN 2004-80027372	20040921
US 20070105901	A1	20070510	US 2006-574087	20060321
IN 2006DN01894	A	20070713	IN 2006-DN1894	20060407

PRIORITY APPLN. INFO.: JP 2003-330758 A 20030922
WO 2004-JP13768 W 20040921

OTHER SOURCE(S): MARPAT 142:355171
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X1, X2 = N, CH; X3 = Os(CH2)m; s = 0, 1; m = an integer that (m+s) is 0 to 4; Y = II; j, k, l = 0, 1; L1 = alkylene, single bond; M = O, NR0; R0 = H, alkyl; Q1 = cyano, etc.] were prepared For example, HBTU mediated acylation of 1-cyclopentyl((3R)-methylamino)pyrrolidine with

L8 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:259680 CAPLUS
DOCUMENT NUMBER: 142:336356
TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors
INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierre; Plas, Pascale
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 213 pp., Cont.-in-part of U.S. Ser. No. 504,033.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050065179	A1	20050324	US 2004-915920	20040811
FR 2851563	A1	20040827	FR 2003-2320	20030226
FR 2851563	B1	20050422		
WO 2004075823	A2	20040910	WO 2004-FR418	20040225
WO 2004075823	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: FR 2003-2320 A 20030226
US 2003-504033 A2 20030920
WO 2004-FR418 W 20040225

OTHER SOURCE(S): MARPAT 142:336356
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH2, CO, (un)substituted COCH2; X = CH, N; R1, R2 = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R1NR2 = (un)substituted hetero(bi)cycloalkyl; R3 = alkyl, alkoxy, alkylthio, heteroaryl, (un)substituted hetero/cycloalkyl, aryl, etc.; R4 = (CH2)sR5; R5 = heterocycloalkyl, heteroaryl, etc.; s = 0-6] were prepared as melanocortin (MC), in particular MC4, receptor modulators (no data given).
For example, II was prepared, in 2 steps, by amination of 3-Fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (preparation given) with 3-(piperidino)propylamine in CH3CN at reflux, followed by one-step

L8 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are included such as pain, inflammatory conditions, etc.
IT 746660-21-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)
RN 746660-21-9 CAPLUS
CN Isoquinoline, 2-[[1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:182640 CAPLUS
DOCUMENT NUMBER: 142:280220
TITLE: Preparation of quinazoline-2,4(1H,3H)-dione derivatives as gonadotropin-releasing hormone antagonists
INVENTOR(S): Hamamura, Kazumasa; Oda, Tsuneo; Kusaka, Masami; Kanzaki, Naoyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 541 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019188	A1	20050303	WO 2004-JP12322	20040820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536313	A1	20050303	CA 2004-2536313	20040820
JP 2005097276	A	20050414	JP 2004-241721	20040820
EP 1657238	A1	20060517	EP 2004-772278	20040820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070010537	A1	20070111	US 2006-569391	20060222
PRIORITY APPLN. INFO.:			JP 2003-298637 A	20030822
			WO 2004-JP12322 W	20040820

OTHER SOURCE(S): MARPAT 142:280220
GI



L8 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title quinazoline-2,4(1H,3H)-dione derivs. I [wherein R1 = H or (un)substituted hydrocarbyl; ring A = (un)substituted aromatic 6-membered ring; ring B = (un)substituted (hetero)cyclyl; W = O or S; X1 and X2 = independently H, (un)substituted hydrocarbyl, or heterocyclyl; or X1 and X2 together form =O, =S, or (un)substituted =NH; Y = a bond or (un)substituted alkylene], or salts or prodrugs thereof are prepared as gonadotropin-releasing hormone antagonists. For example, the compound II was prepared in a multi-step synthesis. I inhibited 75.4-99.9% of human gonadotropin releasing hormone at the concentration of 10 nM. I are useful for the treatment of prostatic hyperplasia, hysteromyoma, endometriosis, uterus fibroma, etc. (no data). Formulations containing I as an active ingredient were also described.
IT 847168-15-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazoline-2,4(1H,3H)-dione derivs. as gonadotropin-releasing hormone antagonists)
RN 847168-15-4 CAPLUS
CN Isoquinoline, 2-[4-chloro-3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:964830 CAPLUS
DOCUMENT NUMBER: 141:410932
TITLE: Preparation of benzo[1,2,5]thiadiazoles as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions
INVENTOR(S): Allison, Brett; McAtee, Laura C.; Phuong, Victor K.; Rabinowitz, Michael H.; Shankley, Nigel P.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: U.S. Pat. Appl. Publ., 81 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224983	A1	20041111	US 2004-811292	20040326
US 7241759	B2	20070710		
AU 2004261547	A1	20050210	AU 2004-261547	20040326
CA 2520546	A1	20050210	CA 2004-2520546	20040326
WO 2005012275	A2	20050210	WO 2004-US9589	20040326
WO 2005012275	A3	20060511		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008899	A	20060418	BR 2004-8899	20040326
EP 1675837	A2	20060705	EP 2004-785868	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829704	A	20060906	CN 2004-80014470	20040326
JP 2006528241	T	20061214	JP 2006-532352	20040326
MX 2005PA10484	A	20060310	MX 2005-PA10484	20050928
NO 2005005002	A	20051214	NO 2005-5002	20051027
IN 2005KN02161	A	20061013	IN 2005-KN2161	20051031
US 20070276016	A1	20071129	US 2007-775535	20070710
PRIORITY APPLN. INFO.:			US 2003-458638P P	20030328
			US 2004-811292 A1	20040326
			WO 2004-US9589 W	20040326

OTHER SOURCE(S): MARPAT 141:410932
GI

L8 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title [[(2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]benzamides I [wherein R1, R2 = independently H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, naphthyl, benzoylalkyl, Ph, etc.; or NR1R2 = (un)substituted 10-oxa-4-azatricyclo[5.2.1.02,6]dec-4-yl, heterocyclyl, 8-oxo-1,5,6,8-tetrahydro-2H-4H-1,5-methanopyrido[1,2-a][1,5]diazocin-3-yl; R1 = independently (cyclo)alkyl, alkenyl, Ph, furanyl, thienyl, benzyl, pyrrolyl, OH, alkoxy, SH, CN, NO2, NH2, halo, etc.; Rb = independently alkyl, halo; and enantiomers, diastereomers, hydrates, solvates, and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin 2 (CCK2) receptor modulators. For example, 4-bromo-2-aminobenzoic acid piperidine amide (3-step preparation given) was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole in pyridine to afford II (74%). The latter showed binding to CCK2R specific zinc finger proteins fused with the herpes simplex virus VP16 activation domain with pKi of 7.6 and behaved as a competitive antagonist in a guinea pig gastric corpeal muscle assay with pKB of 8.8. Thus, I and their pharmaceutical compns. are useful for the treatment of CCK2 mediated conditions, such as pancreatic adenocarcinoma, pain, eating disorders, gastroesophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anemia, and Zollinger-Ellison syndrome (no data).

IT 791099-27-9P, 2,1,3-Benzothiadiazole-4-sulfonic acid N-[5-chloro-2-[(octahydroisoquinolin-2-yl)carbonyl]phenyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCK2 modulator; preparation of [[(benzo[1,2,5]thiadiazol-4-yl)sulfonyl]amino]benzamides as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions)

RN 791099-27-9 CAPLUS

CN Isoquinoline, 2-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-4-chlorobenzoyl]decahydro- (9CI) (CA INDEX NAME)

L8 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780704 CAPLUS
DOCUMENT NUMBER: 141:296035
TITLE: Preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators
INVENTOR(S): Mathews, Ian Richard
PATENT ASSIGNEE(S): Avidex Limited, UK
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081011	A1	20040923	WO 2004-GB1008	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220310	A1	20040923	AU 2004-220310	20040310
CA 2519063	A1	20040923	CA 2004-2519063	20040310
EP 1603917	A1	20051214	EP 2004-719006	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008365	A	20060321	BR 2004-8365	20040310
CN 1761664	A	20060419	CN 2004-80006886	20040310
JP 2006520372	T	20060907	JP 2006-505937	20040310
MX 2005PA09667	A	20060127	MX 2005-PA9667	20050909
NO 2005004710	A	20051213	NO 2005-4710	20051013
IN 2005CN02624	A	20070406	IN 2005-CN2624	20051013
US 20070021428	A1	20070125	US 2006-547448	20060620
US 7276505	B2	20071002		
US 20080045527	A1	20080221	US 2007-845837	20070828

PRIORITY APPLN. INFO.:
GB 2003-5876 A 20030314
GB 2003-19429 A 20030819
WO 2004-GB1008 W 20040310
US 2006-547448 A3 20060620

OTHER SOURCE(S): MARPAT 141:296035
GI

L8 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Title compds. [I; R1, R3 = H, F, Cl, Br, NO2, cyano, alkyl, fluoroalkyl, chloroalkyl, alkoxy, fluoroalkoxy; R4 = CO2H (ester), CONR6R7, NR7COR6, NR7COOR6, NHCONR6R7, NHCSNR6R7; R6 = H, (Alk)mQ; m = 0, 1; Alk = (substituted) alkylene, alkenylene, alkynylene, carbocyclylene which may contain ≥1 O, S, NR8; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl; Q = H, NR9R10; R9, R10 = H, alkyl, alkenyl, alkynyl, cycloalkyl, ester group, (substituted) carbocyclyl, heterocyclyl; R9R10N = (substituted) heterocyclyl; R7 = H, alkyl; R6R7 = atoms to form (substituted) heterocyclyl; X = bond, (Z)n(Alk), (Alk)(Z)n; Z = O, S, NH; n = 0, 1], were prepared Thus, 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoic acid (preparation given) was stirred with DMF, diisopropylethylamine, 3-dimethylaminopropylamine, and HTBU at room temperature for 2 h to give 40% N-[(3-dimethylamino)propyl] 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzamide (AV1142005). The latter inhibited interleukin-2 production by human Jurkat T cells by 65% at 30 μM.

IT 763147-08-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators)

RN 763147-08-6 CAPLUS

CN Isoquinoline, 2-[4-(6-fluoro-1,3-dihydro-3-oxo-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:700364 CAPLUS
DOCUMENT NUMBER: 141:225509
TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors
INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierre; Plas, Pascale
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SOURCE: Fr. Demande, 104 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2851563	A1	20040827	FR 2003-2320	20030226
FR 2851563	B1	20050422		
AU 2004216427	A1	20040910	AU 2004-216427	20040225
CA 2516660	A1	20040910	CA 2004-2516660	20040225
WO 2004075823	A2	20040910	WO 2004-FR418	20040225
WO 2004075823	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1599167	A2	20051130	EP 2004-714348	20040225
EP 1599167	B1	20071003		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007726	A	20060214	BR 2004-7726	20040225
CN 1753670	A	20060329	CN 2004-80005413	20040225
JP 2006519214	T	20060824	JP 2006-502162	20040225
AT 374754	T	20071015	AT 2004-714348	20040225
US 20050065179	A1	20050324	US 2004-915920	20040811
US 20050267147	A1	20051201	US 2004-504033	20040928
MX 2005PA09015	A	20051018	MX 2005-PA9015	20050824

PRIORITY APPLN. INFO.: FR 2003-2320 A 20030226
US 2003-504033 A2 20030920
WO 2004-FR418 A 20040225

OTHER SOURCE(S): MARPAT 141:225509
GI

L8 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH2, CO, CO-CH2 and derivs., X = C or N; R1, R2 = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R1NR2 = (un)substituted hetero(bi)cycloalkyl; R3 = (CH2)p-Z3 or CO-Z'3;
Z3 = alkyl, alkenyl, alkoxy, alkoxycarbonyl, heteroaryl,(un)substituted hetero/cycloalkyl, aryl, etc.; Z'3 = (un)substituted aryl; p = 0-4; R4 = (CH2)s-R'4; R'4 = heterocycloalkyl, heteroaryl, NWW'; W = H, alkyl; W' = (CH2)q-Z4; Z4 = H, alkenyl, (un)substituted cyclo/alkyl, aryl, etc.; q, s = independently 0-6] were prepared as melanocortin (MC), in particular MC4,
receptor modulators. Two biol. protocols are given (no data). For example, II was prepared, in 2 steps, by amination of 3-Fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (preparation given) with 3-(piperidino)propylamine in CH3CN at reflux, followed by one-step hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are implied, i.e. obesity, anxiety, pain, sex behavior, etc.
IT 746660-21-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazoles and imidazopyridines having
affinity for melanocortin (MC), in particular MC4, receptors)
RN 746660-21-9 CAPLUS
CN Isoquinoline, 2-[[1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl]carbonyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:633903 CAPLUS
DOCUMENT NUMBER: 141:173975
TITLE: Preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
INVENTOR(S): Coppola, Gary Mark; Damon, Robert Edson; Kukkola, Paivi Jaana; Stanton, James Lawrence
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065351	A1	20040805	WO 2004-EP571	20040123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
CA 2513349	A1	20040805	CA 2004-2513349	20040123
EP 1590319	A1	20051102	EP 2004-704554	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006938	A	20060103	BR 2004-6938	20040123
CN 1741986	A	20060301	CN 2004-80002540	20040123
JP 2006517199	T	20060720	JP 2006-500009	20040123
US 20060205772	A1	20060914	US 2005-542759	20050816

PRIORITY APPLN. INFO.: US 2003-442532P P 20030124
WO 2004-EP571 W 20040123

OTHER SOURCE(S): MARPAT 141:173975
GI



I



II

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. [I; R1, R2 = H, CN, halo, NO2, etc.; or R1 and R2 together with the carbon atoms they are attached to form an optionally substituted 5-7 membered (hetero)aromatic ring; R3 = alkyl; or R3 and R2 together with the amide group to which R3 is attached and the carbon atoms
to which R2 and the amide are attached form (un)substituted 5-7 membered carbocyclic or heterocyclic ring; R4 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; or NR4R3 = (un)substituted 5-8 membered ring, 8-12 membered fused bicyclic ring (both ring systems may contain another heteroatom selected from O, N and S); W = NR5COR6, NR5CO2R6, NR5CONR6R7, etc.; R5, R7 = H, alkyl, aralkyl; R6 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; X, Y = CH, N; or X:Y = CH2, O, S, NR10 (R10 = H, alkyl)] which lower intracellular glucocorticoid concns. in mammals, in particular, intracellular cortisol levels in humans, were prepared E.g., two alternative routes for preparation of the amide II were given. The compds.
I were tested for inhibition of 11β-HSD1 (specific data given for representative compds. I). The compds. I improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compds. I lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration
in humans, resulting in inhibition of hepatic gluconeogenesis and lowering
of plasma glucose levels. Thus, the compds.I may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compds. I may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore
relates to the use of the compds. I for the preparation of medicaments, in
particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.
IT 735348-52-4P 735348-53-5P 735348-54-6P
735348-55-7P 735348-56-8P 735348-57-9P
735348-58-0P 735348-59-1P 735348-60-4P
735348-61-5P 735348-62-6P 735348-63-7P
735348-64-8P 735348-65-9P 735348-66-0P
735348-67-1P 735348-68-2P 735348-69-3P
735348-70-6P 735348-71-7P 735348-72-8P
735348-73-9P 735348-74-0P 735348-75-1P
735348-76-2P 735348-77-3P 735348-78-4P
735348-79-5P 735348-80-8P 735348-81-9P
735348-82-0P 735348-83-1P 735348-84-2P
735348-85-3P 735348-86-4P 735348-87-5P
735348-88-6P 735348-89-7P 735348-90-0P
735348-91-1P 735348-92-2P 735348-93-3P
735348-94-4P 735348-95-5P 735348-96-6P
735348-97-7P 735348-98-8P 735348-99-9P
735349-00-5P 735349-01-6P 735349-02-7P
735349-03-8P 735349-04-9P 735349-05-0P
735349-06-1P 735349-07-2P 735349-08-3P

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
735349-09-4P 735349-10-7P 735349-11-8P
735349-12-9P 735349-13-0P 735349-14-1P
735349-15-2P 735349-16-3P 735349-17-4P
735349-18-5P 735349-19-6P 735349-20-9P
735349-21-0P 735349-22-1P 735349-23-2P
735349-24-3P 735349-25-4P 735349-26-5P
735349-27-6P 735349-28-7P 735349-29-8P
735349-30-1P 735349-31-2P 735349-32-3P
735349-33-4P 735349-34-5P 735349-35-6P
735349-36-7P 735349-37-8P 735349-38-9P
735349-39-0P 735349-40-3P 735349-41-4P
735349-42-5P 735349-43-6P 735349-44-7P
735349-45-8P 735349-46-9P 735349-47-0P
735349-48-1P 735349-49-2P 735349-50-5P
735349-51-6P 735349-52-7P 735349-53-8P
735349-54-9P 735349-55-0P 735349-56-1P
735349-57-2P 735349-58-3P 735349-59-4P
735349-60-7P 735349-61-8P 735349-62-9P
735349-63-0P 735349-64-1P 735349-65-2P
735349-66-3P 735349-67-4P 735349-68-5P
735349-69-6P 735349-70-9P 735349-71-0P
735349-72-1P 735349-73-2P 735349-74-3P
735349-75-4P 735349-76-5P 735349-77-6P
735349-78-7P 735349-79-8P 735349-80-1P
735349-81-2P 735349-82-3P 735349-83-4P
735349-84-5P 735349-85-6P 735349-86-7P
735349-87-8P 735349-88-9P 735349-89-0P
735349-90-3P 735349-91-4P 735349-92-5P
735349-93-6P 735349-94-7P 735349-95-8P
735349-96-9P 735349-97-0P 735349-98-1P
735349-99-2P 735350-00-2P 735350-01-3P
735350-02-4P 735350-03-5P 735350-04-6P
735350-05-7P 735350-06-8P 735350-07-9P
735350-08-0P 735350-09-1P 735350-10-4P
735350-11-5P 735350-12-6P 735350-13-7P
735350-14-8P 735350-15-9P 735350-16-0P
735350-17-1P 735350-18-2P 735350-19-3P
735350-20-6P 735350-21-7P 735350-22-8P
735350-23-9P 735350-24-0P 735350-25-1P
735350-26-2P 735350-27-3P 735350-28-4P
735350-29-5P 735350-30-8P 735350-31-9P
735350-32-0P 735350-33-1P 735350-34-2P
735350-35-3P 735350-36-4P 735350-37-5P
735350-38-6P 735350-39-7P 735350-40-0P
735350-41-1P 735350-42-2P 735350-43-3P
735350-44-4P 735350-45-5P 735350-46-6P
735350-47-7P 735350-48-8P 735350-49-9P
735350-50-2P 735350-51-3P 735350-52-4P
735350-53-5P 735350-54-6P 735350-55-7P
735350-56-8P 735350-57-9P 735350-58-0P
735350-59-1P 735350-60-4P 735350-61-5P
735350-62-6P 735350-63-7P 735350-64-8P
735350-65-9P 735350-66-0P 735350-67-1P
735350-68-2P

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)

RN 735348-52-4 CAPLUS
CN Butanamide, 3,3-dimethyl-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-53-5 CAPLUS
CN Cyclopentaneacetamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-54-6 CAPLUS
CN Cyclopentanepropanamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 735348-55-7 CAPLUS
CN Benzeneacetamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-56-8 CAPLUS
CN Benzeneacetamide, 4-methoxy-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-57-9 CAPLUS
CN Benzenepropanamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-58-0 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-59-1 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-60-4 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-61-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-62-6 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-63-7 CAPLUS
CN Benzamide, 2,4-difluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-64-8 CAPLUS
CN Isoquinoline, decahydro-2-[4-[[(propylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-65-9 CAPLUS
CN Isoquinoline, decahydro-2-[4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-66-0 CAPLUS
CN Isoquinoline, decahydro-2-[4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-67-1 CAPLUS
CN Isoquinoline, 2-[4-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-68-2 CAPLUS
CN Isoquinoline, decahydro-2-[4-[[(methylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-69-3 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-70-6 CAPLUS
CN Benzamide, 4-chloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-71-7 CAPLUS
CN Benzamide, 2-methoxy-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-72-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-73-9 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-74-0 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-75-1 CAPLUS
CN Carbamic acid, [4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-76-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-77-3 CAPLUS
CN Benzamide, 4-chloro-N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-78-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-79-5 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-cyano-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-80-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(hexyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-81-9 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-82-0 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-83-1 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-84-2 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[(2-ethoxyphenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-85-3 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-86-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-87-5 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-hexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-88-6 CAPLUS
CN Butanamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,3-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-89-7 CAPLUS
CN Cyclohexanecarboxamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-90-0 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-91-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(dimethylamino)-, rel- (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



RN 735348-92-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-93-3 CAPLUS
CN Benzamide, 4-butoxy-N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-94-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-95-5 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-96-6 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-97-7 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735348-98-8 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amin
o]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-99-9 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]b
enzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-00-5 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2,4-difluorophenyl)amino]carbonyl]amino]be
nzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



RN 735349-04-9 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[(cyclohexylamino)carbonyl]amino]benzoyl]deca
hydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-05-0 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]b
enzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-06-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Relative stereochemistry.



RN 735349-01-6 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]
decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-02-7 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[[(2-chlorophenyl)methyl]amino]carbonyl]amin
o]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-03-8 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2-phenylethyl)amino]carbonyl]amino]benzoyl
]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-07-2 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-08-3 CAPLUS
CN Cyclopentaneacetamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-09-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-10-7 CAPLUS
CN Benzamide, 4-chloro-N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-11-8 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-12-9 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735349-16-3 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-17-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(hexyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-18-5 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2,4-difluorophenyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-13-0 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-14-1 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-15-2 CAPLUS
CN Benzamide, 4-butoxy-N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-19-6 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-20-9 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2-phenylethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-21-0 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[(cyclohexylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-22-1 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-23-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-24-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-28-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-29-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-30-1 CAPLUS
CN Butanamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,3-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-25-4 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-26-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-27-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-31-2 CAPLUS
CN Cyclopentaneacetamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-32-3 CAPLUS
CN Cyclohexanecarboxamide, N-[3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-33-4 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-34-5 CAPLUS
CN Benzamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-35-6 CAPLUS
CN Benzamide, 2,6-dichloro-N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-36-7 CAPLUS
CN Benzeneacetamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-40-3 CAPLUS
CN 2-Furancarboxamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-41-4 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[(propylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-42-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-37-8 CAPLUS
CN Benzeneacetamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-38-9 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-39-0 CAPLUS
CN Benzenepropanamide, N-[3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-43-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-44-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-45-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-46-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-47-0 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-48-1 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-52-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-53-8 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



RN 735349-54-9 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-49-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 1-methylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-50-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-51-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-55-0 CAPLUS
CN Isoquinoline, 2-[4-[[(butylamino)carbonyl]amino]-2-chlorobenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-56-1 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[(pentylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-57-2 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[(propylamino)carbonyl]amino]benzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-58-3 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl
]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-59-4 CAPLUS
CN Isoquinoline,
2-[4-[[(butylamino)carbonyl]amino]-2-chlorobenzoyl]decahydro-
, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-60-7 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[(pentylamino)carbonyl]amino]benzoyl]decahydr
o-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-64-1 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-65-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



RN 735349-66-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-61-8 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(2-ethoxyphenyl)amino]carbonyl]amino]benzoy
l]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-62-9 CAPLUS
CN Isoquinoline,
2-[2-chloro-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzo
yl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-63-0 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aR)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX
NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-67-4 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-68-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, pentyl ester, rel- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



RN 735349-69-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-
isoquinolinyl]carbonyl]phenyl]-, 2-propynyl ester, rel- (9CI) (CA INDEX
NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-70-9 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-71-0 CAPLUS
CN Carbamic acid, [3-chloro-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-butynyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-72-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-76-5 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-77-6 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-78-7 CAPLUS
CN Benzamide, 4-methoxy-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-73-2 CAPLUS
CN Benzamide, 4-chloro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-74-3 CAPLUS
CN Benzamide, 4-cyano-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-75-4 CAPLUS
CN Benzamide, 4-fluoro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-79-8 CAPLUS
CN Benzamide, 2-methoxy-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-80-1 CAPLUS
CN Benzamide, 4-butoxy-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-81-2 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-82-3 CAPLUS
CN Benzamide, 3,4-difluoro-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-83-4 CAPLUS
CN Benzamide, 4-butoxy-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-84-5 CAPLUS
CN 2-Furancarboxamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735349-85-6 CAPLUS
CN Benzamide, 2,4-difluoro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-86-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-87-8 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-88-9 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-89-0 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-90-3 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-91-4 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-92-5 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-93-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-94-7 CAPLUS
CN Benzamide, 4-(dimethylamino)-N-[3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-95-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-96-9 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735349-97-0 CAPLUS
CN Benzamide, N-[3-methoxy-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(pentyloxy)- (CA INDEX NAME)



RN 735349-98-1 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(1-methylethoxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-99-2 CAPLUS
CN Benzamide, 2-chloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-00-2 CAPLUS
CN Benzamide, 2-methoxy-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-01-3 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-02-4 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-03-5 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-04-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-05-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-06-8 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-07-9 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-08-0 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-09-1 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-10-4 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-11-5 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-12-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-13-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-14-8 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-15-9 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-butynyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-16-0 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-propynyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-17-1 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(methylamino)carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-18-2 CAPLUS
CN Isoquinoline, 2-[4-[[(ethylamino)carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-19-3 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(propylamino)carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-20-6 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-chlorophenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-21-7 CAPLUS
CN Carbamic acid, [3-methoxy-4-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-22-8 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(phenylamino)carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-23-9 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(4-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-24-0 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(2-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-25-1 CAPLUS
CN Isoquinoline, 2-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-26-2 CAPLUS
CN Isoquinoline, 2-[4-[[(cyclohexylamino)carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-27-3 CAPLUS
CN Isoquinoline, 2-[4-[[(hexylamino)carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-28-4 CAPLUS
CN Benzamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-29-5 CAPLUS
CN Benzamide, 4-fluoro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-30-8 CAPLUS
CN Benzamide, 4-chloro-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-31-9 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-32-0 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(1-naphthalenylamino)carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-36-4 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-37-5 CAPLUS
CN Isoquinoline, 2-[4-[[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-38-6 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(propylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-33-1 CAPLUS
CN Isoquinoline, 2-[4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-34-2 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]-, (4aR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-35-3 CAPLUS

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735350-39-7 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(1-methylethyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-40-0 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[(1-naphthalenylamino)carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-41-1 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-42-2 CAPLUS
CN Benzamide, 4-methoxy-N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-43-3 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[3-methoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-44-4 CAPLUS
CN Isoquinoline, 2-[4-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-2-methoxybenzoyl]decahydro-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735350-45-5 CAPLUS
CN Isoquinoline, decahydro-2-[2-methoxy-4-[[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]benzoyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-46-6 CAPLUS
CN Benzamide, 4-methoxy-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-47-7 CAPLUS
CN Benzamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

propoxyphenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-48-8 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-49-9 CAPLUS
CN Benzamide, 3,4-difluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-50-2 CAPLUS
CN Benzamide, 2,4-difluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 735350-51-3 CAPLUS
CN Benzamide, 4-fluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-52-4 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-53-5 CAPLUS
CN Benzamide, 2-methoxy-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-54-6 CAPLUS
CN Benzamide, 2,6-dichloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-55-7 CAPLUS
CN Benzeneacetamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-56-8 CAPLUS
CN Benzeneacetamide, 4-methoxy-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-60-4 CAPLUS
CN Benzenepropanamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-61-5 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-62-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[3-ethoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-57-9 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-58-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-59-1 CAPLUS
CN Benzamide, 4-chloro-N-[4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-63-7 CAPLUS
CN Benzamide, N-[3-ethoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-64-8 CAPLUS
CN Benzamide, N-[3-ethoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-65-9 CAPLUS
CN Benzamide, 4-chloro-N-[3-ethoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 735350-66-0 CAPLUS
CN Benzamide, N-[3-ethoxy-4-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-67-1 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-68-2 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:376830 CAPLUS
DOCUMENT NUMBER: 138:385441
TITLE: Preparation of quinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040108	A1	20030515	WO 2002-GB4931	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465068	A1	20030515	CA 2002-2465068	20021031
AU 2002341156	A1	20030519	AU 2002-341156	20021031
EP 1444210	A1	20040811	EP 2002-774960	20021031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013842	A	20040831	BR 2002-13842	20021031
HU 2004001646	A2	20041228	HU 2004-1646	20021031
CN 1585754	A	20050223	CN 2002-826384	20021031
JP 2005515176	T	20050526	JP 2003-542154	20021031
NZ 532524	A	20070223	NZ 2002-532524	20021031
IN 2004DN01092	A	20050401	IN 2004-DN1092	20040423
MX 2004PA04219	A	20040910	MX 2004-PA4219	20040503
NO 2004002279	A	20040602	NO 2004-2279	20040602
US 20050043336	A1	20050224	US 2004-494137	20041006
US 20070082921	A1	20070412	US 2006-443208	20060531

PRIORITY APPLN. INFO.:
GB 2001-26433 A 20011103
GB 2001-29059 A 20011205
WO 2002-GB4931 W 20021031
US 2004-494137 B1 20041006

OTHER SOURCE(S): MARPAT 138:385441
GI

L8 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Anilino-, indolylamino-, and benzopyrazolylamino-substituted quinazolines I [wherein R1, R2, R3, and R6 = independently H or alkyl; Z = a bond, O, S, or NR2; Q1 = (un)substituted cycloalkyl(alkyl), cycloalkyl(alkenyl), cycloalkyl(alkynyl), or heterocyclyl(alkyl); with the proviso that alkylene chains within Q1Z are optionally interrupted by O, S, SO, SO2, NR3, CO, CHOR3, CONR3, NR3CO, SO2NR3, NR3SO2, CH=CH, or C.tplbond.C; Q2 = (un)substituted C6H4-4-X2Q2, 1-(X3Q4)indol-5-yl, 1-(X3Q4)-indol-6-yl, 1-(X3Q4)-1H-benzopyrazol-5-yl, or 1-(X3Q4)-1H-benzopyrazol-6-yl; X2 = a bond, O, S, SO, SO2, NR6, CHOR6, CONR6, NR6CO, SO2NR6, NR6SO2, CC(R6)2, C(R6)2O, SC(R6)2, C(R6)2S, CO, C(R6)2NR6, or NR6C (R6)2; or X2Q3 = heterocyclylcarbonyl; X3 = a bond, SO2, CO, SO2NR7, or C(R7)2; Q3 and Q4 = independently (un)substituted (heteroaryl); and pharmaceutically acceptable salts thereof] were prepared for use in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 4-hydroxy-1-methylpiperidine with 5-fluoro-3,4-dihydroquinazolin-4-one using NaH in DMA gave the ether (91%). Reaction with POCl3 and di-isopropylethylamine in DCM provided 4-chloro-5-(1-methylpiperidin-4-yloxy)quinazoline (62%), which was coupled with 5-amino-1-benzylindole in the presence of IPA containing HCl in ether to afford II•HCl (46%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-containing polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 μM - 10 μM. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 μM - 20 μM. In addition, I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.

IT 524954-38-9P, 4-[3-Chloro-4-(decahydroisoquinolin-2-ylcarbonyl)anilino]-5-(1-methylpiperidin-4-yloxy)quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of quinazolines as erbB receptor tyrosine

L8 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
kinase inhibitors for treatment of cancer)
RN 524954-38-9 CAPLUS
CN Isoquinoline, 2-[2-chloro-4-[[5-[(1-methyl-4-piperidinyl)oxy]-4-quinazolinyl]amino]benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.
IT 508216-96-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylurea derivs. as vanilloid receptor agonists)
RN 508216-96-4 CAPLUS
CN Isoquinoline, 2-[2-(diphenylmethoxy)-5-[[(phenylamino)carbonyl]amino]benzoyl]decahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:282524 CAPLUS
DOCUMENT NUMBER: 138:304064
TITLE: Preparation of phenylurea derivatives as vanilloid receptor agonists
INVENTOR(S): Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro, Hiroshi; Mochizuki, Manabu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029199	A1	20030410	WO 2002-JP9995	20020927
WO 2003029199	A9	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002332331	A1	20030414	AU 2002-332331	20020927
EP 1437344	A1	20040714	EP 2002-768103	20020927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004339061	A	20041202	JP 2002-282514	20020927
US 20040259912	A1	20041223	US 2004-489621	20040312

PRIORITY APPLN. INFO.: JP 2001-300564 A 20010928
WO 2002-JP9995 W 20020927

OTHER SOURCE(S): MARPAT 138:304064
GI



I

L8 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:45473 CAPLUS
DOCUMENT NUMBER: 128:154136
TITLE: An Enantioselective Synthesis of Cis Perhydroisoquinoline LY235959
AUTHOR(S): Hansen, Marvin M.; Bertsch, Carl F.; Harkness, Allen R.; Huff, Bret E.; Hutchison, Darrell R.; Khau, Vien V.; LeTourneau, Michael E.; Martinelli, Michael J.; Misner, Jerry W.; Peterson, Barry C.; Rieck, John A.; Sullivan, Kevin A.; Wright, Ian G.
CORPORATE SOURCE: Chemical Process Research and Development Division Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA
SOURCE: Journal of Organic Chemistry (1998), 63(3), 775-785
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:154136
GI



I



II

AB A novel synthesis of NMDA receptor antagonist LY235959 (I) was achieved in 13% overall yield in 17 steps from (R)-pantolactone. Highlights of the synthesis include (a) use of a chiral auxiliary-controlled asym. Diels-Alder reaction to provide the desired absolute and relative stereochem. at C-4a, C-6, and C-8a, (b) an efficient alkylation of hindered [2.2.2]-bicyclic iodide II using a novel amide benzophenone imine, (c) oxidative ring opening of the resulting [2.2.2]-bicyclic system to simultaneously functionalize the mol. for intramol. cyclization and phosphonate introduction, and (d) an increased understanding of how the C-3 stereochem. may be controlled by thermodn. equilibration. Synthesis of the 3-epimer of I in high overall yield makes this synthetic route attractive for future development efforts.
IT 202596-06-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; in enantioselective synthesis of cis perhydroisoquinoline LY235959)
RN 202596-06-3 CAPLUS
CN Isoquinoline, 2-benzoyldecahydro-6-(iodomethyl)-3-(1-pyrrolidinylcarbonyl)-, [3R-(3α,4aβ,6α,8aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:134304 CAPLUS
DOCUMENT NUMBER: 120:134304
TITLE: Antipsychotic nitrogen-containing bicyclic compounds
INVENTOR(S): Gilligan, Paul Joseph
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316050	A1	19930819	WO 1993-US1384	19930216
W: AU, CA, CZ, JP, KR, PL, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5532243	A	19960702	US 1992-836230	19920214
AU 9337200	A	19930903	AU 1993-37200	19930216
EP 626949	A1	19941207	EP 1993-905996	19930216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07505142	T	19950608	JP 1993-514332	19930216
PRIORITY APPLN. INFO.:			US 1992-836230 A	19920214
			WO 1993-US1384 A	19930216

OTHER SOURCE(S): MARPAT 120:134304
GI



I

AB The title compds. I [R1 = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 alkenyl, heterocyclyl, etc.; R2 = H, OH, C1-6 alkoxy, etc.; R3 = C1-6 alkyl, (un)substituted Ph, heteroaryl, naphthyl, etc.; R4, R5 = H, C1-6 alkyl; m,
n, p, q = 1, 2; such that m = n ≠ 2 or p = q ≠ 2], useful in the treatment of physiol. or drug-induced psychosis and as antidyskinetic agents, and which are not expected to produce the extrapyramidal symptoms that are typical of those produced by other antipsychotics that are dopamine receptor antagonists, are prepared Thus, cis-2-benzoyl-6-(4'-fluorophenyl)-6-hydroxydecahydroisoquinoline was reduced with LiAlH4, producing
cis-2-benzyl-6-(4'-fluorophenyl)-6-hydroxydecahydroisoquinoline, which demonstrated potent binding affinity for guinea pig striatum-isolated sigma receptors and for dopamine D2 receptors.

L8 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 52346-10-8P 152620-96-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antipsychotic activity of)
RN 52346-10-8 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro- (9CI) (CA INDEX NAME)



RN 152620-96-7 CAPLUS
CN Isoquinoline, 2-benzoyl-6-(4-fluorophenoxy)decahydro- (9CI) (CA INDEX NAME)



IT 52346-10-8P 152620-96-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antipsychotic activity of, reaction of)
RN 52346-10-8 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro- (9CI) (CA INDEX NAME)



RN 152620-96-7 CAPLUS
CN Isoquinoline, 2-benzoyl-6-(4-fluorophenoxy)decahydro- (9CI) (CA INDEX NAME)

L8 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 152620-97-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antipsychotic agents)
RN 152620-97-8 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



IT 52346-10-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antipsychotic agents)
RN 52346-10-8 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro- (9CI) (CA INDEX NAME)



L8 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:517276 CAPLUS
DOCUMENT NUMBER: 119:117276
TITLE: Novel 4-arylpiperazines and 4-arylpiperidines
INVENTOR(S): Reitz, Allen B.
PATENT ASSIGNEE(S): McNeilab, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304682	A1	19930318	WO 1992-US7754	19920911
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MG, MW, NO, RO, RU, SD				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
ZA 9109629	A	19931206	ZA 1991-9629	19911205
HU 68963	A2	19950828	HU 1993-1362	19911220
HU 217068	B	19991129		
AU 9226599	A	19930405	AU 1992-26599	19920911
AU 657799	B2	19950323		
EP 563345	A1	19931006	EP 1992-920313	19920911
EP 563345	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
HU 64535	A2	19940128	HU 1993-1361	19920911
JP 06502870	T	19940331	JP 1993-505525	19920911
JP 2941945	B2	19990830		
RU 2139867	C1	19991020	RU 1993-41055	19920911
SG 70980	A1	20000321	SG 1996-5506	19920911
AT 219938	T	20020715	AT 1992-920313	19920911
ES 2179822	T3	20030201	ES 1992-920313	19920911
NO 9301695	A	19930527	NO 1993-1695	19930510
NO 9301694	A	19930630	NO 1993-1694	19930510
NO 303780	B1	19980831		
FI 111639	B1	20030829	FI 1993-2104	19930510
US 5569659	A	19961029	US 1995-442600	19950517
PRIORITY APPLN. INFO.:			US 1991-757881 A	19910911
			US 1992-944006 B1	19920911
			WO 1992-US7754 A	19920911
			WO 1992-US9082 W	19921220
			US 1994-365978 B1	19941228

OTHER SOURCE(S): MARPAT 119:117276
GI

L8 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Title compds.4-RX(CH2)nCR1R2X1WNR3R4 [X = (un)substituted piperazino, piperidino; X1 = (un)substituted Ph; R = aryl; CR1R2 = CH2, CO, 1,1-alkanediyl, CHOH; W = CO, CS, SO2; NR3R4 = amino; n = 0-4] (113 compds.) were prepared as antipsychotic agents. Thus, 3-ClCH2C6H4COCl was treated with piperidine and N-(2-isopropoxyphenyl)piperazine to give the piperazine I which had an ED50 against apomorphine-induced emesis in dogs of 0.038mg/kg orally in dogs 1h before treatment with apomorphine..
IT 148827-10-5P 148853-90-1P 148888-36-2P
148888-37-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antipsychotic activity of)
RN 148827-10-5 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148853-90-1 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-, cis-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

L8 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CM 1

CRN 148827-10-5
CMF C30 H41 N3 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 148888-36-2 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 148888-37-3 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-, trans-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 148888-36-2
CMF C30 H41 N3 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

L8 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L8 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:495555 CAPLUS
DOCUMENT NUMBER: 119:95555
TITLE: Novel 4-arylpiperazines and 4-arylpiperidines
INVENTOR(S): Reitz, Alan B.
PATENT ASSIGNEE(S): McNeilab, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304684	A1	19930318	WO 1991-US9082	19911220
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MG, MW, NO, RO, SD, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
ZA 9109629	A	19931206	ZA 1991-9629	19911205
AU 9213633	A	19930405	AU 1992-13633	19911220
EP 562049	A1	19930929	EP 1992-906123	19911220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06502183	T	19940310	JP 1992-506154	19911220
HU 68963	A2	19950828	HU 1993-1362	19911220
HU 217068	B	19991129		
HU 64535	A2	19940128	HU 1993-1361	19920911
SG 70980	A1	20000321	SG 1996-5506	19920911
ES 2179822	T3	20030201	ES 1992-920313	19920911
NO 9301695	A	19930527	NO 1993-1695	19930510
US 5569659	A	19961029	US 1995-442600	19950517
PRIORITY APPLN. INFO.:			US 1991-757881 A	19910911
			WO 1991-US9082 A	19911220
			US 1992-944006 B1	19920911
			WO 1992-US9082 W	19921220
			US 1994-365978 B1	19941228

OTHER SOURCE(S): MARPAT 119:95555
GI



I

L8 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Piperazines and piperidines I [X = N, CH; Z = CO, CS, SO2; R = (un)substituted Ph, heteroaryl; R1, R2 = H, C1-C8 alkyl, (un)substituted Ph, aralkyl, acyl, C4-C10 cycloalkyl, NR1R2 may form a ring; R3, R4 = H, C1-C8 alkyl or alkoxy, NO2, halo, amino, etc.] were prepared as novel antipsychotic agents (dopamine D2 binding activities tabulated for 82 synthesized compds.). Thus, m-ClCH2C6H4COCl was treated with piperidine in THF, then piperidine and N-(2-isopropoxyphenyl)piperazine fumarate, to give 1-[3-[[4-(2-isopropoxyphenyl)-1-piperazinyl]methyl]benzoyl]piperidine, which is isolated as the HCl salt.

IT 148583-20-4P 149270-82-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and affinity for dopamine-2 receptor)

RN 148583-20-4 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 149270-82-6 CAPLUS
CN Isoquinoline, decahydro-2-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 148583-20-4
CMF C30 H41 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

L8 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:408537 CAPLUS
DOCUMENT NUMBER: 115:8537
TITLE: Liquid chromatographic separations of the enantiomers of cyclic amines
AUTHOR(S): Hyun, Myung Ho; Kim, Moon Sung
CORPORATE SOURCE: Dep. Chem., Pusan Natl. Univ., Pusan, 609-735, S. Korea
SOURCE: Bulletin of the Korean Chemical Society (1991), 12(1), 104-6
CODEN: BKCSDE; ISSN: 0253-2964
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II III

AB A chiral stationary phase (CSP)can be used for the liquid chromatog. resolution of cyclic amines, e.g., I (R = H, Me, octyl; R1 = H, octyl; n = 0, 1), II (R = Me, Ph, CH2C6H4OMe-4), and III (R = Me, Ph, CH2Ph; R1 = H, OMe). The racemic cyclic amines are converted to their 3,5-dinitrobenzoyl derivs. or 3,5-dinitrophenylureides by reaction with 3,5-dinitrobenzoyl chloride or 3,5-dinitrophenyl isocyanate before liquid chromatog. on the CSP. 3,5-Dinitrophenylureides showed greater enantioselectivity and longer retention times than the 3,5-dinitrobenzoyl derivs.

IT 134278-93-6 134278-94-7 134278-95-8
134278-96-9 134278-97-0 134278-98-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(liquid chromatog. separation of, from enantiomer on chiral stationary phase)

RN 134278-93-6 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-methyl-, (1α,4aα,8aα)-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

L8 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 134278-94-7 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-methyl-, (1α,4aα,8aα)-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 134278-95-8 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-phenyl-, (1α,4aα,8aα)-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 134278-96-9 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-phenyl-, (1α,4aα,8aα)-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L8 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 134278-97-0 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-[(4-methoxyphenyl)methyl]-, (1α,4aα,8aα)-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 134278-98-1 CAPLUS
CN 4a(2H)-Isoquinolinol, 2-(3,5-dinitrobenzoyl)octahydro-1-[(4-methoxyphenyl)methyl]-, (1α,4aα,8aα)-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L8 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L8 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:89975 CAPLUS
DOCUMENT NUMBER: 84:89975
ORIGINAL REFERENCE NO.: 84:14677a,14680a
TITLE: Synthesis of 1-azatwistane
AUTHOR(S): Deslongchamps, Pierre; Ruest, Luc; Dube, Serge
CORPORATE SOURCE: Lab. Synth. Org., Univ. Sherbrooke, Sherbrooke, QC, Can.
SOURCE: Canadian Journal of Chemistry (1975), 53(23), 3613-19
CODEN: CJCHAG; ISSN: 0008-4042
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 84:89975
GI For diagram(s), see printed CA Issue.
AB 1-Azatwistane (I) was prepared by reducing the decahydroisoquinolinone II (R = COPh, Z = O), mesylating the benzylisoquinolinol II (R = CH2Ph, Z = H, HO), cyclizing the mesylate II (R = CH2Ph, Z = H, MeSO3), hydrogenating the resulting quaternary ammonium salt III (R = CH2Ph) over Pd-C, and treating III (R = H) with NH3.
IT 58620-33-0P 58620-34-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and mesylation of)
RN 58620-33-0 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro-, (4aα,6α,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 58620-34-1 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro-, (4aα,6β,8aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 58620-35-2P 58620-36-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L8 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 58620-35-2 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro-, methanesulfonate (ester), (4aα,6α,8aα)- (9CI) (CA INDEX NAME)



RN 58620-36-3 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro-, methanesulfonate (ester), (4aα,6β,8aα)- (9CI) (CA INDEX NAME)



L8 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:121160 CAPLUS
DOCUMENT NUMBER: 80:121160
ORIGINAL REFERENCE NO.: 80:19510h,19511a
TITLE: Stereoselectivity of ketone reduction with Sporotrichum exile. Resolution of cis- and trans-2-benzoyloctahydro-6(2H)-isoquinolones
AUTHOR(S): Uskokovic, M. R.; Pruess, D. L.; Despreaux, C. W.; Shiuey, S.; Pizzolato, G.; Gutzwiller, J.
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
SOURCE: Helvetica Chimica Acta (1973), 56(8), 2834-44
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB cis-Octahydroquinolinones I and II were resolved by anaerobic incubation with S. exile which preferentially reduced II to give cis-octahydroquinolinol III of 70% optical purity. This was oxidized by chromic acid and recrystd. to yield optically pure II. The trans-octahydroquinolinones IV and V were resolved by recrystn. of their (R,R)-2,3-butanediol ketal derivs. Cinchonidine was oxidized by treatment with Ph2CO in the presence of KOCMe3 and then ring cleaved by O in Me3COH containing KOCMe3 to give the meroquinene ester VI, which underwent successive N-benzoylation, ester hydrolysis, polyphosphoric acid catalyzed cyclization, and hydrogenation to give a mixture of II and IV.
IT 52346-10-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52346-10-8 CAPLUS
CN 6-Isoquinolinol, 2-benzoyldecahydro- (9CI) (CA INDEX NAME)



L8 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:140458 CAPLUS
DOCUMENT NUMBER: 76:140458
ORIGINAL REFERENCE NO.: 76:22790h,22791a
TITLE: Stereochemistry of decahydroisoquinolines and related compounds. X. Configurational assignment of epimeric 4-hydroxy-2-methyl-cisdecahydroisoquinolines
AUTHOR(S): Kimoto, Shoshichiro; Okamoto, Masao; Watanabe, Akiko; Baba, Takako; Dobashi, Itsuo
CORPORATE SOURCE: Kyoto Coll. Pharm., Kyoto, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1972), 20(1), 10-14
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Two isomers of 4-hydroxy-2-methyl-cis-decahydroisoquinoline (I and II) were prepared and their conformations discussed.
IT 36034-52-3P 36034-53-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36034-52-3 CAPLUS
CN 4-Isoquinolinol, 2-benzoyldecahydro-, (4α,4aβ,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36034-53-4 CAPLUS
CN 4-Isoquinolinol, 2-benzoyldecahydro-, benzoate (ester), (4α,4aβ,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L8 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1950:3133 CAPLUS
DOCUMENT NUMBER: 44:3133
ORIGINAL REFERENCE NO.: 44:640i,641a-g
TITLE: Stereochemistry of yohimbine
AUTHOR(S): Witkop, Bernhard
SOURCE: Journal of the American Chemical Society (1949), 71, 2559-66
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A method is described by which yohimbine can be degraded to an optically active 2-methyl-trans-decahydroisoquinoline (I). The identification of this base with synthetic resolved material subsequently established the stereochem. relationship of C atoms 12 and 20 in yohimbine. The previous method of preparation of chano-desoxyyohimbol (II) (earlier designation, desoxyyohimbol) (C.A. 37, 5407.3) is modified to give 8-12% from yohimbic acid (III); not more than 3-5 g. III should be employed for 1 distillation, the ratio of III to Tl2O should be 5:1, and the temperature should be below 300°; in a 2nd method, 2 g. III and 0.4 g. Tl2CO3 were distilled at 0.01 mm. and 280°; 70 g. III yields 1.9 g. II, m. 151°. The MeOH mother liquors front II by the 1st method yielded further II and chano-isodesoxyyohimbol, m. 206°; it forms 2 methiodides, chars about 280°, and m. 254°, the latter being more soluble in MeOH. Reduction of II over Pt oxide in AcOH (15 min.) gives the dihydro derivative (IV), m. 130°, [α]D -2.5°; it yields 2.18% N-Me in the Herzig-Meyer determination; picrate, red, m. 190°. The methiodide of II, converted to the amorphous quaternary base and heated in vacuo at 170°, gives 1-methyl-trans-octahydroisoquinoline, whose picrate, yellow, m. 229-31° (the needles are transformed into prisms at 210°). IV yields an amorphous methiodide (V), which was converted to the picrate, m. 223-5°; the carbonate from V and Tl2CO3, heated at 180°/30 mm., gives 79% I, isolated as the HCl salt, m. 225-7°, [α]D 1.4° (H2O, c 4.9); picrate, yellow, m. 234-7°; picrolonate, golden, m. 199-201°; chloroaurate, m. 90-2°; bis(dibenzoyl-L-tartrate), m. 167-8° (decomposition), [α]D 82.2° (MeOH, c 2.02); α-bromo-camphor-π-sulfonate, m. 170-2° [α]D 71.4° (MeOH). Isoquinoline (VI) yields a bioxalate, m. 148°. VI, hydrogenated with Pt oxide in AcOH to the py-tetrahydro derivative, acetylated (1-Ac derivative, m. 45°), and reduced in EtOH over Raney Ni 17 hrs. at 164°/3000 lb./sq. in., gives 0.7 g. 1-ethyldecahydroisoquinoline, whose picrate, yellow, m. 154° (presumably the trans compound). VI (55 g.) in 400 cc. methylcyclohexane, hydrogenated (15 hrs.) with 15 g. Raney Ni at 180°/4000 lb./sq. in., the hydrogenated base (58 g.) refluxed 24 hrs. with 1 g. Pd black, and the distilled product (b2 75-105°) acetylated, extracted with dilute acid, hydrolyzed, and benzoylated, gives benzoyl-trans-decahydroisoquinoline, m. 97-9°. dl-I (1.53 g.) and 1.5 g. D-tartaric acid in hot EtOH give 1.41 g. of d-I D-bitartrate, m. 167-9° [α]D 14.6° (H2O, c 2.05). dl-I gives a bis(dibenzoyl-L-tartrate), m. 154-5° (decomposition); the salt is suitable for characterization but not for resolution; picrolonate, m. 216-19°; HCl salt, m. 164-5°. These results indicate that in yohimbine rings D and E are trans-locked. No curariform activity was observed for the methochlorides (in doses of 12.5 mg./kg. frog) of II, IV, and quebrachamine.

IT 879276-56-9P, Isoquinoline, 2-benzoyldecahydro-, trans-
RL: PREP (Preparation)
(preparation of)

RN 879276-56-9 CAPLUS
CN Isoquinoline, 2-benzoyldecahydro-, trans- (5CI) (CA INDEX NAME)

Relative stereochemistry.



=>